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ABSTRACT 
MOLECULAR MODELING AND DOCKING ANALYSIS OF THE VARIABLE 
REGIONS OF AN ANTI-N6-METHYLADENOSINE MONOCLONAL ANTIBODY 
 
By 
Avni Patrick Nimani 
 
The previously unknown DNA and amino acid sequences of the 7C7:C5 anti-N6-
methyladenosine (6mAos) variable fragment (Fv) are reported herein.  The 7C7:C5 Fv was 
molecular modeled using a novel approach involving alignment of numerous high 
identity antigen-bound crystallographic structures and antigen-unbound crystallographic 
structures as templates, in which a binding pocket was revealed only in the antigen-
bound-model of the Fv.  Rigid Fv/flexible antigen docking and flexible Fv/flexible 
antigen docking of deoxy-N6-methyladenosine (d6mA), deoxyadenosine (dA), and single-
stranded (ss) DNA trinucleotide (A-6mA-T) revealed three critical residues (TYR L48, 
SER L55, and PRO H103) to be involved in docking of d6mA and related antigens to the 
7C7:C5 Fv.  The N6 methyl group in d6mA was predicted to make more van der Waals 
contacts than the corresponding N6 hydrogen in dA leading to an estimated 6 to 10 fold 
greater affinity for d6mA than dA.  Intermediate dissociation constant (Kd) calculations 
suggest a Kd range of 7.835 x 10-7 M to 5.92 x 10-8 M for the binding of d6mA in ssDNA, 
which corresponds to an affinity most appropriately used for genotyping or diagnostics.  
The binding interactions suggest the possibility of a slightly higher affinity for 
ribonucleoside versus deoxyribonucleoside, suggesting that the 7C7:C5 Fv may be able 
to bind to N6-methyladenosine (6mAos) in RNA. 
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PREFACE 
 
 In my first year (2003) at Northern Michigan University as a Master of Science 
student, I primarily focused on classes and had some early discussions about the kind of 
research I would like to perform with my Academic Advisor, Dr. Mark Paulsen.  At the 
time, I was interested in working with computer modeling.  During the start of my second 
year (Fall 2004), I opted to take a course in Virology instructed by Dr. Osvaldo Lopez.  
After speaking with Dr. Osvaldo Lopez for some time during this course, a project 
working with the 7C7:C5 monoclonal antibody was arrived at.  Also, in Fall 2004, I took 
a course in Protein Structure and Function with Dr. Lesley Putman, which helped me to 
better understand protein and nucleic acid structure in relation to function.  In this class, I 
obtained hands-on experience with analyzing three-dimensional molecular models.  Early 
lab work in 2004 involved becoming familiar with molecular biology techniques such as 
plasmid isolation that would prove useful towards completion of the project.  The earliest 
work reported herein involved blotting on membranes for a general characterization of 
the specificity of the 7C7:C5 monoclonal antibody.   
Early in 2005, the project took shape towards obtaining a three-dimensional 
molecular model of the 7C7:C5 variable fragment.  The initial stages of this project 
required obtaining the DNA sequences for the 7C7:C5 variable regions.  Acquiring 
funding for laboratory work towards obtaining the DNA sequences for the variable 
regions of the 7C7:C5 monoclonal antibody was a major obstacle in the following year 
(2005) and, thus, much effort was placed towards acquiring enough funding.  In Fall 
2006, I enrolled in a molecular modeling course with Dr. M. Paulsen, which helped me to 
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understand and appreciate the theory behind computational modeling.  During this 
course, I also became more familiar with general use of computational modeling.  In 
Winter 2005, I enrolled in a Biotechnology course with Dr. O. Lopez, which focused on 
antibody development and modern day uses of antibodies.  Upon obtaining funding in 
2006, much laboratory work was performed over a two year period, in which the DNA 
sequences for the 7C7:C5 variable regions were successfully sequenced.  In 2008, 
molecular modeling and docking analysis of the 7C7:C5 variable fragment was 
performed leading me to the end of my research at Northern Michigan University. 
My research at NMU was time-consuming but quite enjoyable and rewarding.  I 
have thoroughly benefited from all the techniques I have learned and all the skills I have 
gained.  I honestly feel I have completed a worthwhile project and I am glad that my time 
and diligent effort have been spent on such a project.  For the idea behind the project and 
their help towards the project, I have to sincerely thank Dr. O. Lopez and Dr. M. Paulsen.  
Also, I would like to thank them for their help with obtaining funding for the project.  
They have spent much time and effort in guiding me through completion of my thesis 
work and their efforts are much appreciated.  Lastly, I would like to thank all three 
members of my thesis committee, Dr. M. Paulsen, Dr. O. Lopez, and Dr. L. Putman, for 
their assistance regarding my thesis. 
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INTRODUCTION 
 
DNA Methylation 
DNA methylation is an ordinary biological process in which a methyl group        
(—CH3) or methyl groups covalently link(s) to DNA 1.  Methylation of DNA is distinct 
from other chemical modifications of DNA because methylation is a natural process of 
altering genes and does not result in damaging the DNA reading frame like alkylation, 
deamination, or oxidative damage.  In prokaryotes, DNA methylation acts as a defense 
against bacteriophages, aids in DNA repair, and regulates DNA replication.  In eukaryotes, 
DNA methylation is a method of regulating gene expression, inactivating mammalian X-
chromosomes, and protecting DNA 1.   
For decades, DNA methylation has been known to produce the following 
methylated bases:  N6-methyladenine (6mA), N4-methylcytosine (4mC), and 5-
methylcytosine (5mC) 1.   The nucleotide sequences listed in Table 1 refer to five 
prokaryotic, naturally occurring sites of methylation for N6 of adenine.  In addition to 
prokaryotes, DNA methylation of adenine has been found to naturally occur in “higher 
plants,” of which an adenine methylase known as wadmtase was isolated from wheat 
seedlings (eukaryotes) 2-8.  The presence of 6mA has been found in the DNA of various 
invertebrates (mosquitoes, fruit flies, and mealybugs), particularly in association with 
gravidity or embryonic development 9-11.  The presence of 6mA has also been found in rat, 
bovine, and human sperm DNA 11-12, although one study 13 contradicts those findings.  
Furthermore, the presence of 6mA was observed in a steroid reductase gene expressed in the 
testis and epididymis of adult rat 14.  As a result, although 6mA is most commonly found to 
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naturally occur in prokaryotes, it also appears to be present in higher plant and animal 
genes associated with reproduction. 
Table 1.  Methylases and their sites of methylation 
Methylases Methylation Site 
M.EcoRI GA6mATTC 
M.dam G6mATC 
M.TaqI TCG6mA 
M.BcgI CG6mANNNNNNTGC 
M.AloI GA6mACNNNNNNTCC 
*N = any nucleotide 
 
Methyltransferases/methylases (MT)s require S-adenosyl-L-methionine (SAM), 
as a cofactor which contributes the methyl group to be added to a specific nucleotide base 
of a restriction site sequence 1.  The catalytic mechanism is believed to involve direct 
transfer of the methyl group from SAM to the nucleotide base via SN2 reaction 15-17.  The 
reaction requires coordinated binding of SAM and the target base for methylation.  In the 
case of M.TaqI, the crystal structure revealed a cleft of 15 Å between the methyl group of 
SAM and the N6 of the target adenine, which would normally provide quite an obstacle 
for direct transfer of a methyl group 18.  As a result, base-flipping, or distortion of a base 
out of its usual position in the double helix, is believed to occur to bring the methyl group 
of SAM in closer proximity to the N6 of the target adenine 18-21. 
Cytosine and adenine binding in MTs are quite distinct.  While both cytosine MTs 
and adenine MTs have arginine residues that are positioned for electrostatic interactions 
between the DNA binding cleft and the DNA backbone, the two types of DNA MTs 
differ in their binding interactions with their target bases 1, 18, 22.  Hydrogen bonding 
interactions are believed to play a more significant role in cytosine binding in MTs, while 
hydrophobic interactions are structurally expected to predominate in adenine binding in 
MTs 22. 
  3
In the case of adenine MTs, hydrophobic residues particularly phenylalanine, 
tyrosine, isoleucine, leucine, and valine in the SAM binding region and in the target 
adenine region have been structurally suggested in making favorable face-to-face or 
edge-to-face van der Waals contacts with the adenine moiety in SAM and the target 
adenine in DNA, respectively 18- 20, 22, 23.  In addition, positively charged residues have 
been found to interact with phosphate groups of the DNA backbone and have also been 
implicated in direct interaction with the target base for methylation 18, 23, while negatively 
charged residues have been found to surround the sulfur group of SAM within a radius of 
4-6 Å and to be involved in hydrogen bonding and van der Waals contacts with the 
adenine moiety of SAM 18-20.  These interactions are likely to be important for the 
binding of adenine in MTs and potentially other proteins. 
DNA genotyping methods predominantly use restriction endonucleases (RE)s; 
however, MTs can also be used in genotyping 24-26.  In fact, the use of MTs offers 
advantages in DNA mapping.  The most significant advantage is that site specific 
methylation can be applied to PCR-based formats which are more rapid than RE formats 
based on restriction fragment length polymorphism (RFLP) genotyping 26-28, the standard 
genotyping method from 1985 until the early 1990’s.  Methylation based PCR 
genotyping formats require amplification of DNA, DNA fragmentation, site specific 
methylation, DNA denaturation, DNA fixation, and immunochemical detection, while 
RFLP genotyping requires probe labeling, DNA fragmentation, gel electrophoresis, 
membrane transfer blotting, hybridization of probe with target DNA, membrane washing, 
and autoradiography.  As a result, another advantage is that using DNA MTs in 
combination with REs allows for the DNA to be mapped without the use of radiometric 
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labeling and gel electrophoresis 26.  A final advantage is the ability of some MTs to 
recognize short sequences—2 to 3 base pairs in length 29-30.   
 
Antibodies 
Antibodies have the ability to be produced against any known molecule and, thus, 
antibodies against DNA can be used as a means of detecting DNA in genotyping 
methods.  Antibodies are tetrameric proteins produced by B cells as part of the immune 
response against foreign molecules and organisms that function to neutralize foreign 
molecules.  Antibodies are composed of two identical heavy chains (~125 kDa for both) 
and two identical light chains (~25 kDa for both) and have a total molecular weight of 
~150 kDa 31. 
The two heavy chains are covalently linked to one another through disulfide 
bonds, in a domain known as the hinge region 32.  Due to the limited number of disulfide 
bonds, noncovalent interactions such as hydrogen bonds, electrostatic interactions, van 
der Waals interactions, hydrophobic interactions, and CH2 domain carbohydrate-
carbohydrate interactions are also important for the association of the two heavy chains 
with one another 33-35.  Each heavy chain is covalently linked to a light chain via a 
disulfide bond 32.  In addition to disulfide bonds, the heavy chains associate with the light 
chains through noncovalent interactions 36-37.  Each heavy chain has five domains and 
each light chain has two domains 38.  In each chain, disulfide bonds have also been found 
to covalently link one end of a domain to the other end of the same domain, with the 
exception of the hinge region. 
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Together the heavy chains and light chains are comprised of two main regions:  
the constant (C) region and the variable (V) region 31.  Various antibody heavy chain 
isotypes naturally occur in the immune system:  immunoglobulin mu (IgM), gamma 
(IgG), alpha (IgA), delta (IgD), and epsilon (IgE).  These isotypes are classified 
according to the conformation and properties of the constant regions.  The antibody in the 
current study is an immunoglobulin G (IgG) isotype.  Antibodies of this isotype are the 
smallest yet most abundant of antibodies (75-80% of all antibodies) and are present in all 
bodily fluids 39-41.  Immunoglobulin Gs are typically produced in high quantity as part of 
the secondary antibody response. 
Each heavy chain of an IgG antibody is composed of three constant domains 
(CH1, CH2, and CH3), a hinge region, and a variable domain (VH) 31.    Amino acid 
sequences for the VΗ are generally around 120 amino acids long 36, 42.  The light chain of 
an IgG is composed of a constant domain (CL) and a variable domain (VL) 31.  Two 
subclasses of light chains occur in IgGs:  a kappa light chain and a lambda light chain.  
The kappa light chain occurs more frequently than the lambda counterpart in IgGs in 
serum.  Amino acid sequences for the variable kappa region (Vκ) are typically around 110 
amino acids long 36, 42-43.   
The variable domain of each chain (light or heavy) is comprised of four 
framework regions (FRs)—FR-(L/H)1, FR-(L/H)2, FR-(L/H)3, and FR-(L/H)4—and 
three hypervariable regions called complementarity determining regions (CDRs):  CDR-
(L/H)1, CDR-(L/H)2, and CDR-(L/H)3 36, 43-46.  The CDRs contain the majority of 
residues that contact an antigen and typically either partially or completely form        
loops 36, 43.  The most variable of the CDRs is CDR-H3 36, 44-46.  Murine IgG antibodies 
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have CDR-H3s that range from 2-19 residues in length and human IgG antibodies have 
CDR-H3s that range from 2-26 residues in length 47-48.  Crystal structures of Fab-
oligonucleotide complexes have shown that the length of the CDR-H3s are typically 
directly related to the length of the segments of epitopes (sites on an antigen that interact 
with residues of the antibody variable region that directly involve binding of the antigen 
to the antibody) that interact with them 42, 49-50.   
Limited papain digestion has been used to separate IgG antibodies into three main 
functional fragments:  a crystallizable fragment (Fc) and two antigen-binding fragments 
(Fabs) 32, 43, 51.  The Fc is comprised of a pair of CH2 and CH3 domains and interacts with 
Fcγ receptors on macrophages and other cells and effector molecules involved in 
molecular processes that particularly aid in destruction of pathogens 32, 38, 52-53.  Each Fab 
contains a dominant or determining fragment (Fd), which is comprised of the CH1 
domain and the VH, linked to a light chain, which is comprised of the CL and the VL 51.  
The minimal antigen-binding fragment or variable fragment is the Fv 32, 38.  Each IgG 
antibody has two Fv, one from each Fab.  Each Fv contains a VH and a VL associated 
together through noncovalent interactions 36-37.  Each Fv has a total of six CDRs (three 
from the VL and three from the VH).  Figure 1 illustrates the general composite of an IgG 
antibody.  
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Figure 1.  A model of the general composite of an IgG antibody modified with 
permission from Lopez, O.J. [communication], 2005. 
 
 
Anti-Nucleic Acid Antibodies 
 
Antibodies bind to proteins, nucleic acids, or other antigens 31, 54.  Antibodies of 
the same subclass have highly conserved constant regions and attain most of their 
uniqueness in binding specificity through distinct variable regions 31.  Polyclonal 
antibodies (PAbs) are antibodies with different variable regions produced against an 
antigen.  Monoclonal antibodies (MAbs) are antibodies of the same class with identical 
variable regions produced against an antigen.  Polyclonal antibodies are less specific to a 
particular antigen than MAbs due to the presence of many different variable regions 31.  
Some of these variable regions may detect other antigens occasionally giving false 
positives in detection of a specific antigen.  Thus, MAbs are preferred in detection of 
antigens because they are produced selectively to be specific for a particular antigen 31.  
More specifically, MAbs produced against an antigen bind to residues in a single distinct 
region of the antigen known as the epitope, while PAbs produced against an antigen may 
bind to different epitopes on the same antigen. 
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Monoclonal antibodies have been produced that bind to DNA 50, 55-56.  Although 
not as common, some MAbs have been produced that bind specifically to methylated 
sequences or even methylated nucleotides in DNA 26, 57-64.  Even less common, MAbs 
have been produced that bind to methylated adenosine or deoxy methylated adenosine, in 
which the adenine has been methylated at the 1, 3, or 6 position 26, 59, 64-65.  Only one of 
these MAbs detects deoxy methylated adenosine that has been methylated in the naturally 
occurring 6 position 26. 
Hydrophobic interactions and van der Waals interactions are the two main types 
of interactions that occur between a paratope (the specific amino acids that interact with a 
binding site of an antigen) and its target binding site (an epitope) 31.  The variable regions 
of antibodies are what allow for a diversity of paratopes.  Immunglobulin G antibodies 
belong to a class of antibodies produced by plasma B cells 31.  Immunoglobulin G 
antibodies appear to be used the most for binding to DNA.  Although IgG antibodies are 
able to bind to an oligonucleotide that is twenty nucleotides long (a 20-mer), IgG 
antibodies were found to more effectively bind to a 40-mer 56, 66. 
Furthermore, anti-DNA IgG antibodies produced against DNA through 
immunization tend to be structure specific 55-56, 67-69.  The affinity of an anti-double-
stranded (ds)-DNA antibody is often much greater for dsDNA than single-stranded (ss) 
DNA and vice versa for an anti-ssDNA antibody, showing low cross-reactivity 55-56.  The 
influence of affinity on avidity or vice versa tends to depend on the particular antibody 43, 
56, 66
.  For instance, the avidity of an antibody is affected by the valency of the antibody, 
the affinity of each Fab, and the coordination between the Fabs of the antibody.  
Likewise, the affinity of an antibody measured as a whole unit may have either 
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synergistic or obstructive effects due to coordination between the Fabs or a lack thereof 
resulting from steric constraints, respectively.  Thus, the affinity measured for the binding 
of an antigen to a Fab in a complete antibody may be stronger or weaker than the binding 
affinity of an antigen to a Fab alone.  Each IgG is divalent, in which it has two variable 
binding domains that can each bind to a sequence in the DNA 31, 43, 56, 66.  In the case of a 
20-mer, generally univalent or single variable domain binding occurs; however, in the 
case of a 40-mer divalent binding can occur 56, 66. 
 
Brief Description of Typical Anti-DNA Interactions 
Generally, anti-DNA binding interactions fall into five main categories:  π-
stacking interactions, hydrogen bonds, charge-charge interactions, polar interactions, and 
hydrophobic, non-stacking interactions.  π-Stacking interactions are the strongest non-
covalent interactions producing typically ≥-9 kcal/mol 70-71.  However, a π-stacking 
interaction of a tyrosine residue with adenine in a catalytic site was reported as producing 
approximately -2 kcal/mol of energy 72.  Hydrogen bonds are the second strongest type of 
intermolecular forces producing -2 to -10 kcal/mol of energy 73.  Hydrogen bonds 
increase in strength linearly with aromatic stacking interaction 74.  Other interactions also 
can increase H-bond strength. 
Charge-charge interaction strengths are determined by Coulomb’s law:  E = 
kq1q2/Dr, where k is a proportionality constant, q1 and q2 are charges of two participating 
atoms, D is the dielectric constant, and r is the radius between the two participating  
atoms 75.  In aqueous solutions, charge-charge interactions generally contribute in a 
similar energy range as H-bonds.  Polar contacts occur through dipole-dipole forces, 
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which are typically weaker than H-bonds or charge-charge interactions, producing -1 to   
-3 kcal/mol of energy 73.  Hydrophobic contacts occur through London dispersion forces, 
which are the weakest of the five mentioned forces producing -0.01 to -2 kcal/mol of 
energy.  Aromatic-aromatic hydrophobic contacts produce approximately -1 to -2 
kcal/mol 76.  In a study using AutoDock-4.0, H-bonds were found to produce only -0.6 
kcal/mol per bond and dispersion/repulsion forces were found to produce only -0.3 to      
-0.5 kcal/mol per nonhydrogen contact 77. 
 
Structural Aspects of IgGs 
Hinges of IgGs tend to be flexible, allowing movement and rotation of the   
hinges 48.  As a result, the hinges allow Fab fragments to attain more positions than 
merely open or shut like a door hinge.  Hinge length and domain variability were found 
to limit the reach of the Fab fragments.  Shorter IgG hinges tend to allow for a Y-shaped 
structure, while longer IgG hinges tend to allow for more of a T-shaped structure 48.  
Only three complete structures of IgG mAbs have been reported:  MAb 61.1.3, a murine 
IgG1, MAb 231, a murine IgG2a, and IgG1 b12, a human IgG1 35, 48, 78-79.  Among 
antibodies from the four murine IgG subclasses (IgG1, IgG2a, IgG2b, and IgG3), IgG1 
antibodies possess the shortest hinges and are considered the most rigid 35, 80. 
Interestingly, the 3.2 Å crystal structure of MAb 61.1.3 has one CH2 domain that 
is considerably more mobile than the other 35.  In fact, the highly mobile CH2 domain of 
MAb 61.1.3 is more mobile than both CH2 domains of MAb 231 35, 78.  This finding 
suggests that murine IgG1 antibodies have extensive segmental flexibility simply in a 
different manner than other IgGs.  The MAb 61.1.3, with its Fabs much closer together, is 
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a more compact antibody than MAb 231.  The angle between Fabs in MAb 61.1.3 is 115° 
making a distorted Y shape, while the angle between Fabs in MAb 231 is 172° and Fabs 
in IgG1 b12 is 180° making a distorted T shape and a T shape, respectively 35, 48, 78-79.  
The specific angles between Fabs may be related to the size of an antigen.  For instance, 
the MAb 61.1.3 binds a relatively small antigen, Phenobarbital, compared to MAb 231, 
which binds to an antigen on the surface of canine lymphoma cells, and IgG1 b12, which 
binds to the CD4-binding site of human immunodeficiency virus-1 (HIV-1) gp 120. 
 
Structural Aspects of Anti-Nucleic Acid Fabs and Paratope Interactions  
Over 300 crystal structures of antibodies or antibody fragments are in the Protein 
Data Bank (PDB) 50, 81.  Of all these structures, only four are Fab fragments of anti-
nucleic acid MAbs 42, 49-50, 82-83.  Two of these Fab fragments (BV04-01 and DNA-1) bind 
to deoxythymidine (dT) sequences in ssDNA, one of these Fab fragments (ED-10) binds 
to ssDNA sequences containing dT-deoxycytosine (dC), and the other Fab fragment (Jel 
103) binds to RNA.  Comparison of BV04-01 and DNA-1 provide a good example of the 
similarities and differences commonly found in nucleotide specific binding interactions 
involved in anti-ssDNA binding.   
A 2.0 Å crystal structure of unliganded BV04-01 and a 2.66 Å crystal structure of 
BV04-01 complexed with a deoxythymidine trimer (dT3) revealed that the active-site 
must expand to accommodate the antigen 42.  Stacking interactions and hydrogen bonding 
between BV04-01 residues and thymine-2 (T2) were the critical binding interactions.  
Tyrosine 32 of the light chain (Tyr L32) and tryptophan 100a of the heavy chain (Trp 
H100a) of BV04-01 were the residues involved in the stacking interactions.  
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Nevertheless, hydrogen bonding and van der Waals contacts between polar residues in 
BV04-01 and the phosphate groups, especially phosphate-1, in dT3 contributed to binding 
by stabilizing the phosphodeoxyribose backbone 42.  van der Waals contacts between the 
deoxyribose and Trp H100a, Arg H52, His L27d, and His L93 also contributed to 
stabilizing the phosphodeoxyribose backbone.  Ion pairing occurred between Arg H52, 
which is found in the CDR-H2, and phosphate-2 of dT3.  Typically, CDR-H3s of anti-
DNA MAbs are relatively rich in Arg residues; however, BV04-01 binds to ssDNA not 
dsDNA 42. 
DNA-1 and BV04-01 show similarities and differences in the types of interactions 
that bind to oligo(dT) polynucleotides.  A 2.1 Å crystal structure of DNA-1 complexed 
with dT5 revealed that tyrosine side-chains intercalating between thymine bases were 
responsible for stacking interactions between the Tyr side-chains and the thymine     
bases 50.  The stacking interactions were proposed to be important in generating the 
experimentally observed negative enthalpy of binding 50, 84-85.  The stacking interactions 
are believed to generate a negative enthalpy through the desolvation of the interface 
between binding pocket and nucleotide base 50.  Stacking interactions due to Tyr L32, Tyr 
L49, Tyr H100, and Tyr H100A are the most critical for binding to dT5 or dT3 49-50.  As a 
result, the primary source of binding of dT5 or dT3 to DNA-1 is through stacking 
interactions with the thymine bases, while binding of dT3 to BV04-01 involved a more 
even distribution of interactions between the thymine bases and the phosphodeoxyribose 
backbone. 
Interestingly, the two Fab fragments of DNA-1 in crystal structures are 
assymetrical, in which most of the stacking interactions are made by CDR-H3 of Fab1 
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and CDR-L1 and CDR-L2 of Fab1 49-50.  The CDR-H3 is a peptide about two bases long 
and comprises one side of the narrow groove that interacts with three thymine bases.  The 
CDR-L1 and 2 comprises the other side of the narrow groove 49-50.  DNA-1 binds to a 
deoxythymidine 15-mer (dT15) or longer oligo(dT) with high affinity 84, 86-88.  
Nevertheless, DNA-1 also binds to smaller sequences of oligo(dT), such as dT5 and dT3, 
but with lower affinity than it binds to dT15 49-50, 84-89. 
 
Antibody Variable Regions 
Antibody V regions show high similarity between sequences (at least 50% 
similarity between sequences) 90.  The FRs of V domains have been shown to have rather 
conserved structures and five of the six CDRs have been found to follow canonical 
patterns 44-45, 91-92.  Since CDRs often overlap in range with loops and show more 
variability than the FRs, they require separate consideration during modeling 45.  
Computer modeling of the V region of V-88, an IgG1κ anti-ssDNA antibody, has been 
done based on known crystallographic structures of other antibodies 93-94.   
Antibodies that share the highest degree of identity with sequences for the V-88 
VH and Vκ were searched for on the PDB 93.  V-88 showed a high sequence identity with 
the anti-fluorescein Ab 4-4-20 for both the VH (67%) and the VL (93%), serving as a 
template for the V-88 model.  The final residues of FR-H3 and the entire FR-H4 were 
modeled from BV04-01, which had nearly identical sequences to V-88 in these regions.  
The three light chain CDRs and the CDR-H1 were all constructed according to canonical 
structures found in 4-4-20 93.  The CDR-H2 was different in length than all four of the 
observed canonical structures for this region.   
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As a result, the CDR-H2 of V-88 was partially designed from the canonical 
structures of the CDR-H2 of 4-4-20 and BV04-01 93.  A conformational search was 
performed to determine the structure of the remaining sequence.  No canonical forms 
have been observed for CDR-H3 of V regions.  As a result, the structure for the CDR-H3 
of V-88 was based on the structure of the CDR-H3 from BV04-01 since the final residues 
of FR-H3 and the entire FR-H4 for V-88 and BV04-01 share considerable sequence 
identity.  In addition, the sequence for CDR-H3 of V-88 is only two residues longer than 
the sequence for CDR-H3 of BV04-01 93. 
 
Previous Research from the O.J. Lopez Laboratory 
 
 Polyclonal and monoclonal antibodies have been used in detection of methylated 
sequences within DNA 26, 95.  Rabbit anti-6mA antisera detected deoxy-N6-
methyladenosine (d6mA) in DNA, but did not detect sequences with deoxy-5-
methylcytidine (d5mC) or deoxy-4-methylcytidine (d4mC) as demonstrated by an 
immunochemical genotyping Southern blot 26.  This experiment demonstrated the ability 
of antibodies to distinguish among specific nucleotides.  A monoclonal antibody that 
specifically binds to N6-methyladenosine (6mAos) has been produced jointly by Dr. 
Osvaldo Lopez and Dr. Michael Nelson by inoculation of a murine spleen with 6mAos 
conjugated to hemocyanin. 
The conjugation of 6mAos was performed according to methods previously 
described 96-98.  The immunization of BALB/c mice with 6mAos-hemocyanin conjugate 
and generation of a hybridoma 99 that produced a MAb against 6mAos was previously 
described 96.  The anti-6mAos MAb was purified and isotyped to be IgG1κ.  An enzyme-
  15
linked immunoassay (ELISA) was done to test the resulting hybridomas for production of 
antibodies that detect Chlorella virus NY-2A (CV NY-2A), which is a virus that contains 
a high proportion of methylated nucleotides 96; approximately 37% of adenines in CV 
NY-2A are methylated in the N6 position 100.  Figure 2 shows a diagram of the overall 
process of initial hybridoma production. 
  16
  
Figure 2.  Diagram illustrating the main steps for initial production of hybridomas and, in turn, monoclonal 
antibodies.  Abbreviations:  HGPRT-, hyperxanthine-guanine-phosphoriboxyl transferase negative; PEG, 
polyethylene glycol; and HAT,  hypoxanthine-aminopterin-thymidine.  
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An immunogenotyping ELISA showed that the 7C7:C5 MAb could detect a 
single d6mA in 100 ng of a 97-mer ssDNA strand 26.  An ELISA utilizing the high amount 
of d6mA (~34,000 d6mA per strand of DNA) present in CV NY-2A genomic DNA 
revealed that the 7C7:C5 MAb from ascites bound with twenty-seven fold greater 
intensity to the CV NY-2A DNA than to the DNA sequences that did not contain d6mA 96.  
Competition ELISA revealed that the 7C7:C5 MAb binds to deoxy-N6-methyladenosine-
triphosphate (d6mATP), which, in turn, competitively inhibits binding to sequences with 
d6mA in DNA 96. The competition ELISA also demonstrated that the 7C7:C5 MAb does 
not competitively bind to deoxy-5-methylcytidine-triphosphate (d5mCTP) or to 
deoxyadenosine-triphosphate (dATP), resulting in no inhibition of the 7C7:C5 MAb 
binding to d6mA in DNA.  The results of the immunochemical genotyping ELISA, the CV 
NY-2A ELISA, and the competition ELISA suggest that the 7C7:C5 MAb specifically 
recognizes d6mA in DNA 26, 96. 
 
Summary of Objectives Accomplished Herein 
The 7C7:C5 hybridoma cell line has been used to produce a monoclonal antibody 
that detects d6mA in DNA 26, 96.  It is the only MAb that has been isolated for detecting 
d6mA.  Unfortunately, the anti-6mAos 7C7:C5 MAb has yet to be fully characterized.  The 
genes for the V regions were previously unknown and, thus, the genes were obtained by 
reverse-transcription polymerase chain reaction (RT-PCR).  Subsequently, the PCR 
product for each of these genes was cloned into a vector and the resulting plasmid was 
submitted for DNA sequencing.  Upon obtaining the complete DNA sequences for the V 
regions, the amino acid sequences of the V regions were determined for the purpose of 
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constructing a three-dimensional (3D) molecular model of the variable fragment (Fv) of 
the 7C7:C5 MAb.  The 3D model of the 7C7:C5 Fv was then used to predict the 
interactions involved in the binding of the 7C7:C5 MAb to d6mA in DNA.  Analyses of 
docking experiments with the molecular model were used to better understand the 
specificity of the 7C7:C5 MAb for d6mA and its future usability in DNA and potentially 
RNA genotyping.  Lastly, its potential usage as a carrier of DNA and RNA is also 
discussed. 
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MATERIALS AND METHODS 
 
Obtaining the 7C7:C5 MAb 
 Hybridoma cells of the 7C7:C5 cell line that produce the anti-6mAos MAb were 
grown on RPMI cell medium/20% fetal calf serum (FCS) for two to three weeks in a 
37°C CO2 incubator.  The cells were pelleted by centrifuging at 1,000 x g for ten minutes.  
The supernatant containing the 7C7:C5 MAb was extracted and placed in several 15 mL 
sterile tubes.  The supernatant was stored at -20°C for later use. 
 
Transformation and Growth of Escherichia coli with pUC-18 or pUC-19 Plasmid 
Luria-Bertani (LB) agar broth was made using 12.5 g of LB broth and 7.5 g of 
agar diluted to 500 mL with distilled water.  The LB agar broth was autoclaved and 
trihydrate ampicillin (Sigma) was added to make a final composition of 50 µg/mL of 
ampicillin in LB agar broth when the broth reached 45-50°C.  The solution was 
homogenized by mixing.  The LB agar broth with ampicillin (LBA) was poured onto 
Petri plates, using asceptic technique.  The LBA medium was allowed to solidify 
overnight (~16 hours).  LB plates without ampicillin were made using the same methods, 
excluding the addition of ampicillin.  The plates were inverted and stored at 0-4°C until 
needed.  
Transformation was performed using One Shot TOP10 Chemically Competent 
E.coli (Invitrogen).  Two vials of frozen TOP10 E.coli cells (Invitrogen) were obtained.  
After thawing the vials in ice, 5 µL of 10 pg/µL of pUC-19 in 5 mM Tris-HCl, 5 mM 
EDTA, pH 8, was added to one of the vials.  Both vials were kept in ice for thirty 
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minutes.  The vials were incubated at 43°C in a dry bath with mineral oil.  The vials were 
then placed in ice for two minutes.  To culture the E.coli, 250 µL of SOC medium 
(Invitrogen) was added to each vial.  The vials were then incubated at 37°C for thirty 
minutes in a warm room.  Following the incubation, 50 µL of culture from the vial 
containing TOP10 E.coli with pUC-19 was plated onto an LBA plate and a LB plate.  
Also, 50 µL from the vial containing TOP10 E.coli without pUC-19 was plated onto an 
LBA plate and a LB plate as a negative control to ensure that the E.coli or the medium 
were not faulty.  The plates were incubated overnight (~18 hours) at 32°C.  The plates 
were inverted and stored at 0-4°C until isolation of pUC-19 from transformed E.coli. 
 
Isolation of Plasmid for Blotting Methods 
(1) Lab bench miniprep 101, (2) Fast Plasmid Mini (Eppendorf), and (3) PureYield 
Midiprep System (Promega) were used to obtain pUC-18 or pUC-19 plasmid.  In cases in 
which the concentration of DNA or purity of DNA was too low, a 
phenol/chloroform/isoamyl alcohol extraction of proteins and precipitation of DNA with  
0.3 M sodium acetate and two volumes of 95% ethanol at -80°C for 2.5 hours or at -20°C 
overnight was performed 101.  Approximate DNA concentrations were determined by 
ultraviolet (UV) spectrophotometry, based on a concentration of 50 µg/mL of DNA 
having an absorbance of 1.000 at 260 nm.  Purity of DNA was also determined by 
calculating a ratio of absorbance at 260 nm/absorbance at 280 nm.  A ratio of 1.8-2.0 was 
considered good purity, with 1.8 being the best purity 101. 
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Methylation of Plasmid DNA with EcoRI Methylase 
EcoRI methylase, 32 mM (400X) S-adenosylmethionine, and 10X NE EcoRI 
methylase buffer were purchased from New England Biolabs.  Final composition of the 
methylation solution/mix included 1X NE EcoRI Methylase Buffer (50 mM NaCl, 50 
mM Tris-HCl, 10 mM EDTA, pH 8.0 at 25°C), at least 1 µg of unmethylated DNA, 800 
µM SAM, and 40 U of EcoRI Methylase in storage solution (200 mM NaCl, 100 mM 
KPO4, pH 7.4, 0.1 mM EDTA, 10 mM BME, 200 µg/mL BSA, and 50% glycerol).  The 
final composition was attained by diluting DNA methylation solution with autoclaved 
distilled water to an appropriate final volume.  The DNA methylation solution was 
incubated at 37°C in a water bath for one hour and fifteen minutes.   
A protection assay was performed to determine the extent of methylation.  Two 
DNA samples (one is presumed to be methylated and the other is unmethylated) of equal 
volume and concentration were treated with EcoRI restriction endonuclease (RE).  The 
final composite for the EcoRI RE solution/mix was at least 1 µg of DNA (methylated or 
unmethylated), 1X Buffer Y+/Tango with BSA, and 5 U of EcoRI RE.  The final 
composition was attained by diluting DNA methylation solution with autoclaved distilled 
water to an appropriate final volume.  The EcoRI RE solutions/mixes were incubated at 
37°C in a water bath for thirty-five minutes.  Untreated (unmethylated and undigested) 
DNA was used as a negative control.  To view band movement, 2 µL of bromophenol 
blue 6x loading dye was added to 10 µL of each DNA sample.  Each sample was mixed 
and loaded onto different lanes on a 1% agarose gel (containing ≥0.1 µg/mL of ethidium 
bromide).  Samples underwent gel electrophoresis at 72 V.  Results of the protection 
assay were analyzed by the appearance of bands upon short wavelength UV exposure. 
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Dot Blot 
The general procedure for dot blots was designed based on methods previously 
described 26.  Adjustments to the protocol for dot blots were made in communication with 
Lopez, O.J. 
A solution of 1X phosphate buffered saline (PBS), pH 7.5, was prepared from a 
1:10 dilution of 10X PBS (1.5 M NaCl, 0.16 M of Na2HPO4, and 0.04 M of NaH2PO4; 
pH was adjusted using 10 M NaOH), pH 6.9-7.0.  A solution of 10% nonfat milk in 1X 
PBS, pH 6.65, was prepared from 1 g of Sanalac nonfat dry milk diluted to 10 mL with 
1X PBS, pH7.5.  Suitable sizes of polyvinylidene difluoride (PVDF) membranes were cut 
for each dot blot and transferred to Petri plates, in which they fit securely.  Tweezers 
were used to move and transfer the membrane.  Three edges of the membrane were cut 
for orientation.  Circles were drawn in pencil to show where to distribute each dilution of 
DNA.   
Separate rows or columns of circles were made for methylated and unmethylated 
DNA.  Each DNA (methylated or unmethylated) dilution was prepared in TE (10 mM 
Tris, 1 mM EDTA), pH 8.2, in 1.5 mL polypropylene tubes.  DNA dilutions were then 
heated in a water bath at 95°C for five minutes to denature the DNA.  Immediately after 
heating DNA dilutions were put on ice for two minutes to prevent renaturation.  DNA 
dilutions were centrifuged for five seconds in a tabletop centrifuge to collect all liquid to 
the bottom.  An aliquot of 10 µL of each dilution of DNA was pipetted onto a PVDF 
membrane.  The DNA dots were allowed to air dry at 21-37°C for a minimum of two 
hours.  After DNA dots appeared visibly dried and immobilized on the membrane, DNA 
was fixed to the PVDF membrane by exposure to UV irradiation for two minutes.  The 
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membrane was then inverted and immersed in milk blocking solution (10% nonfat milk 
in 1X PBS, pH 6.65).  The membrane was incubated in milk blocking solution overnight 
(15-18 hours) at 0-4°C. 
The milk blocking solution was discarded and the membrane was washed five 
times with 1X PBS, pH 7.5.  The 7C7:C5 monoclonal antibody (MAb) in RPMI/10% 
FCS was thawed.  The membrane was inverted and immersed in 1.5 mL of 7C7:C5 MAb 
solution and then incubated at room temperature for one hour and fifteen minutes with 
rotating movement.  This period of incubation allows for sufficient binding of 7C7:C5 
MAbs to DNA that has been fixed to the membrane.  The 7C7:C5 MAb solution was 
discarded after incubation and the membrane was washed five times with 1X PBS, pH 
7.5. 
A vial containing 0.1 mg of lyophilized goat polyclonal anti-mouse IgG 
conjugated to alkaline phosphatase (amIgG-AP)/goat serum or bovine serum albumin 
(BSA) (KPL) was dissolved in 50% glycerol (0.5 mL of nuclease-free water and 0.5 mL 
of glycerol) before its use.  Next, 3 µL of the amIgG-AP was mixed with 1.47 mL of milk 
block solution, pH 6.65, to make a 1/500 dilution of the amIgG-AP.  The membrane was 
inverted and immersed in 1/500 amIgG-AP solution and then incubated at room 
temperature for one hour and fifteen minutes with rotating movement.  This period of 
incubation allows for sufficient binding of the amIgG-APs to 7C7:C5 mAbs. 
After incubation, the 1/500 amIgG-AP solution was discarded and the membrane 
was washed five times with 1X PBS, pH 7.5.  The membrane was inverted and immersed 
in 1.5 mL of 0.21 g/L of 5-Bromo-4-chloro-3-indoyl-phosphate/0.42 g/L of nitroblue 
tetrazolium (BCIP/NBT) phosphatase substrate (1-Component) (KPL) in an organic 
  24
base/Tris buffer.  The membrane was incubated in substrate for twenty-five minutes at 
room temperature with rotating movement.  This period of incubation allows for 
sufficient reaction time for alkaline phosphatases to catalytically remove phosphate 
groups from the BCIP/NBT substrates causing the BCIP/NBT solution to change from 
yellow/greenish-yellow to purple in places where a reaction occurred.  The substrate was 
discarded after incubation.  The membrane was inverted and immersed in autoclaved 
distilled water for 20-30 seconds to halt any remaining reactions.  The membrane was 
allowed to air dry overnight in the dark and stored in the dark to prevent stain from 
fading. 
 
Slot Blot 
SSC powder (43.825 g of NaCl and 22.05 g of sodium citrate) (Vysis) was diluted 
to 250 mL in distilled water to make 20X SSC, pH 7.6.   A solution of 2X SSC was 
prepared by a 1:10 dilution of 20 X SSC, pH 7.6, in distilled water.  Essentially the same 
protocol was performed for the slot blot as was done for the dot blot, with the following 
exceptions:  (1) Schleicher & Schuell (S&S) nitrocellulose membrane was used in place 
of PVDF membrane, (2) membrane sizes had to be larger to accommodate the wider 
areas of slits versus dots, (3) little pencil markings rather than circles indicated the 
approximate location for the start of each slit, (4) 10 µL of each DNA dilution in TE was 
diluted to 500 µL in 2X SSC, (4) the S&S Minifold I Slot-Blot Filtration Manifold (in 
place of air drying) was used to immobilize the DNA samples onto the nitrocellulose 
membrane using the procedure described in the instruction manuals for the apparatus, (5) 
DNA was fixed to the nitrocellulose membrane while still damp by using the auto-cross-
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linking (exposure to 1,200 J of UV at 254 nm for approximately thirty seconds) function 
on the 1800 Stratalinker UV Crosslinker (Stratagene) and (6) larger amounts of 7C7:C5 
MAb solution, 1/500 amIgG solution, and BCIP/NBT phosphatase substrate (1-
Component) were used due to larger membrane sizes 
Generally the slot blot membranes were at least twice as large, so 2-5 mL of each 
of the antibody solutions and 2-5 mL of substrate worked well.  In the case of the 
optimized slot blot, the membrane was inverted onto a Kodak DS UV Camera and a 
picture of the membrane was taken by shining UV light through the membrane.  Band 
intensities were determined for all bands that appeared visible using Kodak DS UV 
Software.  Band intensities were determined for equal areas from the left center to the 
middle center of each band, so as to avoid measuring any pencil markings and to make 
band intensity (not band intensity and area) the variable that was measured.  The general 
scheme behind the slot blot is shown in Figure 3. 
 
 
Figure 3.  Slot blot schematic. 
d6mA 
Denatured DNA 
Anti-d6mA MAb 
Goat Anti-mouse IgG 
Antibodies conjugated to 
Alkaline Phosphatase 
Covalent Bond 
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Total RNA Isolation 
For total RNA isolation, a customized version of the TRIzol method was used.  
TRIzol Reagent (Invitrogen), a monophasic solution containing phenol and guanidine 
isothiocyanate, is an improved version of the solution used by Chomczynski and Sacchi 
for the “Single-Step Method of RNA Isolation” 102.  Chomczynski and Sacchi used 4 M 
guanidine isothiocyanate, 25 mM sodium citrate, pH 7, 0.5% sarcosyl, 0.1 M 2-
mercaptoethanol mixed sequentially with 0.1 mL of 2 M sodium acetate, pH 4, 1 mL of 
phenol saturated with water, and 0.2 mL of chloroform-isoamyl alcohol mixture (49:1) 
for the isolation of total RNA.  A modified form of the single-step method for the 
isolation of total RNA was used according to the instruction manual for TRIzol 
(Invitrogen) along with some additional modifications not included in the manual for 
TRIzol. 
7C7:C5 Hybridoma cells were originally grown in RPMI 1640/10% FCS and 
cells/mL of medium were counted under a microscope.  These hybridoma cells were 
stored in RPMI 1640/10% FCS/8% dimethylsulfoxide (DMSO) in a cryotube at greater 
than -70°C.  Each cryotube contained at least 2 x 106 cells but no more than 5 x 106 cells.  
The cells were thawed on ice and then immediately the 1 mL of cells in the cryotube was 
added by sterile pipet to 9 mL of 1X PBS, pH 7, in a sterile 15 mL plastic centrifuge tube.  
The cells were pelleted by centrifugation at 1,500 x g for five minutes and supernatant 
was carefully removed and discarded.  Cell pellets were resuspended in 1mL of 1X PBS, 
pH 7, by gentle vortexing, so as to not break the cells.  The cells in PBS were transferred 
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via pipet to a sterile 1.5 mL Eppendorf tube and the cells were pelleted by centrifugation 
at 8,000 x g. 
The cells were lysed by adding 1 mL of TRIzol Reagent.   The cell pellet was 
rigorously vortexed for two to three minutes to completely breakdown the pellet and 
homogenize the cell contents throughout the TRIzol.  After vortexing, the cell contents 
were incubated in TRIzol for five minutes at room temperature to allow for nucleoprotein 
complexes to completely dissociate.  The RNA was protected from ribonuclease activity 
by the presence of 4M/concentrated guanidine during this incubation 102.  To separate the 
organic phase and the aqueous phase, 0.2 volumes of chloroform was added to the 
TRIzol/RNA supernatant and mixed vigorously.  Three minutes of incubation at room 
temperature allowed for separation of phases.  To completely separate the phases, the 
RNA isolation mix was centrifuged (11,000 x g) for 20 minutes at 4°C.  Cell contents 
were dispersed into three separate layers in TRIzol.  The top layer is the aqueous phase 
and contains all the RNA; the middle layer is the interphase and contains both DNA and 
proteins; and the bottom layer is the red, phenol-choroform phase and contains both DNA 
and proteins. 
After transferring the aqueous phase to a new 1.5 mL tube, 100 µL of 3M sodium 
acetate, pH 5.2, 30 µL of RNA-grade glycogen, and 870 µL of isopropyl alcohol was 
added to the aqueous phase to precipitate the RNA.  The use of glycogen in the 
precipitation of RNA was found to be unnecessary, but the use of 3M sodium acetate 
resulted in greater yields of RNA.  Following a ten minute period of incubation at room 
temperature, the RNA precipitation mix was placed at -20°C for a minimum of ninety 
minutes.  The precipitated RNA was then centrifuged (11,000 x g) at 4°C for a total of 
  28
thirty-five minutes.  The RNA generally formed a barely noticeable gel-like pellet along 
the bottom of the microfuge tube.  The supernatant was carefully removed by decantation 
so as not to disturb the pellet.  The pellet was washed (without resuspension) in 1 mL of 
70% ethanol.  The RNA wash was centrifuged at 4°C for fifteen minutes at 6,000 x g.  
The supernatant was carefully removed by decantation.  Centrifugation for a few seconds 
was used to collect any remaining supernatant followed by supernatant removal by pipet.  
The pellet was air dried for seven minutes.  The pellet was then resuspended in 15-25 µL 
of nuclease-free water. 
An aliquot of 5 µL of RNA in nuclease-free water (with 1 µL of 6X bromophenol 
blue loading dye added to it) was electrophoresed at 72 V for forty minutes on a freshly 
made 1% agarose gel, 0.1 µg/mL ethidium bromide in autoclaved 1X TAE.  Gels for 
RNA gel electrophoresis were all prepared using clean, autoclaved glassware and 
equipment.  The gel electrophroresis apparatus was cleaned with 10% bleach and 
autoclaved DI water to help prevent/limit nuclease contamination.  The results of gel 
electrophoresis were analyzed under UV light.   
Bands of high molecular weight (7-15 kb) RNA may appear.  These bands are for 
mRNA and heterogeneous nuclear RNA (hnRNA).  Two predominant bands (an 18S 
band, approximately 2 kb, and a 28S band, approximately 5 kb) of ribosomal RNA 
(rRNA) should appear.  The 28S band should be brighter.  The 18S band may also be 
comprised of a relatively small portion of mRNA due to the association of some mRNA 
activity with the 18S region 103.  Also, a 12S region of RNA from rabbit globin was found 
to present some mRNA activity.  Nevertheless, the major portion of biologically 
active/poly(A)-containing mRNA occurs as 9S RNA; however, a 9S band does not 
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generally appear on the gel due to the low amounts of poly(A)-containing mRNA in total 
RNA 103-104.  The only RNA bands that appeared in all of the RNA isolation experiments 
using TRIzol method were the 28S and 18S bands and a high molecular weight band 
attributed to DNA contamination from the cells. 
 
Reverse Transcription Polymerase Chain Reaction (RT-PCR) of the 7C7:C5 Vκ and 
VH Genes 
 
Reverse transcription polymerase chain reaction (RT-PCR) was used to produce 
complementary, copy DNA (cDNA) and then amplify cDNA.   Reverse transcription 
polymerase chain reaction is comprised of two main processes:  (1) cDNA synthesis and 
(2) cDNA amplification.  The gene specific 3’-forward (reverse and complement to    
5’→ 3’ template) primers listed in Table 2 were used to produce cDNA of the variable 
part of the light chain gene, excluding most of the Cκ, and cDNA of the variable part of 
the Fd of the heavy chain gene, excluding most of the CΗ1, by reverse transcription. 
The light chain cDNA produced includes the genetic sequence of part to all of the 
leader sequence of the kappa light chain (Lκ), the variable sequence for the variable 
region of the kappa light chain (Vκ), the joining sequence for the variable region of the 
kappa light chain (Jκ), and nucleotides 57-22 of the constant sequence of the kappa light 
chain (Cκ).  The heavy chain cDNA produced includes the genetic sequence of part to all 
of the leader sequence of the gamma 1 heavy chain (LΗ), the variable sequence for the 
variable region of the gamma 1 heavy chain (VΗ), the diversity sequence for the variable 
region of the gamma 1 heavy chain (D), the joining sequence for the variable region of 
  30
the gamma 1 heavy chain (JΗ), and nucleotides 51-16 of the constant region 1 of the 
gamma 1 heavy chain (CΗ1). 
The amount of cDNA was amplified using polymerase chain reaction (PCR) 105.  
In addition to increasing the amount of cDNA, the amplification process converts the 
single-stranded cDNA produced by RT into double-stranded cDNA (a more stable form 
of cDNA).  The amplification of cDNA requires the use of 5’-reverse (identical to 5’→3’ 
template) primers and 3’-forward primers.  The setup used for cDNA synthesis is shown 
in Figure 4 and the setup used for cDNA amplification is shown in Figure 5.   
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JΗ VΗ D CΗ1 
CΗ1 JΗ D VΗ 
Jκ Cκ Vκ 
Cκ Jκ Vκ 
Jκ Cκ Vκ 
JΗ CΗ1 VΗ D 
 
                                (a) cDNA Synthesis of the Vκ 
 
mRNA of the IgG1 Kappa Chain 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                     
 
 
 
                                (b) cDNA Synthesis of the VΗ 
 
mRNA of the IgG1 Fd Region of the Heavy Chain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  General design for cDNA synthesis of genes that code for the (a) Vκ and (b) VΗ 
(Lopez, O.J. [communication], 2005). 
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CΗ1 JΗ D VΗ 
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Cκ Jκ Vκ 
Cκ Jκ Vκ 
Cκ Jκ Vκ 
 
 
                                (a) PCR of the Vκ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                   (b) PCR of the VΗ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.  General design for amplification of the (a) Vκ and (b) VΗ genes (Lopez, 
O.J. [communication], 2005). 
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The primers that were used for the synthesis of cDNA are listed in Table 2 and the 
primers that were used for amplification of cDNA are listed in Table 3.  The 3’-primers 
listed in Table 2 were designed to be reverse and complement for hybridization at 
nucleotides 57-22 of the murine Cκ chain and at nucleotides 51-16 of the murine CH1.  
All MLALT and MHALT 5’-primers listed in Table 3 were designed for the murine 
kappa and gamma 1 chain leader sequences, respectively.  MLALT1-3 contain 
nucleotides for ribosome binding sites (CACC and ACC) in bold.  The 3’-primers 
(CkFORa and Cg1FORa) were designed to be reverse and complement to nucleotides 30-
10 of the Cκ and nucleotides 24-4 of the CΗ1, respectively.  The VH 5’-primers were 
designed for the amino terminus of the VΗ.  All APg1 5’-primers were designed for the 
murine gamma 1 chain leader sequences.  AVg1 5’-primer was designed for the amino 
terminus of the VΗ.  ACg1AF 3’-primer was designed to be reverse and complement to 
nucleotides 18-1 of the CΗ1 and nucleotides 1-6 of the carboxyl terminus of the VΗ.  
ACg1AF 3’-primer was never used because Cg1FORa worked fine for amplification of 
the 7C7:C5 VΗ gene. 
 
Table 2.  Primers for synthesis of cDNA 
 
Light Chain Heavy Chain 
3’-primers  3’-primers  
 
Cka 
 
 
MCκASa 
 
 
 
5’- TGTTAACTGCTCACTGGA -3’ 
 
 
5’- TGGTGGGAAGATGGATAC -3’ 
 
Cg1a 
 
 
MgC.CH1ASa 
 
5’- GGCAGCAGAGCCAGGGGC -3’ 
 
 
5’- CAGTGGATAGACAGATGG -3’ 
 
* The listed 3’-primers are partially derived from 3’-primers previously used for cDNA synthesis 
of variable regions 106.  All primers were synthesized by IDT DNA. 
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Table 3.  Primers for amplification of Vκ and VΗ genes 
 
Light Chain 
 
 
Heavy Chain 
 
5’-primers 
 
 
5’-primer sequences 
 
5’-primers 
 
 5’ primer sequences 
 
MLALT1.RV 
MLALT2.RV 
MLALT3.RV 
MLALT4.RV 
MLALT5.RV 
MLALT6.RV 
 
 
5’-ACCATGGAGACAGACACACTCCTGCTAT-3’ 
5’- ACCATGGATTTTCAAGTGCAGATTTTCAG-3’ 
5’-ATGRAGTCACAKACYCAGGTCTTYRTA-3’ 
5’-CACCATGKCCCCWRCTCAGYTYCTKGT-3’ 
5’-ATGAAGTTGCCTGTTAGGCTGTTG-3’ 
5’-ATGATGAGTCCTGCCCAGTTC-3’ 
 
MHALT1.RV 
MHALT2.RV 
MHALT3.RV 
MHALT4.RV 
 
VH1.RV 
VH2. RV 
VH3.RV 
VH4.RV 
 
APg1XM.RV  
APg1KEA.RV 
APg1AMU.RV 
APg1AZ.RV 
APg1AM.RV 
AVg1XM.RV 
 
5’-ATGGRATGSAGCTGKGTMATSCTCTT-3’ 
5’-ATGRACTTCGGGYTGAGCTKGGTTTT-3’ 
5’-ATGGCTGTCTTGGGGCTGCTCTTCT-3’ 
5’-ATGGRCAGRCTTACWTYY-3’ 
 
5’-TGAGGTGCAGCTGGAGSAGTC-3’ 
5’-TGAGGTGCAGCTGGAGSAGAC-3’ 
5’-TGAGGTGCAGCTGGAGSAATC-3’ 
5’- TGAGGTGCAGCTGGAGSAAAC-3’ 
 
5’-AGCTGGTMTTTYTCTTCCT-3’             
5’-GCTCAGCTTGATTTWCCTTG-3’                 
5’-ATGYCTGTYWKTCCCAAGYT-3’          
5’-TGYTRTWCCTGWTGGRCAGC-3’            
5’-TKGACAGSCWTWCYT -3’               
5’-CAGRTYARCTGCAGCARTCTGG-3’                      
 
3’-primer 
 
 
3’-primer sequence 
 
3’-primers 
 
3’-primer sequence 
 
CkFORa 
 
 
5’- GATGGATACAGTTGGTGCAGC-3’ 
 
Cg1FORa 
 
ACg1AF.FR 
 
5’- GACAGATGGGGGTGTCGTTTT -3’ 
 
5’-TGGGGGTGTCGTTTTGGCTGA-3’  
            
 
* All MLALT and MHALT 5’-primers were partially derived from 5’-primers previously used 
for cDNA amplification of IgG variable regions 106-107.  MLALT4 contains a ribosome binding 
site (CACC) and MLALT1-2 contain partial ribosome binding sites (ACC) in bold.  All VH 5’-
primers were supplied by Lopez, O.J.  The CkFORa and Cg1FORa 3’-primers were derived from 
3’-primers previously used for cDNA amplification of IgG variable regions 108.  All A series 
primers (APg1, AVg1, and ACg1 primers) were designed by Nimani, A., based on known murine 
gamma 1chain leader sequences.  The names of the primers that successfully amplified the 
7C7:C5 Vκ and VH genes are underlined.  All primers were synthesized by IDT DNA.  IUB 
symbol and corresponding degeneracies are R = (A, G), Y = (C, T), M = (A, C), K = (G, T), S = 
(C, G), and W = (A, T). 
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Only reverse primers with the appropriate complementary sequences annealed 
with the 5’ leader sequences (sequences that code for the signal peptide in the immature 
antibody) of mRNA that codes for the 7C7:C5 MAb.  Primers for the leader sequences 
were chosen in place of primers for the start of the Vκ or VΗ sequences because 
amplifying from the leader sequence prevents the loss or alteration of sequences that code 
for the amino terminus of the variable region.  In the case of amplification of the VΗ, 
reverse 5’-primers for the amino terminus (VH series) were also used in PCR reactions to 
attempt to amplify the 7C7:C5 VΗ gene because none of the MHALT series of reverse 5’-
primers for the leader sequence resulted in successful amplification of the 7C7:C5 VΗ 
gene after repeated attempts. 
Unfortunately, none of the VH series of primers successfully amplified the 
7C7:C5 VΗ gene after repeated attempts.  As a result, I designed the A (APg1, AVg1, and 
ACg1) series of primers for amplification of murine gamma 1 variable regions.  The 
APg1 primers were designed based on existing leader sequences found on Genbank.  
These leader sequences were collected into groups based on sequence similarities 
allowing for one primer to be developed for a small group of similar leader sequences.  
Degeneracies were placed in areas of each primer that seemed appropriate, so as to 
increase the efficiency of annealing the primer with leader sequences of high diversity.   
The 3’-primer for amplification of the Vκ hybridizes to nucleotides 30-10 and the 3’-
primer for amplification of the VΗ hybridizes to nucleotides 24-4. 
Copy DNA synthesis of the Vκ and VH genes was performed using Moloney 
murine leukemia virus (M-MuLV) reverse transcriptase (RT) (Fermentas), according to 
the protocol in the product description for M-MuLV RT.  Moloney murine leukemia 
  36
virus RT has the ability to use either RNA or DNA primers and RNA or single-stranded 
DNA templates for cDNA synthesis, although greater cDNA yield occurs with an RNA 
template 109-110.  It has inherent ribonuclease H activity which selectively degrades RNA 
in RNA-DNA hybrids, but does not degrade ssRNA, ssDNA, dsRNA, or dsDNA 109, 111-
112
.   
A nuclease-free 1.5 mL Eppendorf tube was kept on ice and the following 
solutions—10 µL of total RNA in nuclease-free water from TRIzol extraction and 0.65 
µL of each 10 µM 3’-primer for the kappa chain or the gamma 1 chain from Table 2—
were added sequentially to the tube.  The tube was heated at 70°C for six minutes and 
then chilled on ice for two minutes to anneal the primers.  The following solutions were 
added sequentially to the tube:  4 µL of 5X  Reaction Buffer, 2 µL of 10 mM 
deoxynucleotide triphosphate (dNTP) mix, and 0.7 µL of 40 U/µL Ribolock 
Ribonuclease Inhibitor (Fermentas) to inhibit ribonuclease A, B, and C activity.  The tube 
was incubated at 37°C for five minutes.  Then, 2 µL of 20 U/µL M-MuLV RT 
(Fermentas) was added to the tube to make a final solution containing 20 µL total. 
The final contents of the cDNA synthesis solution were total RNA (unknown 
concentration), one set (κ or H chain) of  325 nM 3’-primers listed in Table 2, 1X 
Reaction Buffer, 1 mM dNTP, 1 U/µL Ribolock Ribonuclease Inhibitor, and 2 U/µL M-
MuLV RT.  The cDNA synthesis reaction mix was incubated at 70°C for ten minutes to 
allow for cDNA synthesis to occur.  After incubation, the reaction mix was chilled on ice 
for two minutes to halt the reaction and conclude cDNA synthesis.    
TrueStart Taq Polymerase (Fermentas) is a recombinant Taq DNA polymerase 
(TaqPol) with heat-labile blocking groups that have been chemically joined to amino 
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acids in the polymerase.  These thermolabile inhibitors/switches allow for a “hot start” 
PCR, which prevents nonspecific amplification of fragments such as “primer dimer” 
artifacts by keeping the polymerase inactive until the initial denaturation at 95°C 113-116.  
TrueStart TaqPol has been shown to produce significantly higher PCR yields and 
specificity over Taq DNA polymerase (Fermentas). 
Methods used for the polymerase chain reaction essentially followed the protocol 
outlined in the product description for TrueStart TaqPol from Fermentas.  Volumes and 
amounts listed below are for single PCR reactions and are typically scaled according to 
the number of PCR reactions performed, in which as many PCR reagents and materials as 
possible were fit in one homogenized mix before dispersing the mix evenly into 
individual PCR tubes.  The following ingredients were added to each nuclease-free PCR 
tube in sequential order:  10X TrueStart Taq Buffer, 10 mM dNTP mix, 25 mM MgCl2, 
10 µM of gene-specific 5’-reverse primer for the Lκ or LΗ listed in Table 3, 10 µM gene-
specific 3’-forward primer for the 5’ end of the Cκ or CΗ1, and 2.5-5 µL of cDNA 
template, and 2.5 U of TrueStart TaqPol.  The contents were diluted in the PCR tube to 
50 µL with DEPC-treated water to make a final solution containing 1X TrueStart Taq 
Buffer, 0.2 mM dNTP mix, 2.5 mM MgCl2, 100 nM mix of gene-specific 5’-reverse 
primers, 100 nM gene-specific 3’-forward primer, and 0.05 U/µL of TrueStart TaqPol.  
The contents were mixed and centrifuged for a few seconds.  The contents of each PCR 
tube were then overlayed with 100 µL of mineral oil to help heat contents more evenly 
and prevent evaporation. 
The cDNA amplification process was set for thirty-five cycles in a DNA 
Thermocycler 480 (Perkin Elmer Cetus).  Following a single cycle initial denaturation at 
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95°C for ninety seconds, the cDNA was incubated at the following temperatures and 
corresponding durations per cycle for thirty-five cycles:  94°C for one minute to denature 
DNA, 55°C for one minute to anneal primers, and 70°C for thirty seconds to extend 
primer sequence into a cDNA sequence.  After the thirty-five cycles of amplification, the 
cDNA was incubated at 72°C for fifteen minutes to allow for final extension.  A 10 µL 
aliquot of the cDNA product (with 2 µL of 6X orange G loading dye added to the aliquot 
and mixed) was loaded on a 1% agarose, ≥0.1 µg/mL ethidium bromide gel.  
O'RangeRuler™ 100 + 500 bp DNA Ladder (Fermentas) was loaded onto the gel to 
measure an approximate size of the PCR product.  Gels were generally electrophoresed at 
59 V for seventy minutes.  The results were analyzed by exposure of the gel to UV. 
The main PCR product obtained using the primers CkFORa and MLALT2.RV 
was double-stranded cDNA for the Lκ-Vκ-Jκ-Cκ”gene displayed in Figure 5(a).  The PCR 
product for the Lκ-Vκ -Jκ-Cκ” should be 400-450 bp 36, 42-43, 117.  The main PCR product 
obtained using the primers Cg1FORa and APg1AZ.RV was double-stranded cDNA for 
the LΗ-VΗ-D-JΗ-CΗ” gene displayed in Figure 5(b).  The PCR product for the LΗ-VΗ-D-
JΗ-CΗ” should be 425-475 bp 36, 42-43, 117.  Analysis of cDNA products were performed 
under UV exposure.  The entire RT-PCR procedure was performed separately for the Lκ-
Vκ -Jκ-Cκ” and LΗ-VΗ-D-JΗ-CΗ” genes using primers corresponding to the appropriate 
chain listed in Tables 2 and 3. 
Unfortunately, a naturally occurring aberrant kappa chain, or non-expressing 
kappa chain, is transcribed along with the functional kappa chain in hybridomas 118-119.  
Of particular interest is the aberrant kappa chain derived from SP2/0 MOPC21 myeloma 
cells.  This strain of myeloma cells was used in the fusion process for generating the 
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7C7:C5 hybridoma and, thus, are responsible for the production of the aberrant kappa 
chain by the 7C7:C5 hybridoma.  In order to eliminate the possibility of the 7C7:C5 Vκ 
PCR product being part of the aberrant kappa chain gene, the 7C7:C5 Vκ PCR product 
was digested with KpnI RE.  Many Vκ sequences contain KpnI sites, however, the SP2/0 
MOPC21 aberrant kappa chain does not have a KpnI site in its variable gene.  Digestions 
with KpnI RE were performed as follows:  8 µL of PCR product was mixed with 10 U of 
KpnI RE and a final 1X Tango/Y+ buffer in a 1.5 mL tube.  The tube was then incubated 
in a 37°C water bath for seventy minutes.  Results were analyzed by standard gel 
electrophoresis. 
 
Cloning of the 7C7:C5 Vκ and VH Genes into Plasmids 
The cloning process can be broken into three parts:  the cloning reaction, the 
transformation, and the isolation and analysis of the plasmid.  The PCR products for the 
7C7:C5 Vκ and VΗ were cloned into separate pJET1/blunt Cloning Vectors using the 
GeneJET PCR Cloning Kit (Fermentas).  The pJet1/blunt vector contains a toxic gene to 
E.coli.  However, upon receiving an insert, this toxic gene is split up and E.coli can 
survive with that plasmid.  As a result, the pJet1/blunt vector is a positive selection vector 
(a vector that only replicates in E.coli if it contains an insert). 
For each cloning reaction the following solutions were added to a nuclease-free 
PCR tube:  2X Reaction Buffer, 2 µL of PCR product (non-purified), 5 µL of nuclease-
free water, and 1 µL of DNA Blunting Enzyme.  The contents of this PCR tube were 
mixed by vortexing briefly and centrifuging for a few seconds.  The mixture was 
incubated at 70°C for five minutes to allow for a blunting reaction of the PCR product 
  40
and then chilled on ice for one minute to halt the blunting reaction.  The following 
solutions were added to the blunting mix:  50 ng of pJET1/blunt Cloning Vector and 5 U 
of T4 DNA Ligase. 
The final ligation solution contained 1X Reaction Buffer, 1:10 dilution of PCR 
product, DNA Blunting Enzyme, 2.5 ng/µL pJET1/blunt Cloning Vector, and 0.25 U/µL 
of T4 DNA Ligase.  The contents of this PCR tube were vortexed briefly and centrifuged 
for a few seconds to mix.  The ligation solution was incubated at room temperature 
(22°C) for eight minutes.  The PCR tube containing the ligation reaction was placed on 
ice for two minutes to halt the reaction. The pJET1 Vector inserted the PCR product 
between nucleotides 498-497 of the vector.  The known sequence of the pJET1 Vector 
now included the sequence of the unknown Lκ-Vκ -Jκ-Cκ” or LΗ-VΗ-D-JΗ-CΗ” gene of the 
7C7:C5 MAb, depending on which PCR product insert was used in that particular cloning 
reaction. 
 
Transformation and Growth of E.coli with Plasmids Containing the 7C7:C5 Vκ and 
VH Genes 
 
The vectors with the Lκ-Vκ -Jκ-Cκ” or LΗ-VΗ-D-JΗ-CΗ” inserts were then used to 
transform competent E.coli cells to allow for selection, amplification, and isolation of the 
plasmid later on.  Competent E.coli cells were prepared using TransformAid Bacterial 
Transformation Kit (Fermentas).  Untransformed JM109 E.coli cells were grown on a 
sterile LB plate at 37°C for sixteen hours the night before transformation to have fresh 
colonies ready for the transformation process.  A single colony of JM109 E.coli was 
selected and grown in 1.5 mL of C-Medium in a 25 mL sterile glass test tube at 205 rpm 
in a 37°C warm room for 3-3.5 hours.  The transformation solution was prepared by 
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mixing 250 µL of T-Solution A with 250 µL of T-Solution B.  The resulting T-Solution 
mix was kept on ice until use. 
The culture of JM109 E.coli was transferred to a sterile 1.5 mL Eppendorf tube.  
The culture of JM109 E.coli was centrifuged at 13,200 x g for one minute at room 
temperature.  Supernatant was discarded and the cell pellet was resuspended in 300 µL of 
T-Solution mix immediately followed by incubation on ice for five minutes.  The cell 
suspension was centrifuged at 13,200 x g for one minute at room temperature.  
Supernatant was discarded and the cell pellet was resuspended in 200 µL of T-Solution 
mix.   The resupension was immediately followed by incubation on ice for five minutes. 
For the transformation, a 10 µL aliquot of vector product was added to 100 µL of 
cell suspension in T-Solution mix in a 1.5 mL Eppendorf tube.  The contents (110 µL of 
transformation mix) in the tube were gently mixed and the tube was incubated on ice for 
five minutes.  The newly transformed JM109 were then spread across a prewarmed LB 
plate containing 50 µg/mL of ampicillin.  The plate was incubated overnight for sixteen 
hours at 37°C.  In addition to the 7C7:C5 transformation mix, generally, 55 µL of 
transformation mix was prepared with the pJet1/blunt vector containing (+)-control PCR 
product and 55 µL of transformation mix was prepared with (-)-control vector 
(pJet1/blunt vector with no insert) to ensure that the transformation was working properly 
and that only vectors with inserts survived.  All transformation mixes were grown on 
separate LB-ampicillin (LBA) plates. 
Only E.coli colonies that successfully incorporated the plasmid contained the 
ampicillin resistance gene and, thus, only they grew on the LBA medium.  Next, a 
transformed colony was swiped and placed in 13 mL of LB broth containing 50 µg/mL of 
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ampicillin in a 25 mL sterile glass test tube.  An untransformed colony was grown in a 
separate glass test tube containing LBA broth as a negative control to ensure that only 
transformed colonies were growing in the prepared LBA broth.  The inoculated broth was 
incubated at 205 rpm at 37°C for 16 hours.  The next day ~1.5 mL of successfully 
transformed culture was placed in eight sterile 1.5 mL Eppendorf tubes for mini-prep 
using a kit. 
 
Isolation and Analysis of Plasmids Containing the 7C7:C5 Vκ and VH Genes 
Plasmid DNA was isolated using the GeneJET Plasmid Miniprep Kit (Fermentas).  
The protocol for the GeneJET plasmid isolation was performed with at least a few 
changes and customizations to the protocol to get better plasmid isolation results.  Each 
tube containing transformed culture was centrifuged at 8,000 x g for two minutes.  The 
supernatant was discarded by decantation.  The pellet was washed with 1X PBS, pH 7, 
vortexing gently so as to not resuspend the pellet but rather to lift the pellet from the 
bottom of the tube.  The pellet was centrifuged for one minute at 12,000 x g.  One more 
wash with PBS followed by centrifugation was performed, only if the pellet still appeared 
dirty. 
GeneJET plasmid isolation was adjusted from the standard protocol for the next 
steps using the following customizations:  the pellet was vortexed for resuspension in the 
Resuspension Solution, the resuspended pellet was then lysed three to four minutes after 
mixing with the Lysis Solution, a few minutes of room temperature incubation were 
allowed for the white precipitate to form after mixing with the Neutralization Solution, 
and the white precipitate that formed was centrifuged for ten minutes at 12,000 x g to 
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help keep the precipitate in tact against the walls of the 1.5 mL Eppendorf tube while 
decanting the DNA supernatant into the GeneJET Spin Column.  The remainder of the 
GeneJET Miniprep protocol from Fermentas was followed.   
A 5 µL aliquot of the plasmid obtained was loaded on a 1% agarose gel, ≥0.1 
µg/mL ethidium bromide along with single and double digested samples of the plasmid.  
The double digestion of the plasmid was performed as follows:  A 14 µL aliquot of 
plasmid was digested with two FastDigest Units (FDU) of FastDigest (FD) XhoI 
(Fermentas) and FD XbaI (Fermentas) restriction endonucleases (RE)s at a concentration 
of 1 FDU/µL per RE in a 1X FD buffer.  The digestion was performed by incubation of 
the digestion mix in a nuclease-free 1.5 mL Eppendorf tube in a 37°C water bath for one 
hour. 
As additional controls, single digested aliquots of plasmid (one digested with FD 
XhoI and the other digested with FD XbaI) were loaded onto the gels to ensure that the 
enzymes were working properly in the digestion reactions and that the insert was not 
being digested by either of the REs.  Each sample contained a final concentration of 1X 
orange G loading dye before loading samples onto a gel.  An aliquot of O'RangeRuler™ 
100 + 500 bp DNA Ladder (Fermentas) was loaded onto the gel for band measurements.  
The gel was electrophoresed at 59 V for one hour. The pJET1 vector contains an XbaI 
site at nucleotide 503 and an XhoI site at nucleotide 478 on opposite sides of the plasmid 
insertion site and, thus, the inserted gene is excised along with twenty-five additional 
nucleotides when treated with FD XbaI and XhoI REs. 
For plasmids cloned with Vκ inserts, a KpnI digestion was performed to check for 
linearization of the plasmid using the following mix:  8 µL of plasmid DNA and 10 U of 
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KpnI RE in a final 1X Tango/Y+ buffer.  The digestion was performed by incubation of 
the reaction mix in a 37°C water bath for seventy minutes.  The pJET1 vector does not 
contain a KpnI site, so digestion depends on the presence of a KpnI site in the insert.  
Results were analyzed by standard gel electrophoresis as previously described in the 
Materials and Methods for PCR products. 
 
Preparation of Plasmids Containing the 7C7:C5 Vκ and VH Gene Inserts for 
Sequencing 
 
The plasmids were prepared for DNA sequencing at the University of Michigan 
DNA Sequencing Facility.  The concentration of plasmids were measured as 1:10 
dilutions in 10 mM Tris·Cl, pH 8, in a 100 µL quartz cuvette for Shimadzu 
spectrophotometers.  An aliquot of 100 µL of 10 mM Tris·Cl, pH 8, was used as a 
reference and a blank for measurements.  All plasmid samples were 
spectrophotometrically measured at absorbance 260 nm and 280 nm on a UV3101PC 
UV-VIS-NIR Scanning Spectrophotometer using UV Probe v.2.10.  A purity 
(A260/A280 ratio) of 1.7-1.9, of which 1.8 is the best, was attained for all plasmids sent 
for sequencing.   
Additional purification and concentration of plasmids was typically achieved by 
phenol/chloroform/isoamyl alcohol extraction of impurities followed by precipitation 
with 2 volumes of 95% EtOH and 0.1 volumes of 3M Na(OAc), pH5.2.  The plasmids 
were diluted to 70-80 ng/µL when possible, although plasmids of approximately 50 
ng/µL were also sent to the University of Michigan DNA Sequencing Facility when 
higher concentrations were not available.  Generally, these less concentrated plasmids did 
not result in as high quality sequences as plasmids in the 70-80 ng/µL range of 
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concentration.  The pJet1 forward and reverse primers were diluted in separate sterile 1.5 
mL Eppendorf tubes. 
 
Analysis of the Obtained DNA Sequences for the 7C7:C5 Vκ and VH Genes 
Upon receiving the DNA sequences of the plasmids with the Lκ-Vκ -Jκ-Cκ” and 
LΗ-VΗ-D-JΗ-CΗ” genes, the DNA sequences for the Lκ-Vκ -Jκ-Cκ” and LΗ-VΗ-D-JΗ-CΗ” 
genes were first translated using the translate tool in the Expert Protein Analysis System 
(ExPASy) 120.  The DNA sequences and corresponding amino acid translations were then 
processed in a National Center for Biotechnology Information (NCBI) Blast and pBlast to 
search for areas of identity with other murine IgG1 variable genes and regions, 
respectively. 
The beginning and ending of the complete DNA sequence for the Lκ-Vκ -Jκ-Cκ”  
and LΗ-VΗ-D-JΗ-CΗ” genes were located based on two accounts:  1) by finding at least 
part of the DNA sequences for the Lκ and LH and for the Cκ” and CH1” and 2) by finding 
similarity between the variable region DNA and amino acid sequences of the 7C7:C5 Fv 
and the variable DNA and amino acid sequences of other antibodies, particularly in areas 
that code for or comprise the amino terminus.  The sequences of the Lκ-Vκ -Jκ-Cκ” and 
LΗ-VΗ-D-JΗ-CΗ” genes were extracted from the sequences of the plasmids and, thus, the 
DNA sequences for the Lκ-Vκ -Jκ-Cκ” and LΗ-VΗ-D-JΗ-CΗ” genes were isolated.  The 
amino acid sequences were used to construct molecular models of the Fv fragment of the 
7C7:C5 MAb. 
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Homology Modeling of the 7C7:C5 Fv 
Homology modeling of Fvs requires using similar Vκ and VΗ amino acid 
sequences with crystallographic structures in the PDB as templates.  Using Modeller9v4 
121
 required producing a command file which tells the software exactly what to model and 
any specialized restraints to place on the model.  In this case, the automodel function of 
Modeller 9v4 was applied in which spatial restraints were applied based on the listed 
templates.  The only other necessary script files are the alignment file and the 
corresponding PDB files for the structures mentioned in the alignment file.  Amino acids 
of crystallographic structures used as templates were aligned by keeping not only 
identical but also similar residues lined up with the corresponding residues in the 7C7:C5 
variable sequences.  While using similar residues is not as good as using identical 
residues for homology modeling, using similar residues should help to produce an overall 
good fit for residues that are not as common among the selected templates by maintaining 
overall coordinate consistency with templates. 
The first template (PDB #1QOK 122) listed in the alignment files was a 
crystallographic structure of a peptide linked murine IgG1 Fv.  This template was for an 
entire Fv in which the VH and Vκ are covalently linked in normal spatial alignment to one 
another using a peptide linker comprised entirely of glycine residues.  The template 
1QOK was selected mainly for the purpose of bringing the two variable chains within 
contact of each other.  Listing this template first to be read in the alignment files allowed 
for its coordinates to be read first successfully bringing together the two chains.  This 
template was a recombinant anti-CEA single chain Fv and showed only 52% amino acid 
sequence identity (65% similarity) with the 7C7:C5 Fv.   
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The remaining templates for each chain were selected based on PDB similarity 
rankings to sequences of the 7C7:C5 VΗ and Vκ separately.  Two separate groups of 
templates (crystallographic structures in unbound and antigen-bound conformations) 
were selected for each variable chain of the Fv.  The templates of unbound and antigen-
bound conformations were used to generate separate models of the 7C7:C5 Fv in 
consideration of the relative twists or rotations that occur in the Fv upon antigen binding, 
some of which can be large in size 123-125.   
In addition to 1QOK, two groups of templates for modeling the Vκ were 
downloaded from the PDB:  unbound templates (PDB # 1E6O 124, 2FAT 125, and       
1AIF 126) and antigen-bound templates (PDB # 1E6J 124, 2FD6 127, and 2FBJ (Bhat, T.N., 
Padlan, E.A. & Davies, D.R. [To be published]).  Only a few templates were chosen for 
modeling the 7C7:C5 Vκ simply because the identity among these templates is relatively 
high.  Furthermore, Modeller9v4 software collectively incorporates spatial restraints from 
these templates.  The spatial restraints generated generally improve with higher numbers 
of templates used, with the exception of having an excellent or a few excellent high 
identity templates that resemble the targeted structure quite closely 121. 
These few templates in this case are good choices for modeling the 7C7:C5 Vκ 
because structures tend to be conserved among like sequences.  The basis for this 
assumption is that high identity sequences of like proteins have many of the same 
building blocks in the same sequential order.  This assumption is further supported for 
antibody variable regions in a study by Chothia et al. 45, in which conformations for five 
of the six CDR loop regions are believed to be determined by some key conserved 
residues.  Furthermore, comparisons of these loop regions showed that they have a small 
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repertoire of conformations, in which conserved residues lead towards one particular 
conformation. 
The closest match to the 7C7:C5 Vκ that has a crystal structure is the Vκ from 
Fab13b5 Anti-p24 HIV-1 capsid protein (PDB # 1E6O for unbound and 1E6J for 
antigen-bound).  The match starts with EIVLTQ, the active Vκ amino terminus, and 
shares 95% identity (including RADAAP of amino terminus of Cκ).  In fact, only five 
amino acids out of 105 amino acids in the active Vκ are different.  Another similar active 
Vκ with a crystal structure is from an anti-urokinase plasminogen activator receptor 
(Upar) (PDB # 2FAT for unbound and 2FD6 for antigen-bound).  The anti-Upar shares 
93% identity with the 7C7:C5 active Vκ plus RADAAP.  Only seven amino acids out of 
105 amino acids in the active Vκ are different.  These crystal structures served as a good 
starting point for modeling the 7C7:C5 Vκ.  A crystal structure of an active Vκ was used 
from an anti-idiotypic Fab (PDB # 1AIF) as an additional unbound template for part of 
the CDR-L3, the carboxy1 terminus, and the amino terminus of the Cκ.  A final active Vκ 
crystal structure (sharing 93% identity with the 7C7:C5 Vκ) was used from an anti-
galactan Fab (PDB # 2FBJ) for generating the antigen-bound model.  Galactan is a 
galactose based polysaccharide and, thus, may help to model the possibility of Fv 
interactions with the sugar moieties of nucleic acids. 
A collective approach to generating coordinates for the VΗ was chosen, in which 
many VH chains of crystallographic structures from murine IgG1 Fab fragments were 
used as templates for generating complete sets of coordinates for the unbound template 
and bound template VΗ models.  Generally, spatial restraints improve for a given model 
with increasing number of templates used.  Probability density functions (pdfs) for 
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individual spatial restraints, such as Cα-Cα distances and main-chain dihedral angles, are 
combined to find the most probable coordinates for a given residue.  As a result, more 
templates essentially equal more data to use in calculation of pdfs for each residue 
leading to calculated residue coordinates closer to a true value 121.  Also, the model tends 
to improve in structure with higher percentage identity templates in like proteins. 
The VΗ was modeled based on sixteen total templates (1QOK, 1HQ4 128,       
1F8T 129, 1S5I 130, 32C2 131, 1AY1 132, 1KCU 133, 3CFE 134, 2A0L 135, 1ORS 136,      
1EZV 137, 1BAF 138, 1KEN 139, 1KCS 133, 2FON 140, and 1I9I 141) for the unbound 
template model and seventeen total templates (1QOK, 1ORS, 1CF8 142, 1F90 143, 1BAF, 
1KCR 144, 1KEN, 2A0L, 1BGX 145, 1KC5 133, 1NCW 146, 3CFD 134, 1EZV, 1S5I, 1KCS, 
2FON, 1I9I) for the antigen-bound template model.  The purpose of the first template was 
already described.  The main templates used to construct the 7C7:C5 VH were the 
following PDB files:  1HQ4, 1F8T, 1S5I, 32C2, 1AY1, 1KCU, and 3CFE for unbound 
conformation and PDB # 1ORS, 1CF8, 1F90, 1BAF, 1KCR, 1KEN, 2A0L, 1BGX, 
1KC5, 1NCW, and 3CFD for antigen-bound conformation.  The main unbound and 
antigen-bound templates both ranged from 84% to 80% identity and 91% to 86% 
similarity with the 7C7:C5 VΗ sequence.   
The remaining templates were used in both unbound and antigen-bound template 
VΗ models in a given region, regardless of whether or not the crystal structure of the Fab 
was with antigen bound or not.  These remaining templates for unbound and antigen-
bound conformations of the VΗ were used as a means of adding extra templates for 
refining the CDR regions of the 7C7:C5 VΗ, in which only the parts of these templates 
that showed high identity with a certain part of the 7C7:C5 VΗ were used.  For the 
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unbound template model these templates included 2A0L, 1ORS, 1EZV, 1BAF, 1KEN, 
1KCS, 2FON, and 1I9I.  Of these templates 2A0L, 1ORS, 1EZV, 1BAF, and 1KEN were 
considered to be good templates for refining CDR-H1; 1KEN and 1KCS were considered 
to be good templates for refining CDR-H2; and 2FON, 1BAF, and 1I9I were considered 
to be good templates for refining CDR-H3. 
The basis for choosing the majority of these templates was simply based on high 
sequence identities in a particular CDR and the framework area surrounding that CDR; 
however, the templates (2FON, 1BAF, and 1I9I) picked for CDR-H3 all bind to 
compounds that contain phenyl groups (acyl-Coenzyme A (CoA), dinitrophenyl, and 
testosterone, respectively).  The only non-antibody template used in generating these 
models is 2FON, an acyl-CoA oxidase.  Nevertheless, it is also the only template that 
contained the complete 101-WLPLAY-106 of CDR-H3 and, furthermore, it binds to 
acyl-CoA, of which CoA is a coenzyme that contains adenosine in a major portion of its 
structure.  As a result, 2FON was deemed to be a rather significant template despite being 
non-antibody and despite being used for only a small portion of the generated antibody 
model.   
In the bound template model, the following partial templates were used:  1EZV, 
1S5I, 1KCS, 2FON, and 1I9I.  By using partial (2A0L and 1ORS) and whole (1BAF and 
1KEN) templates that are present in the bound template model also for the unbound 
template model, the two models are kept similar enough that they still resemble each 
other.  Such integration of templates between models while allowing for unique templates 
to stay specific to each model, such as 3CFE (a crystal structure of purple-fluorescent Fv 
of Ep2-25c10) for the unbound template model and 3CFD (a crystal structure of purple-
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fluorescent Fv of Ep2-25c10 in complex with stilbene hapten) for the bound template 
model, should provide reasonable models of the unbound Fv and the antigen-bound Fv in 
relation to conformational similarity with one another while still maintaining key 
conformational distinctions between the two models. 
 
Refinement of the Homology Models of the 7C7:C5 Fv 
Protonation status of residues was assessed and modified according to pKa using 
the program H++ 147-148.  Salinity was set to the default, 0.15 M, which is a typical 
physiological salinity.  The external dielectric coefficient was set to the default, 80, as a 
typical dielectric coefficient for saline solvents and the internal dielectric coefficient was 
set to 6, which is slightly higher than the default internal dielectric coefficient of 4.  The 
purpose of raising the internal dielectric coefficient was that the binding pocket of an Fv 
lies near the surface as opposed to the center of the Fv, in which dielectric coefficients 
around 10 are more accurate for pKa prediction.  Nevertheless, 10 was not selected as an 
internal dielectric coefficient because His L33 was the deepest residue in the binding 
pocket and, thus, lay in between the center of the Fv and the surface residues.  His L33 is 
one of the only two residues that are polar amino acids in the binding pocket and, thus, 
was one of the main residues to which the pKa calculation was actually relevant.  As a 
result, an intermediate internal dielectric coefficient of 6 was chosen.  Poisson-Boltzmann 
calculations of pKa at a solvent pH of 7 were performed by H++ for each residue in the 
Fv model. 
Both unbound-template and bound-template based models of the 7C7:C5 Fv were 
minimized by a limited memory Broyden-Fletcher-Goldfarb-Shanno (L-BFGS)     
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method 149-150 to an RMS gradient of 0.1 kcal/mol/Å using AMBERff99 parameters 151 in 
Tinker v. 4.2 152-153.  The L-BFGS minimization method uses a large scale unconstrained 
non-linear quasi-Newton approximation to converge to a gradient.  The overall goal of 
the minimization was to leave the models as close as possible to the original applied 
crystallographic data that was used to generate the models, while fixing any major 
problems with the models such as overextended bond distances or unusual bond angles.  
The resulting minimized models of the 7C7:C5 Fv were converted from a XYZ format (a 
Tinker coordinate file format providing three-dimensional coordinates or coordinates of 
the X, Y, and Z planes) into a PDB format (the PDB coordinate file format providing 
three-dimensional coordinates accepted by various widely used modeling software) in 
Tinker v. 4.2 
To help pinpoint unusual structural areas of the 7C7:C5 Fv models, the Cα root 
mean square deviations (RMSDs) of the areas aligned for generation of the 7C7:C5 Fv 
models were calculated using DeepView/Swiss-PDB Viewer 154.  The Cα RMSDs were 
calculated using three different reference structures.  The first reference structure upon 
which other structures (template crystal structures) were superimposed was the energy 
minimized model of the 7C7:C5 Fv.  The second and third reference structures were the 
only complete Fv template (PDB #1QOK) and the most similar template in amino acid 
sequence to the 7C7:C5 VH or Vκ (varies with model and segment), respectively.   
All Cα RMSDs were calculated excluding residues of the constant region.  This 
area is incomplete in the 7C7:C5 Fv models and, thus, may have folded differently than 
typical during minimization.  The first two residues of the 7C7:C5 VH and the first five 
residues of the 7C7:C5 Vκ were also excluded from Cα RMSD calculations.  The Cα 
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RMSDs in the amino terminus of the CH1 and the amino terminus of the Vκ indicated an 
unnatural association between residues of these two areas since including these areas 
resulted in at least a two fold increase in Cα RMSD.  As a result, these areas were not 
included in the Cα RMSD calculations. 
The “stereochemical quality” of the 7C7:C5 Fv model was assessed by 
PROCHECK 155-156, a suite of programs for comparing the geometry of residues in a 
subject protein to stereochemical parameters for such residues derived from well-refined, 
high resolution crystallographic structures.  Special consideration in the model was given 
to residues in the binding site as well as to residues of the amino terminus of the CH1 and 
Cκ.  Residues of the binding site may fluctuate from the allowed range for that residue 
due to conformational changes as a result of ligand binding, while CH1 and Cκ N-
terminus residues may fluctuate from the allowed range due to the lack of the remainder 
of the CH1 and Cκ normally present in a Fab fragment. 
The model quality assessment was performed before and after minimization using 
Tinker v. 4.2.  The PDB file for the energy minimized model of the 7C7:C5 Fv was 
loaded into ADT-1.5.2 157 to setup for docking studies in AutoDock-4.0 77, 158.  Ligands 
for AutoDock-4.0 were built in SpartanES-02 159 using a library of nucleic acid 
fragments.  Hydrogens were added in SpartanES-02 to complete the ligands and then the 
ligands were saved as PDB files and loaded into AutoDockTools (ADT)-1.5.2 to setup 
for docking studies in AutoDock-4.0. 
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Preliminary “Blind Docking” Studies of the 7C7:C5 Fv with d6mA and Related 
Antigens 
 
The general area of the paratope was predicted by a set of rigid protein “blind 
docking” experiments with flexible ligand using a Lamarckian Genetic Algorithm (LGA) 
in AutoDock-4.0.  For the “blind docking” experiments with d6mA, dA, and ssDNA A-
6mA-T trinucleotide as ligands, the xyz-dimensions in all of the grid boxes were set to 61 
x 61 x 61, in which the total number of grid points was 226,981.  The center of the Fv 
was at the following coordinates for all rigid Fv docking experiments:  (7.765, 33.508, 
9.928).  A total of four, three, and one rigid Fv docking experiment(s) were performed for 
d6mA, dA, and A-6mA-T, respectively.  All of the docking experiments were performed 
with wide grid boxes along the upper Vκ-VH interface (region of the Fv in the opposite 
direction of the constant regions that lies proximal to the midline of the Fv where the Vκ 
and VH associate together).   
Two docking experiments for d6mA and two for dA used a spacing factor of  
0.508 Å between grid points, in which the central coordinates of the grid boxes are the 
following:  (4.696, 30.018, 26.196) and (9.156, 40.607, 22.156).  The spacing factor was 
adjusted to 0.853 Å for the grid box for A-6mA-T to accommodate the larger size of this 
antigen, in which the central coordinates of this box are (4.772, 39.569, 20.052).  The 
spacing factor of 0.853 Å and the central grid box coordinates of (4.772, 39.569, 20.052) 
were also used for one docking experiment for d6mA and dA separately.  One additional 
docking experiment was performed for d6mA using a spacing factor of 0.375 Å and the 
central grid box coordinates of (2.027, 36.135, 27.448).  The grid boxes with the spacing 
of 0.508 Å and the central coordinates of (4.696, 30.018, 26.196) resulted in the highest 
energy binding modes for d6mA and dA.  These conformations were selected for further 
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analysis.  A binding mode for A-6mA-T that resembled the selected binding modes of 
d6mA and dA was found using the grid box spacing of 0.853 Å and the central coordinates 
of (4.772, 39.569, 20.052). 
The docking parameter file for these three ligands was set for a population of 150 
individual ligand binding modes, a maximum of 2.5 x 106 energy evaluations, a 
maximum of 2.7 x 104 generations, a mutation rate of 2%, and a crossover rate of 80%.  
The probability of performing a local search on an individual ligand mode was set to 6%.  
The number of individual modes that proceed to the next generation was set to 1 and the 
number of generations analyzed to determine the threshold least favorable conformation 
in the population was set to 10.  The local search algorithm was set for 300 iterations with 
a lower bound step size of 0.01.  Four successive successes or failures were required for 
lower bound step size to change.  A total of 10 LGA trial runs were performed. 
Ligand torsional degrees of freedom were set to 4 for d6mA and dA and 15 for A-
6mA-T.  Torsional degrees of freedom were set for the fewest active atoms.  The torsional 
coefficient was set to 0.274 for each of the ligands.  The translation step, quarternion 
step, and torsion step were set to 2 steps/Å, 50 steps/degree, and 50 steps/degree, 
respectively, for each of the ligands.  All results were clustered according to rmsd and 
ranked according to total binding energy (the sum of the intermolecular energy, the 
internal energy, the unbound system’s or starting state energy, and the torsional free-
energy penalty) represented as ∆G.  All grid and docking parameter files were prepared 
using ADT-1.5.2 with the corresponding tutorial 157 as a guide.  A dissociation constant 
(Kd) was calculated for each viewable docking mode using the equation 
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 Kd = exp((∆G*1000 cal/kcal)/(RT)), where ∆G is the binding energy in kcal/mol, R is 
the gas constant 1.98719 cal*mol-1*K-1, and T is 298.15 K. 
 
Refined Docking Studies with Flexible Protein Residues 
Further docking experiments using AutoDock-4.0 involved binding of the 
antigens d6mA, dA, and A-6mA-T, in which five residues in the area of the binding pocket 
were selected to be flexible (Tyr H104, Tyr L35, Ile L46, Tyr L48, and Ser L55).  In 
addition, grid boxes and certain docking parameters were adjusted for a more refined 
analysis.  The Fv with five flexible residues was centered at (7.824, 33.593, 9.791) for all 
flexible binding pocket docking experiments.  All grid boxes for the flexible binding 
pocket docking experiments were centered around the binding pocket, according to the 
site of docking of d6mA, dA, and A-6mA-T from selected binding modes found in rigid Fv 
docking experiments.   
Grid boxes for d6mA and dA were set to xyz-dimensions 51 x 51 x 51, in which 
the total number of grid points was 132,651.  The grid boxes for d6mA and dA were 
centered at (0.022, 29.553, 20.207).  The grid box for A-6mA-T was set to xyz-dimensions 
71 x 75 x 57, in which the total number of grid points was 303,525.  The grid box for A-
6mA-T was centered at (0.075, 29.19, 20.95).  The spacing factor between grid points was 
set to 0.375 Å for d6mA and dA and 0.392 Å for A-6mA-T.   
Adjusted docking parameters include a maximum of 12.5 x 106 energy 
evaluations and a maximum of 7.5 x 104 generations for d6mA and dA.  A maximum of 
15 x 106 energy evaluations and a maximum of 1.0 x 105 generations were set for A-6mA-
T.  A total of 25, 50, and 50 LGA trial runs were performed for d6mA, dA, and A-6mA-T, 
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respectively.  The number of active torsions were set to 16 for d6mA and dA and 27 for A-
6mA-T.  Ligand torsional degrees of freedom were set to 4 for d6mA and dA and15 for A-
6mA-T, in which the fewest active atoms were selected for torsions.  All other parameters 
were kept the same as the parameters used for the preliminary “blind docking” 
experiments.  A Kd was calculated for each viewable binding mode.  Changes in dihedral 
angles and atom distances were measured for each of the five flexible residues in the 
selected binding modes using ADT-1.5.2, in which the corresponding rigid residues 
served as initial conformations.  The five flexible Fv residues in each of the selected 
binding modes were superimposed on the corresponding rigid Fv residues to find a 
relative axis of measurement and to visually inspect all calculated angles. 
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RESULTS 
 
Blotting Results for the Detection of d6mA in DNA with the 7C7:C5 MAb  
Results of two dot blot experiments and one optimized slot blot experiment were 
used to compare binding of the 7C7:C5 MAb to single-stranded DNA containing a single 
deoxy-N6-methyladenosine (d6mA) and to unmethylated DNA.  The comparison 
essentially demonstrated the affinity difference between the 7C7:C5 MAb against a 
single d6mA versus a single deoxyadenosine (dA) in DNA.  All methylated DNA used in 
the blotting studies was methylated with EcoRI methylase.  The first dot blot was for 1:10 
dilutions of methylated DNA versus unmethylated DNA from 0.1 ng to 1 µg, in which a 
dark purple dot at 0.1 µg of methylated DNA was detected and a faint, circular purple 
outline at 1 µg of unmethylated DNA was detected.  No other purple stains were detected 
for this blot.   
The second dot blot compared treatment with the 7C7:C5 MAb to treatment 
without the 7C7:C5 MAb for the following dilutions of methylated and unmethylated 
DNA:  0.0625 µg, 0.1 µg, 0.125 µg, 0.25 µg, 0.5 µg, 0.75 µg, and 1 µg.  One membrane 
was treated with 7C7:C5 MAb/RPMI/10% FCS and the other membrane was treated with 
RPMI/10% FCS.  The membrane with 7C7:C5 MAb treatment showed dark purple dots 
for methylated DNA at 0.25 µg to 0.1 µg and only purple, circular outlines for 
unmethylated DNA of which the most intense was at 1 µg.  The membrane without 
7C7:C5 MAb treatment showed only one or two extremely faint purple outlines for 
unmethylated DNA. 
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As a result, the 7C7:C5 MAb is clearly the ingredient in the 7C7:C5 
MAb/RPMI/10% FCS medium that is recognizing methylated and unmethylated DNA.  
A barely visible background may be due to RPMI/10% FCS medium or simply the 
staining process.  Although treatment with RPMI/10% FCS resulted in one or two barely 
visible purple outlines for unmethylated DNA, it did not result in any staining for 
methylated DNA.  This result also suggests the possibility that some ingredient in 
RPMI/10% FCS may be binding only to unmethylated DNA with low affinity or in low 
amount.  This ingredient must be some molecule that the anti-mouse IgG antibody shows 
cross-reactivity for, even if it is only with extremely low affinity.   
Slot blots are more reliably quantifiable than the dot blots due to the use of the 
S&S Minifold Slot Blot Filtration Apparatus.  Results from a protection assay provided 
evidence that the methylated DNA used in the optimized slot blot was indeed methylated 
(Figure 6). 
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Figure 6.  The protection assay for verifying methylation of DNA used in the optimized 
slot blot.  Negative control (unmethylated pUC-19 without EcoRI RE treatment) is in the 
left lane, positive control (unmethylated pUC-19 with EcoRI RE treatment) is in the 
middle lane, and pUC-19 methylated with M.EcoRI and treated with EcoRI RE is in the 
right lane.  A 10 µL aliquot of each DNA sample was mixed with a final 1X loading dye 
and the samples were then loaded onto a 1% agarose, ≥0.1 µg/mL EtBr gel.  The gel was 
electrophoresed at 72 V for approximately two hours.  Picture of the gel was taken by the 
UV Kodak 120 Camera with two seconds of UV exposure. 
 
 
The optimized slot blot was performed for the following dilutions of methylated 
and unmethylated DNA:  0.6 ng, 0.9 ng, 4.5 ng, 9 ng, 45 ng, 90 ng, 0.18 µg, 0.45 µg, 0.9 
µg, and 1.8 µg.  Unmethylated DNA at a dilution of 1.8 µg and 0.9 µg showed not only 
the most intense stains on the blot, but also showed stains with the largest areas.  The 
stain at 1.8 µg of unmethylated DNA showed a 1.6 fold greater intensity and a 
considerably greater stain area than the stain at 0.9 µg of unmethylated DNA.  No band 
detection was noticed at 1.8 µg of methylated DNA.  Methylated DNA at a dilution of 0.9 
µg showed a 4.5 fold lower intensity and a smaller stain area than unmethylated DNA at 
a dilution of 0.9 µg.  These results have actually been seen in a similar manner in the first 
Unmethylated and cut 
Unmethylated and uncut 
Methylated and cut 
treatment, but not cut  
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and second dot blots since the highest concentrations of methylated DNA on these blots 
did not give the most intense dot stains for methylated DNA. 
Although these results may seem to contrast the notion that the 7C7:C5 MAb is 
specific for DNA containing d6mA, they can be explained in such a manner that further 
supports that the 7C7:C5 MAb is specific for DNA containing d6mA.  The amount of 
7C7:C5 MAb that binds to methylated DNA at 1.8 µg and 0.9 µg is too much biomass for 
the membrane to hold onto.  Additionally, the amount of amIgG-AP that in turn binds to 
the 7C7:C5 MAb also contributes biomass.  As a result, the DNA-antibody complex 
breaks free at some point after the addition of the 7C7:C5 MAb when the biomass 
becomes too great for the membrane to hold and is pulled by the accumulated mass of the 
antibody into solution.  Characteristically, at 2 µg of DNA, antibodies only with high 
affinity (Kd lower than 10-8 M) for the DNA antigen can break the covalent linkage of the 
bound DNA to the nitrocellulose and pull the DNA into solution 43. 
Simply, the lack of appearance and low appearance of stain on the membrane at 
methylated DNA dilutions of 1.8 and 0.9 µg, respectively, is a result of too much binding 
(too high binding affinity) rather than too little binding (too low binding affinity).  This 
explanation is supported by the appearance of substrate solution turning purple in areas 
around the 1.8 and 0.9 µg dilutions of methylated DNA, in which the stain did not stick 
to the membrane.  An opposite trend, however, starts to occur at 0.45 µg of methylated 
DNA because the biomass of the DNA+antibody+anti-antibody+substrate complex is low 
enough for the membrane to hold onto a good portion of the complex.  At 0.45 µg of 
methylated DNA, the intensity was 1.8 fold greater than the intensity at 0.45 µg of 
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unmethylated DNA.  Also, the area at 0.45 µg of methylated DNA was larger than the 
area for 0.45 µg of unmethylated DNA.   
At 0.18 µg of methylated DNA, the intensity was 5.7 fold greater than the 
intensity at 0.18 µg of unmethylated DNA.  Plus, the area at 0.18 µg of methylated DNA 
was larger than the area for 0.18 µg of unmethylated DNA.  Methylated DNA at a 
dilution of 0.09 µg showed a 3.1 fold greater intensity than unmethylated DNA at a 
dilution of 0.18 µg.  No detectable stain appeared at 0.09 µg of unmethylated DNA.  
These results suggest that the 7C7:C5 MAb has a binding affinity for DNA containing a 
single d6mA that is approximately six fold greater than the binding affinity it has for 
unmethylated DNA.  Results for the optimized slot blot are shown in Figure 7 and listed 
in Table 4. 
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Figure 7.  Two pictures of the results from the optimized slot blot under different 
lighting.  Pictures were taken of a section of the nitrocellulose membrane where bands 
appeared.  Pictures were taken by (a) a digital camera under a desk lamp for lighting and 
(b) a Kodak DS UV Camera with two seconds of UV exposure.  The membrane was 
inverted for the picture in (b). The picture in (b) was used for measurement of band 
intensities. 
 
 
 
Table 4.  Slot blot band intensities comparing binding of the 7C7:C5 MAb to M.EcoRI 
methylated pUC-19 DNA versus unmethylated pUC-19 DNA 
 
 Band Intensity 
Amount of 
DNA (µg) Unmethylated DNA Methylated DNA 
1.8 287.64  
0.9 180.72 40.31 
0.45 42.24 76.94 
0.18 7.7143 44.13 
0.09 0 24 
 
*Band intensities were measured by using Kodak DS UV software.   
The intensity of each band was measured from left center of the band to  
middle center of the band.  Equal areas of measurement were used for  
each band intensity measurement. 
 
Unmethylated Methylated 
1.8 µg 
1.8 µg 
0.9 µg 0.9 µg 
0.45 µg 
0.45 µg 
0.18 µg 
0.09 µg 
0.18 µg 
0.09 µg 
Unmethylated Methylated 
1.8 µg 1.8 µg 
0.9 µg 0.9 µg 
0.45 µg 0.45 µg 
0.18 µg 0.18 µg 
0.09 µg 0.09 µg 
(a) (b) 
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Amplification of cDNA for the 7C7:C5 Vκ and VH Genes 
 
The 7C7:C5 Vκ and VH genes were successfully synthesized and amplified by 
performing RT-PCR on RNA isolated from thawed 7C7:C5 hybridoma cells that were 
previously frozen at ≥-70°C.  Figure 8a shows a 1% agarose, 0.1 µg/mL EtBr gel 
prepared as described in the Material and Methods section with successful 7C7:C5 total 
RNA isolation.  The isolation of RNA was performed as described in the Material and 
Methods section using TRIzol/chloroform separation of phases.  The result shown in 
Figure 8a suggested that enough RNA was isolated for cDNA synthesis and 
amplification, respectively.  The Vκ gene was successfully amplified with this RNA.  The 
result shown in Figure 8b suggested that only trace levels of RNA led to the successful 
amplification of the VH gene.  In each RNA isolation using the TRIzol method, DNA 
contamination was produced and, thus, this co-isolate appears to be inherent to the 
method.  This DNA contamination did not cause a problem for cDNA synthesis. 
 
 
                                                                 
Figure 8.  Total RNA isolation used for cDNA synthesis of the (a) Vκ and (b) VH genes.  
Isolation of total RNA was done on thawed 7C7:C5 hybridoma cells using the TRIzol 
method as described in the Material and Methods.  A 5 µL aliquot of RNA from each 
RNA sample was mixed with a final 1X bromophenol blue loading dye and loaded onto a 
1% agarose, 0.1 µg/mL EtBr gel.  The gels were electrophoresed at 72 V for forty 
minutes.  Gels were analyzed by UV exposure. 
 
DNA Contamination 
28S 
18S 
Trace 
amounts of 
RNA 
DNA Contamination  
(b) (a) 
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The 7C7:C5 Vκ and VH cDNAs were synthesized and amplified using RT-PCR.  
Both the 7C7:C5 Vκ and VH cDNAs were reamplified by PCR to produce more of each 
and simply to repeat the experiment to confirm the first result.  Figures 9 and 10 show 
results of the amplification of the 7C7:C5 Vκ and VH genes, respectively.  The RT-PCR 
was performed as described in the Materials and Methods section.  The primers used are 
listed in Tables 2 and 3.   
 
 
                         
 
 
 
 
 
 
 
 
 
Figure 9.  (a) Amplification of the 7C7:C5 Vκ gene and (b) measurement of the Vκ gene 
amplicons.  cDNA synthesis and amplification were performed according to standardized RT-
PCR protocol listed in the Materials and Methods.  For (a) and (b), a 10 µL aliquot of each PCR 
product mixed with a 1X loading dye was loaded into separate lanes on a 1% agarose, 0.1 
µg/mL EtBr gel and electrophoresed at 59 V for seventy minutes.  For (b), 8 µL of a DNA 
ladder is in Lane 1.  Gels were analyzed by UV exposure. 
 
7C7:C5 Vκ 
MLALT2 
SP2/0 Aberrant Vκ 
MLALT1 SP2/0 Aberrant Vκ 
(~426 bp) 
MLALT1 
7C7:C5 Vκ 
(~426 bp) 
MLALT2 
(a) (b) 
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Figure 10.  Amplification and measurement of the 7C7:C5 VH gene.  cDNA synthesis and 
amplification were performed using standardized RT-PCR protocol found in the Material 
and Methods.  Aliquots of 10 µL of each PCR product mixed with a final 1X loading dye 
were electrophoresed on a 1% agarose, ≥0.1 µg/mL EtBr gel at 59 V for seventy minutes 
in top lanes 3-10.  PCR products were distributed as follows, according to LH 5’ primer 
name:  APg1AZ, AVg1XM, APg1XM, APg1AM, APg1AMU, APg1KEA, VH1, and 
VH2 in lanes 3-10 respectively.  Lane 1 has 8 µL of a DNA ladder.  Gels were analyzed 
by UV exposure. 
 
In the case of the Vκ cDNA, two 5’ primers (MLALT1 and MLALT2) and the 3’ 
CkFORa resulted in amplicons of appropriate size at ~426 bp.  Amplification with 
MLALT1 produced a much fainter band with more primer dimers than MLALT2.  In 
turn, MLALT2 gave a much cleaner PCR product.  Reamplification of the MLALT1 and 
2 PCR products produced a noticeable band at ~426 bp only for the MLALT2 PCR 
product (Figure 11a).  Also, primer dimers seemed even more abundant for the 
reamplification with MLALT1 than the original amplification with MLALT1, while 
reamplification with MLALT2 still maintained relatively low amount of primer dimers 
despite being slightly fainter than the original amplification with MLALT2.  The primers 
that gave successful amplification of the VH gene were the 5’ APg1AZ and the 3’ 
AZ PCR Product 
7C7:C5 VH Gene 
~432 bp 
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Cg1FORa. The VH gene appeared at ~432 bp.  The reamplification of the VH gene with 
APg1AZ and Cg1FORa produced a band at least as intense as the original amplification 
if not more (Figure 11b). 
 
 
                                              
 
 
 
 
 
 
Why were two PCR products of the same size produced using two distinct 
primers?  The likely reason is that an inherent gene for the aberrant kappa chain is present 
in the 7C7:C5 hybridoma cells.  The aberrant kappa chain gene is known to be produced 
by hybridomas from the murine SP2/0 MOPC21 cell line (the cell line from which the 
7C7:C5 hybridoma originates) along with the functional kappa chain gene 118-119.  One of 
the 5’ primers may be amplifying the aberrant Vκ gene, while the other 5’ primer is 
Figure 11.  (a) Reamplification of 7C7:C5 (a) Vκ and (b) VH PCR products.  An aliquot of 2 µL 
of PCR product was reamplified using standardized PCR protocol listed in the Materials and 
Methods.  A 10 µL aliquot of each reamplified PCR product mixed with a final 1X loading dye 
was electrophoresed at 59 V for seventy minutes on a 1% agarose, ≥0.1 µg/mL EtBr gel.  Gels 
were analyzed by UV exposure. 
 
Aberrant 
Vκ Gene? 
MLALT1 
7C7:C5 
Vκ Gene 
MLALT2 
500 bp 
400 bp 
 
7C7:C5 VH 
Amplicon 
~432 bp 
(a) (b) 
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amplifying the 7C7:C5 Vκ gene.  The desired DNA sequence is of course the one for the 
active Vκ gene and not for the inactive, aberrant Vκ gene.   
Upon performing a sequence alignment using LALIGN 160 in ExPASy, MLALT1 
shared 96% identity with the SP2/0 aberrant Vκ sequence and, thus, is quite likely to 
anneal to the aberrant Vκ sequence; while MLALT2 shares only 42% identity with the 
SP2/0 aberrant Vκ sequence and, thus, is unlikely to anneal to the aberrant Vκ sequence.  
Annealing of the forward and reverse primers is essential to the success of the 
amplification during PCR.  Thus, the most likely possibility is that MLALT2 annealed to 
the 7C7:C5 Vκ cDNA resulting in its amplification. 
Furthermore, the sequence for the SP2/0 aberrant Vκ gene was checked using 
NEBcutter 161 v.2.0 and does not contain a KpnI restriction site, a fairly common 
restriction site among murine Vκ sequences.  Looking at Figure 12, the 7C7:C5 MLALT2 
amplicon was successfully digested with KpnI and, thus, must contain a KpnI restriction 
site.  The presence of a KpnI site along with alignment results suggested that the 7C7:C5 
MLALT2 amplicon is indeed the 7C7:C5 Vκ sequence and not the SP2/0 aberrant Vκ 
sequence.  Fortunately, no additional test was needed for the obtained VH gene since the 
majority of hybridomas only produce the functional heavy chain transcript. 
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Cloning of the 7C7:C5 Vκ and VH Amplicons 
The 7C7:C5 Vκ and VΗ amplicons were then cloned into two separate pJet1/Blunt 
vectors using methods described in the Material and Methods.  The purpose of cloning is 
1) to produce enough DNA for sequencing and 2) to make sequencing of small PCR 
products more feasible by incorporating them into a plasmid.  This plasmid was used to 
transform chemically competent JM109 E.coli.  The plasmid amount replicated along 
with the replicating transformed E.coli. 
After growing the transformed E.coli overnight, the plasmid DNA was isolated 
from the rest of the cell contents by GeneJet mini-prep.  A kit proved necessary for 
successful isolation of these plasmids, as the method described for lab bench mini-prep 
Figure 12.  Digestions of 7C7:C5 Vκ and HB8747 Vκ genes with KpnI RE.  HB8747 is a 
hybridoma cell line that produces anti-carcinoembryonic antigen (CEA) monoclonal antibodies.  
The HB8747 Vκ gene contains a known KpnI site and, thus, this sequence was used as a control 
for digestion with KpnI RE to show that the restriction enzyme is indeed working properly.   
Digestions with KpnI RE were performed as described in the Materials and Methods.  Each 
sample used a total of 8 µL of PCR product and a total reaction mix of 10 µL mixed with a final 
1X loading dye.  Samples were loaded onto a 1% agarose, ≥0.1 µg/mL EtBr gel and 
electrophoresed at 59 V for one hour.  Gels were analyzed by UV exposure. 
 
HB8747
Vκ Gene 
~426 bp 
HB8747 
Vκ Gene 
Digested 
w/KpnI 
7C7:C5 
Vκ Gene 
~426 bp 
7C7:C5 
Vκ Gene 
Digested 
w/KpnI 
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used for producing plasmid DNA for dot/slot blots in the Materials and Methods section 
did not function well for isolation of the 7C7:C5 Vκ and VH plasmids (plasmids 
containing either the 7C7:C5 Vκ or VH PCR product insert).  In addition, despite using a 
kit for isolation of the 7C7:C5 Vκ and VH plasmids, the plasmids often required further 
purification by phenol/chloroform/isoamyl alcohol extraction followed by precipitation of 
DNA in the aqueous phase as described in the Material and Methods section before 
submitting samples to the University of Michigan for DNA sequencing.  Figure 13 shows 
an example of a 7C7:C5 Vκ purified plasmid. 
                                      
 
Figure 13.  Purification and precipitation of a 7C7:C5 Vκ plasmid. A 5 µL aliquot of 
purified and precipitated plasmid was mixed with a final 1X loading dye and 
electrophoresed at 72 V for one hour on a 1% agarose, 0.1 µg/mL EtBr gel. 
 
Generally, isolation of plasmid was performed on more than one culture of 
transformed E.coli, but plasmid isolated from each culture was kept separate so as to not 
mix products from separate sets of growth.  Mixing plasmid products can lead to two 
different plasmids in one mix and, as a result, both plasmids may become unable to be 
sequenced.  DNA cannot be separated from DNA, especially like DNA (same vector but 
different inserts), so easily, in which the best case was to avoid this problem. 
Purified 7C7:C5 Vκ Plasmid 
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A double digestion experiment using Fast Digest (FD) XhoI and FD XbaI 
restriction endonucleases was performed to demonstrate that an appropriately sized insert 
was cloned into the pJet1/blunt vector before submitting samples for sequencing.  In this 
case, the insert was ~451 bp (426 bp of PCR product plus 25 bp of vector) for the 7C7:C5 
Vκ excised fragment and ~457 bp (432 bp of PCR product plus 25 bp of vector) for the 
7C7:C5 VH excised fragment.  Figure 14 shows a double digestion result for two 
separately isolated 7C7:C5 Vκ plasmids from two separate colonies at different locations 
along the same plate of growth.  Each of these plasmids shows an excised fragment close 
to the expected size, but the bands for these fragments are faint.  The band from the 
7C7:C5 Vκ Plasmid #1 (P1) was stronger than the band from 7C7:C5 Vκ Plasmid #2 (P2). 
 
 
 
 
 
 
 
 
Figure 14.  Double digestion with FD XhoI and XbaI to excise the 7C7:C5 Vκ DNA 
insert fragment from isolated 7C7:C5 Vκ plasmids.  An 8 µL aliquot of Vκ plasmid 
DNA was double digested as described in the Materials and Methods.  Samples were 
mixed with a final 1X loading dye and electrophoresed at 59 V for one hour on a 1% 
agarose, 0.1 µg/mL EtBr gel.  The excised fragments for the Vκ inserts and the (+)-
control insert are circled in orange. 
 
Vκ P1 
 
Undigested    Digested 
 
Vκ P2 
 
Undigested    Digested 
 
(+)-Control Plasmid 
 
Undigested    Digested 
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Both Vκ P1 and P2 were tested for the presence of a KpnI site by digesting with 
KpnI restriction endonuclease.  The pJet1/blunt vector does not contain a KpnI site, so 
that linearization of the plasmid represents the presence of the 7C7:C5 Vκ gene inserted 
into the plasmid.  The 7C7:C5 Vκ sequence was demonstrated to possess a KpnI site 
previously by digestion of the 7C7:C5 Vκ PCR product with KpnI RE.  Figure 15 shows 
that the 7C7:C5 Vκ P1 was successfully linearized by digestion with KpnI RE.  The KpnI 
digestion result for the Vκ P2 (data not shown) appeared to be identical to that for Vκ P1.  
Unfortunately, not enough 7C7:C5 Vκ P1 and P2 remained for sequencing by the end of 
all the analysis of these plasmids. 
 
 
 
 
                                                                   
 
 
 
 
 
 
 
Successful sequencing of the 7C7:C5 Vκ and VH genes required producing 
numerous plasmids.  The purpose of producing numerous 7C7:C5 Vκ and VH plasmids 
was to compensate for various preparation problems and difficulties involved in the 
Undigested 
7C7:C5 Vκ P1 
7C7:C5 Vκ P1 
Digested with KpnI 
Figure 15.  Digestion of the 7C7:C5 Vκ P1 with KpnI RE.  An aliquot of 8 µL of plasmid was 
digested with KpnI RE as described in the Materials and Methods.  Samples were loaded with 
a final 1X loading dye onto a 1% agarose, 0.1 µg/mL EtBr gel.  This gel was electrophoresed 
at 72 V for one hour and analyzed by UV exposure.  Lane 9 (left) has 1st batch Vκ P1 plasmid 
digested with KpnI RE and Lane 10 (right) has 1st batch undigested Vκ P1 plasmid. 
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sequencing of these plasmids.  Due to the lack of Vκ P1 and P2 that remained, an adjacent 
colony to the colony that produced Vκ P1 had been transferred to another LBA plate and 
cultured on that plate.  The isolated plasmid (7C7:C5 Vκ Plasmid #3) from this colony 
was the first Vκ plasmid to be sequenced, in which one of the most informative Vκ 
sequencing results were obtained. 
Figure 16 shows a double digestion of 7C7:C5 Vκ Plasmid #* (P*), in which only 
a partial 7C7:C5 Vκ amplicon was excised from the pJet1/blunt vector.  The 7C7:C5 Vκ 
P* is a plasmid that was produced from a separate cloning reaction than Vκ P1 or P2.  
The Vκ P* resulted in highly informative sequencing results for approximately the first 
two-thirds of the Vκ DNA sequence.   
 
 
 
                           
 
 
 
 
400 bp 
300 bp 
VκP* 
Plasmid 
Intact 
 
VκP* Plasmid 
Double Digested 
w/FD XhoI+XbaI 
VκP* Plasmid 
Digested w/XhoI 
VκP* Plasmid 
Digested w/XbaI 
2000 bp Size Marker 
3500 bp Size Marker 
Figure 16.  Double digestion of the 7C7:C5 Vκ Partial Insert Plasmid (P*) using FD XhoI 
and FD XbaI.  Aliquots of 5 µL of plasmid DNA samples were used for each digestion in 
each lane.  Samples were loaded with a final 1X loading dye onto a 1% agarose, 0.1 µg/mL 
EtBr gel.  This gel was electrophoresed at 59 V for one hour and analyzed by UV exposure.  
The band for the partially degraded Vκ insert is circled in black in Lane 3. 
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Figure 17 shows results of a double digestion of 7C7:C5 Vκ P3 (a, b, and c) 
plasmids produced from a separate isolation of plasmid than the original 7C7:C5 Vκ P3.  
They are named the same merely because the same purified plasmid was stored at -20°C 
and then used to transform more JM109 E.coli.  Two of the plasmids were prepped from 
transformed colonies cultured on two separate plates (Plate A and B) and the third 
plasmid on a third plate (Plate C) was prepped from a fresh growth of a colony from Plate 
A.  As a result, the plasmids are essentially the same excluding possible mutations that 
may occur from one transformation to the next.  The Vκ P3a and P3c were sequenced, 
assisting in a final determination of any controversial nucleotides in the Vκ DNA 
sequence.  The double digestion experiment in Figure 17 used higher volumes of plasmid 
than used in other double digestion experiments, simply to produce a more intense band 
for the excised 7C7:C5 Vκ DNA insert. 
 
 
 
 
 
 
 
 
 
 
 
  75
 
 
 
 
Figure 17.  Double digestion of 7C7:C5 Vκ P3 (a, b, and c) plasmids with FD XhoI and 
FD XbaI.  Lane 2 contains reamplified Vκ PCR product.  Lanes 3-6 contain undigested, 
XhoI digested, XbaI digested, and double digested 7C7:C5Vκ P3a plasmid from Plate 
A/Prep A, respectively.  Lanes 7-8 contain undigested and double digested 7C7:C5 Vκ 
P3b plasmid from Plate B/Prep B, respectively.  Lanes 9-10 contain undigested and 
double digested 7C7:C5 Vκ P3c plasmid from Plate C/Prep A, respectively.  Double 
digestions using 20 µL of plasmid DNA were performed as described in the Materials 
and Methods. Samples were loaded with a final 1X loading dye onto a 1% agarose, 0.1 
µg/mL EtBr gel.  This gel was electrophoresed at 59 V for one hour and analyzed by UV 
exposure.  The bands for the Vκ inserts are circled in black in Lanes 6, 8, and 10. 
 
 
The 7C7:C5 VH plasmids were not only difficult to isolate in sufficient 
concentration from JM109 E.coli transformed with them, but also these plasmids in 
particular generally suffered from higher impurity than the Vκ plasmids after GeneJet 
mini-prep.  As a result, the strategy of using a purified plasmid from an original isolation 
to transform more JM109 was incorporated.  The 2nd generation of transformed JM109 
generally grew more efficiently than the original transformation and also resulted in 
better isolation of plasmid (higher concentration and purity).  Furthermore, the colonies 
7C7:C5 Vκ Gene 
~426 bp Excised 7C7:C5 Vκ  Gene Insert ~451 bp 
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produced from this 2nd generation were likely to exclusively contain the desired plasmid, 
diminishing the possibility of picking out a colony that may not contain the desired 
plasmid for isolation.  Figure 18 shows a double digestion result for two separately 
isolated 7C7:C5 VΗ plasmids.  Only the 7C7:C5 VΗ Plasmid #2 (P2) shows an excised 
fragment close to the expected size.  The VH P2 was sequenced in duplicate, in which 
both sets of sequencing gave identical high quality DNA sequences for the VH. 
 
 
 
 
Figure 18.  Double digestion of the 7C7:C5 VH Plasmids with FD XhoI and FD XbaI.  
Each sample had a final 1X loading dye and was loaded onto a 1.5% agarose, 0.1 µg/mL 
EtBr gel in the respective order:  Lane 1, DNA ladder; Lane 2, empty; Lane 3, undigested 
7C7:C5 VH P1 plasmid; Lane 4, 7C7:C5 VH P1 plasmid digested with XhoI; Lane 5, 
7C7:C5 VH P1 plasmid digested with XbaI; Lane 6, double digested 7C7:C5 VH P1 
plasmid; Lane 7, undigested 7C7:C5 VH P2 plasmid; Lane 8, 7C7:C5 VH P2 plasmid 
digested with XhoI; Lane 9, 7C7:C5 VH P2 plasmid digested with XbaI; and Lane 10, 
double digested 7C7:C5 VH P2 plasmid.  This gel was electrophoresed at 59 V for one 
hour and analyzed by UV exposure.  An excised VH insert from the 7C7:C5 VH P2 is 
circled in black in Lane 10. 
 
 
 
 
7C7:C5 VH 
Excised Insert 
(~457 bp) 
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Obtaining the DNA Sequences for the 7C7:C5 Vκ and VH 
Sequencing results obtained from the University of Michigan DNA Sequencing 
Core were further analyzed for errors and missing nucleotides.  The Vκ sequences 
commonly showed errors and missing nucleotides.  The overall process of isolating a 
plasmid containing the 7C7:C5 Vκ gene insert along with additional purification steps 
was repeated for numerous sequencing attempts, of which eight provided useful 
sequencing results.  Six of the eight significant Vκ sequencing results were all plasmid 
isolates derived from the Vκ P3 isolate that contained the 7C7:C5 Vκ gene insert.  A 
separate cloning reaction was done to produce the 7C7:C5 Vκ P*, in which this plasmid 
actually contained only a partial/degraded 7C7:C5 Vκ gene. 
The reported eight sequencing results for the 7C7:C5 Vκ gene and corresponding 
chromatogram analyses were used to determine the complete 7C7:C5 Vκ DNA sequence.  
The nucleotide sequence for the 7C7:C5 Vκ from residue -16 to 54 was primarily 
obtained from the reverse sequencing reaction results for the 7C7:C5 Vκ P* and is in 
congruence with four other informative sequencing results for the Vκ.  The latter half of 
the Vκ sequence was first primarily constructed from the forward and reverse sequencing 
results for the 7C7:C5 Vκ P3, and then from 7C7:C5 Vκ P3a and c forward and reverse 
sequencing results.  The forward sequencing results were overall more informative for 
this latter half of the Vκ sequence.  However, the reverse sequencing result for the 
7C7:C5 Vκ P3c decisively showed that residue 86 was in fact a tyrosine.  In addition, this 
same sequencing result showed that residue 105 was in fact a lysine.  The 7C7:C5 Vκ 
sequence is accurate through extensive analysis of the chromatograms along with 
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comparison of the various sequencing results.  The 7C7:C5 VH P2, on the other hand, 
gave sequencing results without any errors or missing nucleotides and, thus, the only 
difficulties with obtaining the VH sequence were in obtaining a plasmid in high enough 
amount, concentration, and purity for sequencing.  The complete DNA sequences and 
amino acid translations for the 7C7:C5 Vκ and VH are reported in Figures 19 and 20, 
respectively. 
 
gtgcagattttcagcttcctgctaatcagtgtcacagtgtccagagga 
 V  Q  I  F  S  F  L  L  I  S  V  T  V  S  R  G 
-16-15-14-13-12-11-10 -9 -8 -7 -6 -5 -4 -3 -2 -1 
 
            gaaattgtgctcactcagtctccagccatcacagctgcatctctgggg 
             E  I  V  L  T  Q  S  P  A  I  T  A  A  S  L  G  
             1  2  3  4  5  6  7  8  9 10 11  12 13 14 15 16 
 
caaaaggtcaccatcacctgcagtgccagctcaactgtcagttacatccattggtaccag 
 Q  K  V  T  I  T  C  S  A  S  S  T  V  S  Y  I  H  W  Y  Q  
17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 
 
cagaagtcaggcacctcccccaaaccatggatttatgaaatatccaaactggcttctgga 
 Q  K  S  G  T  S  P  K  P  W  I  Y  E  I  S  K  L  A  S  G  
37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 
 
gtcccagctcgcttcactggcagtgggtctgggacctcttactctctcacaatcagcagc 
 V  P  A  R  F  T  G  S  G  S  G  T  S  Y  S  L  T  I  S  S  
57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 
 
atggaggctgaagatgctgccatttattactgccagcagtggaattatccgtacacgttc 
 M  E  A  E  D  A  A  I  Y  Y  C  Q  Q  W  N  Y  P  Y  T  F   
77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96  
 
ggagggggg accaagttggaa ata aaa  cgggct gatgct gcacca 
 G  G  G   T  K  L  E   I   K    R  A   D  A   A  P  
97 98 99  100 101 102 103 104   105   106 107  108 109 110 111 
 
Figure 19.  The complete 7C7:C5 Vκ DNA sequence and its amino acid translation.  Each 
amino acid is placed directly below the middle of its codon and the corresponding amino 
acid number is directly below the amino acid.  The active 7C7:C5 Vκ is 105 amino acids 
long.  Residues -16 to -1 are residues of the Lκ and, thus, are not part of the active Vκ.  
Residues 106 to 111 are residues of the amino terminus of the Cκ.  Underlined in bold are 
the three kappa chain CDRs in sequential order from CDR-L1 to CDR-L3.  Nucleotides 
and amino acids in red or grey required analysis of the chromatograms and/or comparison 
of the obtained sequencing results. 
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tgctattcctgttgggcagccattcctggtatcctgtct         gatgaacagctt 
 C  Y  S  C  W  A  A  I  P  G  I  L  S           D  E  Q  L  
-13-12-11-10-9 -8 -7 -6 -5 -4 -3 -2 -1           1  2  3  4 
 
caggagtcaggacctggcctcgtgaaaccttctcagtctctgtctctcacctgctctgtc 
 Q  E  S  G  P  G  L  V  K  P  S  Q  S  L  S  L  T  C  S  V  
 5  6  7  8  9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
 
actggctactccatcaccaataattattactggaactggatccggcagtttccaggaaac 
 T  G  Y  S  I  T  N  N  Y  Y  W  N  W  I  R  Q  F  P  G  N  
25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 
 
aaactggaatggctgggctacataagatacgacggcagcactacctacaacccatctctc 
 K  L  E  W  L  G  Y  I  R  Y  D  G  S  T  T  Y  N  P  S  L  
45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 
 
aaaaatcgagtctccatcactcgtgacacatctaagaaccagtttttcctgaagttgaat 
 K  N  R  V  S  I  T  R  D  T  S  K  N  Q  F  F  L  K  L  N  
65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 
 
tctgtgactactgaggacacagctacatattactgtgcaagatacggctggttacctctt 
 S  V  T  T  E  D  T  A  T  Y  Y  C  A  R  Y  G  W  L  P  L  
85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 
 
gcttactggggc caa ggg actctg gtc actgtctctgca   gccaaaacgacaccc 
  A  Y  W  G   Q   G   T  L   V   T  V  S  A     A  K  T  T  P  
105 106 107 108 109   110 111  112  113 114 115 116 117    118 119 120 121 122 
 
Figure 20.  The complete 7C7:C5 VΗ DNA sequence and its amino acid translation.  
Each amino acid is placed directly below the middle of its codon and the corresponding 
amino acid number is directly below the amino acid.  The active 7C7:C5 VΗ is 117 amino 
acids long.  Residues -13 to -1 are residues of the LΗ and, thus, are not part of the active 
VΗ.  Residues 118 to 122 are residues of the amino terminus of the CΗ1.  Underlined in 
bold are the three gamma 1 chain CDRs in sequential order from CDR-H1 to CDR-H3. 
 
 
 
Sequence Blast Results for the 7C7:C5 Vκ 
 
 Commonly, murine IgG1s seem to be a combination of sequences from 
Chromosome 6 for the Vκ sequence and a combination of sequences from Chromosome 
12 for the VH sequence.  Coincidentally, the 7C7:C5 Vκ DNA sequence appears to be a 
combination of genomic sequences from Chromosome 6.  Nucleotides 36 to 326 of the 
7C7:C5 Vκ DNA sequence shares 98% identity with nucleotides 21173662 to 21173372 
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of strain C57BL/6J Mus musculus Chromosome 6 (ref|NT_039353.7|Mm6_39393_37).  
Nucleotides 1 to 35 of the 7C7:C5 Vκ DNA sequence share 100% identity with 
nucleotides 21070652 to 21070618 of the previously mentioned strain C57BL/6J Mus 
musculus Chromosome 6.  Nucleotides 327 to 365 of the 7C7:C5 Vκ DNA sequence 
share 97% identity with nucleotides 22985873 to 22985910 of the previously mentioned 
assembly of Mus musculus Chromosome 6.  Nucleotides 366-384, primarily Cκ” codons, 
of the 7C7:C5 kappa DNA sequence share 100% identity with nucleotides 22989391 to 
22989407 of the previously mentioned assembly of Mus musculus Chromosome 6.  As a 
result, a majority of the 7C7:C5 Vκ DNA sequence seems to have originated from 
different parts of one assembly of Chromosome 6.   
 In addition, much of the 7C7:C5 Vκ DNA sequence (including the Lκ) showed 
high similarity to predicted Mus musculus Vκ DNA sequences such as 
ref|XM_001476590.1| (88% identity from nucleotide 1 to 339 of the 7C7:C5 Vκ), 
ref|XM_001476823.1| (87% identity from nucleotide 1 to 311 of the 7C7:C5 Vκ), and 
ref|XM_001477017.1| (87% identity from nucleotide 2 to 308 of the 7C7:C5 Vκ).  
These results support that the 7C7:C5 Vκ is a Vκ that has not been previously sequenced.  
The amino acid sequence, however, reveals the primary structure of the antibody.  The 
highest similarity in amino acid sequence viewed was 94% identity with 
gb|ABC86056.1| through all 127 amino acids of the obtained 7C7:C5 kappa sequence.  
This amino acid sequence and others were not very useful for modeling because no 
crystal structures are available for them. 
 An IgBlast was done to align known Vκ sequences with the 7C7:C5 Vκ 
sequence and, in turn, identify the positions of the CDRs in the Vκ sequence.  Starting 
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with EIVLTQ, amino acids 1-23 are part of FR-L1, amino acids 24-33 are part of CDR-
L1, amino acids 34-48 are part of FR-L2, amino acids 49-55 are part of CDR-L2, and 
amino acids 56-87 are part of FR-L3.  The remaining CDR-L3, residues 88-95, and FR-
L4, residues 96-105, were identified by a combination of Kabat numbering 46 and 
comparative analysis with other similar Vκ sequences since the IgBlast does not clearly 
indicate these regions. 
 
Sequence Blast Results for the 7C7:C5 VH 
 
 The 7C7:C5 VΗ DNA sequence appears to be a combination of genomic 
sequences from Chromosome 12.  Nucleotides 28 to 333 of the 7C7:C5 VΗ DNA 
sequence shares 96% identity with nucleotides 26479777 to 26479472 of strain 
C57BL/6J Mus musculus Chromosome 12 (ref|NT_166318.1|Mm12_163492_37).  
Nucleotides 2 to 14 and 15 to 27 of the 7C7:C5 Vκ DNA sequence share 100% identity 
with nucleotides 19157316 to 19157328 and 19624190 to 19624178 of the previously 
mentioned strain C57BL/6J Mus musculus Chromosome 12.  Nucleotides 337 to 349 of 
the 7C7:C5 VΗ DNA sequence share 100% identity with nucleotides 2502975 to 2502987 
of the previously mentioned assembly of Mus musculus Chromosome 12.  Nucleotides 
350-387 of the 7C7:C5 VΗ DNA sequence share 100% identity with nucleotides 
25620444 to 25620407 of the previously mentioned assembly of Chromosome 12.  
Nucleotides 390 to 405, primarily CΗ1”, codons of the obtained 7C7:C5 gamma 1 
sequence share 100% identity with nucleotides 25521843 to 25521828.  As a result, a 
majority of the 7C7:C5 VΗ DNA sequence seems to have originated from different parts 
of one assembly of Chromosome 12.   
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 In addition, much of the 7C7:C5 VΗ DNA sequence (including the LΗ) showed 
high similarity to predicted Mus musculus VH DNA sequences ref|XM_913981.1| and 
ref|XM_973656.2| (90% identity from nucleotide 17 to 333 of the 7C7:C5 VΗ) and  
ref|XM_001474194.1| (85% identity from nucleotide 8 to 336 of the 7C7:C5 VΗ).  
These results support that the 7C7:C5 VΗ is a VΗ that has not been previously sequenced.  
The amino acid sequence, however, reveals the primary structure of the antibody.  The 
highest similarity in amino acid sequence viewed was 83% identity with 
gb|AAB06744.1| through amino acids 5 to 135 of the obtained 7C7:C5 gamma 1 
sequence.  This amino acid sequence and others were not very useful for modeling 
because no crystal structures are available for them. 
 An IgBlast was done to align known VΗ sequences with the 7C7:C5 VΗ 
sequence and, in turn, identify the positions of the CDRs in the VΗ sequence.  Starting 
with DEQLQE, amino acids 1-30 are part of FR-H1, amino acids 31-36 are part of CDR-
H1, amino acids 37-50 are part of FR-H2, amino acids 51-66 are part of CDR-H2.  The 
remaining FR-H3, residues 67-98, CDR-H3, residues 99-105, and FR-H4, residues 106-
117, were identified by a combination of Kabat numbering 46 and comparative analysis 
with other similar VΗ sequences since the IgBlast does not clearly indicate these regions. 
 
 
Homology Models of the 7C7:C5 Fv 
 
Homology models of the 7C7:C5 Fv were generated using the software program 
Modeller9v4.  The homology modeling process required aligning the amino acid 
sequence of the 7C7:C5 Fv with corresponding amino acid sequences of murine IgG1 VH 
and Vκ chains (Figures 21-28).  After the initial homology models were generated, the 
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protonation states of the models were assessed and hydrogens were added accordingly 
using the online software program H++.  The homology models were then energy 
minimized by L-BFGS method.  Both unbound and bound template model Fvs showed 
highly favorable total energies (-5582.5997 kcal/mol and -5719.1920 kcal/mol, 
respectively) after the minimization process.  Interestingly, the bound template Fv model 
was energetically more favorable than the unbound template Fv model by -136.5920 
kcal/mol. 
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Alignments for Antigen Unbound Template Model of the 7C7:C5 Fv 
 
FR-H1           CDR-H1        FR-H2 
 
7C7:C5:   Chain H:  Residues 1-50 
D-EQLQESG--PGLVK---P-SQS-L-SLTC--S-VTGYSIT---N-NY-YW-NWIRQ-FPGNK---LEW-L-G 
 
1QOK:  Chain A:  Residues 29-75 
---KLQQSGAE--LVRSGT----S-VK-LSC--TA-SGFNI-K--D-SYM---HWLRQG-P---EQGLEW-I-G 
 
1HQ4: Chain B:  Residues 1-50 
DV-QLQESG--PGLVK---P-SQS-L-SLTC--T-VTGYSIT---SG-YA-W-NWIRQ-FPGNK---LEW-M-G 
 
1F8T: Chain H:  Residues 3-50 
---QLQESG--PGLVK---P-SQS-L-SLTC--T-VTGYSIT---S-DYA-W-NWIRQ-FPGNK---LEW-M-G 
 
1S5I: Chain H:  Residues 3-50 
---QLQESG--PGLVK---P-SQS-L-SLTC--T-VTGYSIT---S-DYA-W-NWIRQ-FPGNK---LEW-M-G 
 
32C2: Chain B:  Residues 1-50 
DV-QLQESG--PGLVK---P-SQS-L-SLTC--T-VTGYSIS---S-DYA-W-NWIRQ-FPGNK---LEW-M-G 
 
1AY1: Chain H:  Residues 3-50 
---QLQESG--PGLVK---PY-QS-L-SLSC--T-VTGYSIT---S-DYA-W-NWIRQ-FPGNK---LEW-M-G 
 
1KCU: Chain H:  Residues 3-50 
---KLQQSG--PGLVK---P-SQS-L-SLTC--T-VTGYSIT---S-DYA-W-NWIRQ-FPGNK---LEW-MA- 
 
3CFE: Chain B, H:  Residues 3-50 
---QLQESG--PGLVK---P-SQS-L-SLTC--T-VTGYSIT---S-DYA-W-NWLRQL-PGNK---LEW-M-G 
 
2A0L: Chain D:  Residues 3-50 
---QLQESG--PGLVK---P-SQS-L-SLTC--T-VTGYSIT---N-NYA-W-NWIRQ-FPGNK---LEW 
 
1ORS: Chain B:  Residues 1-48 
DV-QLQESG--PGLVK---P-SQS-L-SLTC--T-VTGYSIT---N-NYA-W-NWIRQ-FPGNK---LEW 
 
1EZV: Chain X:  Residues 26-36 
-------------------------------------GYSITSG----Y-YW-N 
 
1BAF: Chain H:  Residues 1-50 
DV-QLQESG--PGLVK---P-SQSQ--SLTC--T-VTGYSIT---S-DYA-W-NWIRQ-FPGNK---LEW-M-G 
 
1KEN: Chain H:  Residues 4-50 
----LQESG--PGLVK---P-SQS-L-SLTCY---VTGYSIT---SG-Y-YWT-WIRQ-FPGNK---LEW-M-G 
 
 
Figure 21.  Alignment of residues 1-50 of the 7C7:C5 VH with crystal structures used for 
homology modeling of the antigen unbound template model of the 7C7:C5 VH.  Residues 
in red were not aligned with the 7C7:C5 VH.  Residues in black are FR residues.  
Residues in blue are CDR residues.    
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             CDR-H2                                            FR-H3 
 
7C7:C5:   Chain H:  Residues 51-98 
YI--RY-D-G-S-T-TY-NP--SL-K-NR-VS-IT-RDTS-KN--QFFL-KL-NSVT-T-EDTA-TY-YC-A-R— 
 
1QOK:   Chain A:  Residues 76-126 
WIDP---ENGD--TE-YA-PKF---QG-KA-TF-TT-DTSS-NTA--YL-QL-SSLT-S-EDTAV-Y-YCN-E-GT 
 
1HQ4:  Chain B:  Residues 51-98 
YI--RYS--GD--TR-Y-NP--SL-K-SR-IS-IT-RDTS-KN--QFFL-QL-NSVT-T-EDTA-TY-YC-AI--- 
 
1F8T:  Chain H:  Residues 51-98 
YI-T-YS--G-S-TG-Y-NP--SL-K-SR-IS-IT-RDTS-KN--QFFL-QL-NSVT-T-EDTA-TY-YC-AS--- 
 
1S5I:  Chain H :  Residues 51-98 
YI-T-YS--G-S-TG-Y-NP--SL-K-SR-IS-IT-RDTS-KN--QFFL-QL-NSVT-T-EDTA-TY-YC-AS--- 
 
32C2:  Chain B:  Residues 51-100 
YI-S-YS--G-S-T-SY-NP--SL-K-SR-IS-IT-RDTS-KN--QFFL-QL-SSVT-T-EDTA-TY-YC-A-RGY 
 
1AY1:  Chain H:  Residues 51-98 
YI-T-YS--G-T-TD-Y-NP--SL-K-SR-IS-IT-RDTS-KN--QFFL-QL-NSVT-T-EDTA-TY-YC-A-R-- 
 
1KCU:  Chain H:  Residues 51-99 
YI-S-YS--G-S-T-TY-NP--SL-K-SR-IS-IT-RDTS-KN--QFFL-QL-NSVT-T-EDTAI-Y-YC-A-RG- 
 
3CFE:  Chain B, H:  Residues 51-100 
YI-S-YS--GR-I-R-Y-NP--SL-KR-R-IS-IT-RDTS-KN--QFFL-QL-NSVT-T-EDTA-TY-YC-A-RSD 
 
1BAF:  Chain H:  Residues 51-98 
YM-S-YS--G-S-TR-Y-NP--SL-R-SR-IS-IT-RDTS-KN--QFFL-QLK-SVT-T-EDTA-TY-FC-A-R-- 
 
1KEN:  Chain H:  Residues 51-98 
YI-S-Y-D-G-SN-N-Y-NP--SL-K-NR-IS-IT-RDTS-KN--QFFL-KL-NSVTA--EDTA-SY-YC-AA--- 
 
1KCS:  Chain H:  Residues 51-99 
YIS--YS--G-S-T-SY-NP--SL-K-SRI-S-IT-RDTS-KN--QFFL-QL-NSVT-TD-DTA-TY-YC-A-RG- 
 
1I9I:  Chain H:  Residues 93-98 
------------------------------------------------------------------Y-YC-A-RE- 
 
 
Figure 22.  Alignment of residues 51-98 of the 7C7:C5 VH with crystal structures used 
for homology modeling of the antigen unbound template model of the 7C7:C5 VH.  
Residues in red were not aligned with the 7C7:C5 VH.  Residues in black are FR residues.  
Residues in blue are CDR residues.    
  86
    CDR-H3              FR-H4            CH1 
 
7C7:C5:  Chain H: Residues 99-122 
Y--GW----LP---L-AYWG-QGT-LVTVS-AA-KTTP 
 
1QOK:  Chain A:  Residues 127-146 
-PTG-PYYF--D-----YWG-QGTT-VTVS-S------ 
 
1HQ4:  Chain B:  Residues 99-121 
---GYGNSD--------YWG-QGT-LVTVS-AA-KTTP 
 
1F8T:  Chain H:  Residues 99-123 
YDD-YTWFT--------YWG-QGT-LVTVS-AA-KTTP 
 
1S5I:  Chain H:  Residues 99-123 
YDD-YTWFT--------YWG-QGT-LVTVS-AA-KTTP 
 
32C2:  Chain B:  Residues 101-124 
Y--G-SSHS-PV------WGA-GTT-VTVS-SA-KTTP 
 
1AY1:  Chain H:  Residues 99-123 
YYYGYWYFD--V------WG-QGTT-LTVS-SA-KTT 
 
1KCU:  Chain H:  Residues 99-121 
---G-TGFD--------YWGA-GTT-LTVS-AAA-TTP 
 
3CFE:  Chain B, H:  Residues 101-125 
Y--G-NYGR--GD----YWG-QGTS-VTVS-SA-KTTP 
 
1BAF:  Chain H:  Residues 99-120 
---GW-----P---L-AYWG-QGTQ-VSVSE-A-KTTP 
 
1KEN:  Chain H:  Residues 99-125 
F---YYDYD--FFF-D-YWG-QGTT-LTVS-SA-KTTP 
 
1KCS:  Chain H:  Residue 100 
---G 
 
2FON:  Chain A:  Residues 122-127 
----W----LP---L-AY 
 
1I9I:  Chain H:  Residues 99-123 
Y-YGYVG-------L-AYWG-QGT-LVTVS-AA-KTTP 
 
 
Figure 23.  Alignment of residues 99-117 of the 7C7:C5 VH with crystal structures used 
for homology modeling of the antigen unbound template model of the 7C7:C5 VH.  
Residues in red were not aligned with the 7C7:C5 VH.  Residues in black are FR residues.  
Residues in blue are CDR residues.   Residues 118-122 in plum are the first five residues 
of the CH1, which were also aligned for generating the model. 
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(a) 
 
     FR-L1                               CDR-L1          FR-L2               CDR-L2     FR-L3 
 
7C7:C5:  Chain L:  Residues 1-68 
E-IVLTQSP-AI-TAAS-LGQKVTITCSASSTVSYIHWYQQK-SGTSPK-PWIY--EIS-KLASGVPARFTGSGSGT 
 
1QOK:  Chain A:  Residues 162-229 
EN-VLTQSP-AIM-SASP-GEKVTITCSASSSVSYMHWFQQKP-GTSPKL-WIYST--SN-LASGVPARFSGSGSGT 
 
1E6O:  Chain L:  Residues 1-68 
E-IVLTQSP-AI-TAAS-LGQKVTITCSASSSVSYMHWYQQK-SGTSPK-PWIY--EIS-KLASGVPARFSGSGSGT 
 
2FAT:  Chain L:  Residues 1-68 
D-IVLTQSPD-I-TAAS-LGQKVTITCSASSSVSYMHWYQQK-SGTSPK-PWIF--EIS-KLASGVPARFSGSGSGT 
 
 
 
    (b) 
 
               FR-L3                CDR-L3        FR-L4        Cκ 
 
7C7:C5:  Chain L:  Residues 69-111 
SYSLTIS-SMEAEDAA-IYYCQQ-W--NYP-YTFG-GGTKLEIKRA-DAAP 
 
1QOK:  Chain A:  Residues 230-267 
SYSLTISR-MEAEDAAT-YYCQQR-S-SYPL-TFGA-GTKLELK 
 
1E6O:  Chain L:  Residues 69-111 
SYSLTIS-SMEAEDAA-IYYCQQ-W--NYP-FTFGS-GTKLEIKRA-DAAP 
 
2FAT:  Chain L:  Residues 69-111 
SYSLTIS-SMEAEDAA-IYYCQQ-W--NYP-FTFG-GGTKLEIKRA-DAAP 
 
1AIF:  Chain L:  Residues 95-114 
----------------------------YP-YTFG-GGTKLEIKRA-DAAP 
 
Figure 24.  Alignment of residues (a) 1-68 and (b) 69-105 of the 7C7:C5 Vκ with crystal 
structures used for homology modeling of the antigen unbound template model of the 
7C7:C5 Vκ.  Residues in red were not aligned with the 7C7:C5 Vκ.  Residues in black are 
FR residues.  Residues in blue are CDR residues.   Residues 106-111 in plum are the first 
six residues of the Cκ, which were also aligned for generating the model. 
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Alignments for Antigen Bound Template Model of the 7C7:C5 Fv 
 
                           FR-H1                                           CDR-H1            FR-H2 
 
7C7:C5:  Chain H:  Residues 1-50 
D-EQLQESG--PGLVK---P-SQS-L-SLTC--S-VTGYSIT---N-NY-YW-NWIRQ-FPGNK---LEW-L-G 
 
1QOK:  Chain A:  Residues 29-75 
---KLQQSGAE--LVRSGT----S-VK-LSC--TA-SGFNI-K--D-SYM---HWLRQG-P---EQGLEW-I-G 
 
1ORS:  Chain B:  Residues 1-50 
DV-QLQESG--PGLVK---P-SQS-L-SLTC--T-VTGYSIT---N-NYA-W-NWIRQ-FPGNK---LEW-M-G 
 
1CF8:  Chain H:  Residues 1-50 
DV-QLQESG--PGLVK---P-SQS-L-SLTC--T-VTGYSIT---SG-YA-W-NWIRQ-FPGNK---LEW-M-G 
 
1F90:  Chain H:  Residues 3-50 
---QLQESG--PGLVK---P-SQS-L-SLTC--T-VTGYSIT---S-DYA-W-NWIRQ-FPGNK---LEW-M-G 
 
1BAF:  Chain H:  Residues 1-50 
DV-QLQESG--PGLVK---P-SQSQ--SLTC--T-VTGYSIT---S-DYA-W-NWIRQ-FPGNK---LEW-M-G 
 
1KCR:  Chain H:  Residues 4-50 
----LQESG--PGLVK---P-SQS-L-SLTC--T-VTGYSIT---S-DYA-W-NWIRQ-FPGNK---LEW-M-G 
 
1KEN:  Chain H  Residues 4-50 
----LQESG--PGLVK---P-SQS-L-SLTCY---VTGYSIT---SG-Y-YWT-WIRQ-FPGNK---LEW-M-G 
 
2A0L:  Chain D:  Residues 3-50 
---QLQESG--PGLVK---P-SQS-L-SLTC--T-VTGYSIT---N-NYA-W-NWIRQ-FPGNK---LEW-M-G 
 
1BGX:  Chain H:  Residues 5-50 
-----QESG--PGLVK---PY-QS-L-SLSC--T-VTGYSIT---S-DYA-W-NWIRQ-FPGNK---LEW-M-G 
 
1KC5:  Chain H:  Residues 3-50 
---KLQQSG--PGLVK---P-SQS-L-SLTC--T-VTGYSIT---S-DYA-W-NWIRQ-FPGNK---LEW-MA- 
 
1NCW:  Chain H:  Residues 3-50 
---QLQQSG--PGLVK---P-SQS-L-SLTC--T-VTGYSIT---S-DFA-W-NWIRQ-FPGNK---LEW-M-G 
 
3CFD:  Chain H:  Residues 3-50 
---QLQESG--PGLVK---P-SQS-L-SLTC--T-VTGYSIT---S-DYA-W-NWLRQL-PGNK---LEW-M-G 
 
1EZV:  Chain X:  Residues 26-36 
-------------------------------------GYSITSG----Y-YW-N 
 
1S5I:  Chain H:  Residues 3-48 
---QLQESG--PGLVK---P-SQS-L-SLTC--T-VTGYSIT---S-DYA-W-NWIRQ-FPGNK---LEW 
 
Figure 25.  Alignment of residues 1-50 of the 7C7:C5 VH with crystal structures used for 
homology modeling of the antigen bound template model of the 7C7:C5 VH.  Residues in 
red were not aligned with the 7C7:C5 VH.  Residues in black are FR residues.  Residues 
in blue are CDR residues.   
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                    CDR-H2                                              FR-H3 
 
7C7:C5:  Chain H:  Residues 51-98 
YI--RY-D-G-S-T-TY-NP--SL-K-NR-VS-IT-RDTS-KN--QFFL-KL-NSVT-T-EDTA-TY-YC-A-R-- 
 
1QOK:  Chain A:  76-126 
WIDP---ENGD--TE-YA-PKF---QG-KA-TF-TT-DTSS-NTA--YL-QL-SSLT-S-EDTAV-Y-YCN-E-GT 
 
1ORS:  Chain B:  Residues 51-99 
YIN--YS--G-T-T-SY-NP--SL-K-SR-IS-IT-RDTS-KN--QFFL-QL-NSVT-T-EDTA-TY-FCV--R-G 
 
1CF8:  Chain H:  Residues 51-98 
YI--RYS--GD--TR-Y-NP--SL-K-SR-IS-IT-RDTS-KN--QFFL-QL-NSVT-T-EDTA-TY-YC-AI--- 
 
1F90:  Chain H:  Residues 51-98 
YI-T-YS--G-S-TG-Y-NP--SL-K-SR-IS-IT-RDTS-KN--QFFL-QL-NSVT-T-EDTA-TY-YC-AS--- 
 
1BAF:  Chain H:  Residues 51-98 
YM-S-YS--G-S-TR-Y-NP--SL-R-SR-IS-IT-RDTS-KN--QFFL-QLK-SVT-T-EDTA-TY-FC-A-R-- 
 
1KCR:  Chain H:  Residues 51-98 
YI--RNG--G-S-T-TY-NP--SLA--SR-IS-IT-RDTS-KN--QFFL-QL-NSVT-T-EDTA-TY-YC-A-R-- 
 
1KEN:  Chain H:  Residues 51-98 
YI-S-Y-D-G-SN-N-Y-NP--SL-K-NR-IS-IT-RDTS-KN--QFFL-KL-NSVTA--EDTA-SY-YC-AA--- 
 
2A0L:  Chain D:  Residues 51-99 
YI-N-YS--G-T-T-SY-NP--SL-K-SR-IS-IT-RDTS-KN--QFFL-QL-NSVT-T-EDTA-TY-FCV--RG- 
 
1BGX:  Chain H:  Residues 51-100 
YI-T-YS--G-T-TD-Y-NP--SL-K-SR-IS-IT-RDTS-KN--QFFL-QL-NSVT-T-EDTA-TY-YC-A-RYY 
 
1KC5:  Chain H:  Residues 51-98 
YIS--YS--G-S-T-TY-NP--SL-K-SR-IS-IT-RDTS-KN--QFFL-QL-NSVT-T-EDTAI-Y-YC-A-R-- 
 
1NCW:  Chain H:  Residues 51-100 
YI-N-YS--GF--T-SH-NP--SL-K-SR-IS-IT-RDTS-KN--QFFL-QL-NSVT-T-EDTA-TY-YC-AG-LL 
 
3CFD:  Chain H:  Residues 51-100 
YI-S-YS--GR-I-R-Y-NP--SL-KR-R-IS-IT-RDTS-KN--QFFL-QL-NSVT-T-EDTA-TY-YC-A-RSD 
 
1KCS:  Chain H:  Residues 51-99 
YIS--YS--G-S-TS-Y-NP--SL-K-SR-IS-IT-RDTS-KN--QFFL-QL-NSVT-TD-DTA-TY-YC-A-RG- 
 
1I9I:  Chain H:  Residues 93-98 
------------------------------------------------------------------Y-YC-A-RE- 
 
Figure 26.  Alignment of residues 51-98 of the 7C7:C5 VH with crystal structures used 
for homology modeling of the antigen bound template model of the 7C7:C5 VH.  
Residues in red were not aligned with the 7C7:C5 VH.  Residues in black are FR residues.  
Residues in blue are CDR residues.    
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      CDR-H3          FR-H4             CH1 
 
7C7:C5:  Chain H:  Residues 99-122 
Y--GW----LP---L-AYWG-QGT-LVTVS-AA-KTTP 
 
1QOK:  Chain A:  Residues 127-146 
-PTG-PYYF--D-----YWG-QGTT-VTVS-S------ 
 
1ORS:  Chain H:  Residues 100-123 
YD--YFAMD--------YWG-QGTS-VTVS-SA-KTTP 
 
1CF8:  Chain H:  Residues 99-121 
---GYGNSD--------YWG-QGT-LVTVS-AA-KTTP 
 
1F90:  Chain H:  Residues 99-123 
YDD-YTWFT--------YWG-QGT-LVTVS-AA-KTTP 
 
1BAF:  Chain H:  Residues 99-120 
---GW-----P---L-AYWG-QGTQ-VSVSE-A-KTTP 
 
1KCR:  Chain H:  Residues 99-121 
---G--GTG--FT----YWGA-GT-LVTVSAAA--TTP 
 
1KEN:  Chain H:  Residues 99-125 
F-Y-YDYD---FFF-D-YWG-QGTT-LTVS-SA-KTTP 
 
2A0L:  Chain H:  Residues 100-116 
Y-D-YFA-------MD-YWG-QGTS-VTV 
 
1BGX:  Chain H:  Residues 101-123 
Y--GYWYFD--V------WG-QGTT-LTVS-SA-KTT 
 
1KC5:  Chain H:  Residues 99-121 
---G-GTGF--D-----YWGA-GTT-LTVS-AAA-TTP 
 
1NCW:  Chain H:  Residues 101-123 
----WYDGG--AGS----WG-QGT-LVTVS-AA-KTT 
 
3CFD:  Chain H:  Residues 101-125 
Y--G-NYGR--GD----YWG-QGTS-VTVS-SA-KTTP 
 
1KCS:  Chain H:  Residue 100 
---G 
 
2FON:  Chain A:  Residues 122-127 
----W----LP---L-AY 
 
1I9I:  Chain H Residues:  99-123 
Y-YGYVG-------L-AYWG-QGT-LVTVS-AA-KTTP 
 
Figure 27.  Alignment of residues 99-117 of the 7C7:C5 VH with crystal structures used 
for homology modeling of the antigen bound template model of the 7C7:C5 VH.  
Residues in red were not aligned with the 7C7:C5 VH.  Residues in black are FR residues.  
Residues in blue are CDR residues.  Residues 118-122 in plum are the first five residues 
of the CH1, which were also aligned for generating the model. 
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           FR-L1                              CDR-L1           FR-L2               CDR-L2     FR-L3 
 
7C7:C5:  Chain L:  Residues 1-68 
E-IVLTQSP-AI-TAAS-LGQKVTITCSASSTVS-YIHWYQQK-SGTSPK-PWIY--EIS-KLASGVPARFTGSGSGT 
 
1QOK:  Chain A:  Residues 162-229 
EN-VLTQSP-AIM-SASP-GEKVTITCSASSSVS-YMHWFQQKP-GTSPKL-WIYST--SN-LASGVPARFSGSGSGT 
 
1E6J:  Chain L:  Residues 1-68 
E-IVLTQSP-AI-TAAS-LGQKVTITCSASSSVS-YMHWYQQK-SGTSPK-PWIY--EIS-KLASGVPARFSGSGSGT 
 
2FD6:  Chain L:  Residues 1-68 
D-IVLTQSPD-I-TAAS-LGQKVTITCSASSSVS-YMHWYQQK-SGTSPK-PWIF--EIS-KLASGVPARFSGSGSGT 
 
2FBJ:  Chain L:  Residues 1-68 
E-IVLTQSP-AI-TAAS-LGQKVTITCSASSSVSS-LHWYQQK-SGTSPK-PWIY--EIS-KLASGVPARFSGSGSGT 
 
 
          FR-L3                   CDR-L3           FR-L4      Cκ 
 
7C7:C5:  Chain L: Residues 69-105  
SYSLTIS-SMEAEDAA-IYYCQQ-W--NYP-Y-TFG-GGTKLEIKRADAAP 
 
1QOK:  Chain A:  Residues 230-267 
SYSLTISR-MEAEDAAT-YYCQQR-S-SYPL--TFGA-GTKLELK 
 
1E6J:  Chain L:  Residues 69-111 
SYSLTIS-SMEAEDAA-IYYCQQ-W--NYP-F-TFGS-GTKLEIKRADAAP  
 
2FD6:  Chain L:  Residues 69-111 
SYSLTIS-SMEAEDAA-IYYCQQ-W--NYP-F-TFG-GGTKLEIKRADAAP 
 
2FBJ:  Chain L:  Residues 69-112 
SYSLTIN-TMEAEDAA-IYYCQQ-W-T-YPL-ITFGA-GTKLELKRADAAP 
 
Figure 28.  Alignment of residues (a) 1-68 and (b) 69-105 of the 7C7:C5 Vκ with crystal 
structures used for homology modeling of the antigen bound template model of the 
7C7:C5 Vκ.  Residues in red were not aligned with the 7C7:C5 Vκ.  Residues in black are 
FR residues.  Residues in blue are CDR residues.   Residues 106-111 in plum are the first 
six residues of the Cκ, which were also aligned for generating the model. 
 
 
To compare the overall structure of the 7C7:C5 Fv models with its crystal 
structure templates, the template structures were superimposed on three different 
reference structures (the 7C7:C5 Fv models; the complete Fv template, 1QOK; and the 
most similar template in primary structure to the 7C7:C5 VH or Vκ) using 
DeepView/Swiss-PDB Viewer.  The Cα RMSDs for each superimposed structure were 
calculated also in DeepView/Swiss-PDB Viewer.  Tables 5 and 6 show Cα RMSDs of the 
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areas aligned for generation of the 7C7:C5 Fv models.  Overall, the Cα RMSD is 
consistent among templates.  The most similar template in primary structure to the 
7C7:C5 Fv shows the smallest Cα RMSD when superimposed with all the other 
templates.  The 1QOK template shows an overall two fold larger Cα RMSD than the most 
similar template in primary structure to the 7C7:C5 Fv, when superimposed with all the 
other templates. 
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Table 5.  The Cα RMSD for each crystal structure template aligned in generation of the 
antigen unbound model of the 7C7:C5 Fv 
 
VH Unbound Template Model Cα RMSD 
 
Structure    RMSD (Å)      
7C5U  reference    ---------- ----------- 
1QOK  1.58      reference ----------- 
1HQ4  1.35      1.06   reference 
1F8T  1.18      1.06   0.39  
1S5I  1.22      1.10   0.41  
32C2  1.21      1.45   0.65  
1AY1  1.55      1.28   0.93  
1KCU  1.06      1.38   0.49  
3CFE  1.33      1.42   0.44  
2A0L  1.27      1.35   0.65  
1ORS  1.22      1.37   0.48  
1EZV  0.58      0.95   0.18  
1BAF  1.16      1.72   0.46  
1KEN  1.69      1.36   1.08  
1KCS  0.84      1.41   0.37  
2FON  3.54   WLP  0.25, LAY 0.66   NA  NA 
1I9I  1.73   excluding YGY 1.20   1.42   0.36  
 
 
Vκ Unbound Template Model Cα RMSD 
 
Structure    RMSD (Å)      
7C5U  reference    ----------- ----------- 
1QOK  1.02      reference ----------- 
1E6O  0.92      0.66   reference 
2FAT  0.84      0.66   0.32  
1AIF  0.84      0.45   0.60  
 
 
*7C5U is the energy minimized antigen unbound model of the 7C7:C5 Fv.  Reference 
indicates structure in PDB format upon which other structures were superimposed.  
RMSDs highlighted in blue are for the indicated parts of the template. 
NA = not applicable 
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Table 6.  The Cα RMSD for each crystal structure template aligned in generation of the 
antigen bound model of the 7C7:C5 Fv 
 
VH Bound Template Model Cα RMSD 
 
Structure    RMSD (Å)       
7C5V               reference    ----------- ----------- 
1QOK  1.67      reference ----------- 
1ORS  1.49      1.16   reference 
1CF8  1.83      1.15   0.53  
1F90  1.50      1.07   0.45  
1BAF  1.34      1.18   0.54  
1KCR  1.42      1.22   0.63  
1KEN  1.77      1.37   1.19  
2A0L  1.54      1.26   0.58  
1BGX  1.73      1.70   1.32  
1KC5  1.38      1.18   0.56  
1NCW  1.43      1.15   0.62  
3CFD  1.66      1.63   0.71  
1EZV  0.89      0.95   0.25  
1KCS  1.30      0.87   0.28  
1S5I  1.30      1.10   0.58  
2FON  3.51    WLP  0.09, LAY 0.05   NA   NA 
1I9I  2.20      excluding YGY 1.59  1.39   0.56  
 
 
Vκ Bound Template Model Cα RMSD 
 
Structure  RMSD (Å)        
7C5V  reference    ----------- ----------- 
1QOK  1.06      reference ----------- 
1E6J  1.06      0.67   reference 
2FD6  1.24      0.72   0.59  
2FBJ  1.28      0.70   0.84  
 
*7C5V is the energy minimized antigen bound model of the 7C7:C5 Fv.  Reference 
indicates structure in PDB format upon which other structures were superimposed.  
RMSDs highlighted in blue are for the indicated parts of the template. 
NA = not applicable 
 
The Cα RMSDs with the 7C7:C5 Fv as the reference structure are the largest Cα 
RMSDs among the three reference structures.  Nevertheless, this result is quite logical for 
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a few reasons.  First, the Cα deviations in the 7C7:C5 Fv models are a combination of the 
deviations of 1QOK and the other templates used specifically for the VH or Vκ.  Thus, the 
Cα deviation of the templates superimposed on the 7C7:C5 Fv models is greater than that 
of the other templates when superimposed on 1QOK, but is not necessarily additive as 
much overlap in deviation occurs among templates keeping the overall Cα RMSDs of the 
7C7:C5 Fv models reasonable.   
Second, 1QOK was first the template listed in the alignment file and, thus, it is 
expected to have set the initial framework for generating the 7C7:C5 Fv models.  It has 
the lowest amino acid sequence identity of the templates used for generating either the 
7C7:C5 VH or Vκ and was selected only because the other templates showed high identity 
in either the VH or Vκ but not both.  The template 1QOK had the highest amino acid 
sequence identity of a complete Fv with the 7C7:C5 Fv.  As a result, the VH and Vκ of the 
7C7:C5 Fv are a relatively unique combination that are expected to vary in association 
from its templates, especially after the energy minimization process.   
Lastly, the CDR-H3 had a rather limited selection of templates to homology 
model it.  As a result, only the Cα RMSDs calculated with the 7C7:C5 Fv models as 
reference points included any residues of the CDR-H3 that aligned with a superimposed 
template structure.  The two template reference structures in Tables 5 and 6 excluded 
residues of the CDR-H3 due to the lack of similar residues in this area in a majority of the 
templates.  The templates 2FON and 1I9I both show relatively higher Cα RMSDs than 
the other templates when superimposed on the 7C7:C5 Fv models.  The residues of the 
CDR-H3 showed much higher Cα RMSDs than any of the other CDRs.   
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Table 7 shows Cα RMSDs calculated for CDR-H3 and L2 (the CDRs that 
comprise the majority of the predicted binding pocket).  The template 1BAF appears to 
have resulted in the lowest Cα RMSD for the CDR-H3 and aligns with six of the eight 
residues in this CDR.  The templates 1I9I and 2FON also align with six of the eight 
residues in this CDR.  The overall 1I9I template has a reasonable Cα RMSD when 
superimposed with the 7C7:C5 CDR-H3, particularly if the residues 99-Y, 101-GY-102 
of the 1I9I template and 99-YGW-101 of the 7C7:C5 VH are excluded from the 
alignment.  Also, if the alignment of 2FON with the 7C7:C5 CDR-H3 is broken into two 
parts (WLP and LAY), then the Cα deviation is barely noticeable.  The major Cα 
deviation appears to originate from the Pro H103 to Leu H104 linkage.  The 
conformation of this linkage appears to be more consistent with the 1BAF template, as 
suggested by the lower Cα deviations from this template in the CDR-H3 area. 
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Table 7.  The Cα RMSDs for CDRs of the predicted binding pocket of the 7C7:C5 Fv 
CDR-H3 Antigen Bound Templates 
 
Structure    RMSD (Å)      
7C5V              reference    ----------- ----------- 
1BAF  1.14     reference ----------- 
1I9I  1.84     2.44  reference 
2FON  3.46    WLP  0.18, LAY  0.03  2.62  1.57 
 
CDR-L2 Antigen Bound Templates 
 
Structure    RMSD (Å)      
7C5V  reference    ----------- ----------- 
1QOK  0.33      reference ----------- 
1E6J  0.50      0.20   reference 
2FD6  0.56      0.16   0.24  
2FBJ  0.42      0.06   0.19  
 
*7C5V is the energy minimized antigen bound model of the 7C7:C5 Fv.  Reference 
indicates structure in PDB format upon which other structures were superimposed.  
RMSDs highlighted in blue are for the indicated parts of the template. 
 
Models were assessed for stereochemical quality using the software program 
PROCHECK before and after an energy minimization.  Results of the PROCHECK 
assessment before minimization actually showed high percentages of residues (88.6% of 
residues for the unbound-template model and 89.1% of residues for the bound-template 
model) in the most favored backbone conformations; however, total energy calculations 
for both of these models were highly unfavorable, particularly due to overextended bond 
distances between residues.  PROCHECK assessment was performed for the bound 
template model after minimization by L-BFGS method.  The unbound template model 
underwent the same minimization process as the bound template model and, thus, 
assessment of the stereochemical quality was only deemed necessary for the more 
important of the two models.   
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A Ramachandran plot 162 for determining the stereochemical quality of the bound 
template model of the 7C7:C5 Fv is shown in Figure 29.  The plot shows that 147 
residues (72.8% of residues) are in the most favored conformations; 45 residues (22.3% 
of residues) are in the additional allowed conformations; 8 residues (4.0% of residues) are 
in the generously allowed conformations, and 2 residues (1.0% of residues) are in 
disallowed conformations.  Based on this plot, 99% of all residues in the minimized 
bound template model of the 7C7:C5 Fv were found to be in allowed conformations. 
 
 
Figure 29. Ramachandran plot generated by PROCHECK for the L-BFGS minimized 
bound template model of the 7C7:C5 Fv using an applied cutoff resolution of 2.0 Å. 
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Another significant assessment showed that the minimized model contained no 
bad contacts, or contacts in which one residue is intruding into another residue’s spatial 
arrangement.  Also, no main-chain bond distances varied from “ideal” bond distances by 
more than 0.05Å.  Lastly, only three main-chain bond angles (Thr H114-Val H115, Pro 
H122, and Pro H122-Glu L1) in the entire model were slightly greater than 10° of “ideal” 
bond angles and all three of these bond angles were at or near the amino terminus of the 
CH1 domain and, thus, none of the residues involved in these bond angles were deemed 
likely to have a significant effect on antigen binding as well as overall model quality. 
Two separate models of the 7C7:C5 Fv were generated.  One of the models, 
referred to as the unbound template model, was generated primarily using VH and Vκ 
chain coordinate data from crystallographic structures of Fabs in conformations with no 
antigen bound.  The other model, referred to as the bound template model, was generated 
primarily using VH and Vκ chain coordinate data from crystallographic structures of Fabs 
in antigen bound conformations as templates.  Only the bound template model was used 
for docking studies due to the likelihood that crystallographic structures of Fabs in an 
antigen bound form should give a better prediction of a suitable binding pocket.  The 
reasoning behind this assumption is that the Fvs of Fabs undergo induced fit 
conformations that influence binding activity and binding pocket formation 82, 123-125.  In 
fact, in some cases a binding pocket is not even noticeable until after the appropriate 
conformational changes in the Fv occur during the antigen binding process 82. 
Although only a theoretical prediction, visual comparison of the predicted binding 
pocket of the 7C7:C5 Fv in the energy minimized unbound and bound template models 
shown in Figure 30 demonstrates a good example of the possible differences between the 
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conformation of the binding pocket area of an unbound and an antigen-bound Fv.  In the 
unbound template Fv model, no obvious binding pocket is noticeable in the highlighted 
region.  The bound template Fv model, on the other hand, shows a binding pocket that is 
not only obvious in appearance, but appears to be a custom fit for a single d6mA antigen 
based on docking studies discussed next in this paper. 
 
 
        (a)  No Binding Pocket                                      (b) Binding Pocket 
            
            
Figure 30.  Comparison of the two energy minimized models of the 7C7:C5 Fv.  Two 
different viewpoints of (a) the (left top and bottom) model generated primarily using 
crystallographic VH and Vκ structures of Fabs in antigen unbound conformations as 
templates and (b) the (right top and bottom) model generated primarily using 
crystallographic VH and Vκ structures of Fabs in antigen bound conformations as 
templates.  Comparison of the highlighted (dotted) region between the model images on 
the left and the corresponding model images on the right clearly shows the presence of a 
binding pocket in the model on the right that is not present in the model on the left.  The 
highlighted residues included His L33, Tyr L35, Pro L45, Ile L47, Tyr L48, Ser L55, Leu 
H102, Pro H103, Leu H104, and Ala H105 and were based on paratope residues found in 
docking studies with d6mA. 
L2 
L1 
L3 
H2 
H1 
H3 
H2 
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Rigid Fv and Flexible Ligand Docking Analysis of the 7C7:C5 Fv 
Preliminary “blind docking” studies using wide-range grid boxes covering much 
of the top (viewpoint away from the amino termini of the constant regions and the 
carboxyl termini of the variable regions) center interface between the VH and Vκ chains 
(including areas proximal to the heavy and light CDR interface) were done to help predict 
the binding pocket.  The preliminary docking studies were all performed using rigid body 
docking for the Fv and flexible docking for the antigen.  Docking studies were performed 
with the grid box centered at different positions along the upper VH and Vκ interface.  
The docking experiment that revealed a docked conformation for d6mA with the most 
favorable (most negative) binding energy was selected as the most likely area for the 
paratope.   
The most favorable binding energy found for d6mA was -5.15 kcal*mol-1* K-1 and 
the corresponding dissociation constant, Kd, (inverse of the association constant, Ka) was 
1.69 x 10-4 M.  The selected paratope area visually appears to be a binding pocket that 
seems to fit a single d6mA securely (Figure 31a, b).  Furthermore, rigid body docking of 
dA and ssDNA trimer (A-6mA-T) each revealed at least one conformation which highly 
resembled the most favorable conformation for d6mA binding (Figure 31c-f).  In fact, the 
most favorable rigid body docking of d6mA and dA (Figure 31a-d) seem to be virtually 
identical conformations, in which the main difference is that d6mA has a methyl group 
instead of a hydrogen in the N6 position of the adenine base sticking down towards the 
deepest portions of the binding pocket.  The docking energies for dA and A-6mA-T were  
-3.56 kcal*mol-1*K-1 and -2.37 kcal*mol-1*K-1, respectively.  The corresponding Kd for 
dA and A-6mA-T were 2.46 x 10-3 M and 1.82 x 10-2 M, respectively. 
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Figure 31.  Preliminary “blind docking” studies using a wide range grid box, a rigid body 
model of the 7C7:C5 Fv, and a flexible antigen.  The top (a) (b) models show binding of 
the 7C7:C5 Fv to d6mA.  The middle (c) (d) models show binding of the 7C7:C5 Fv to 
dA.  The bottom (e) (f) models show binding of the 7C7:C5 Fv to a ssDNA trinucleotide 
of deoxyadenosine-deoxy-N6-methyladenosine-deoxythymidine (A-6mA-T).  Atomic 
color code (grey for carbon and non-polar hydrogens, cyan for polar hydrogens, blue for 
nitrogen, and red for oxygen) was used for docked antigens.  See color code in Figure 30 
for the Fv, p.100. 
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The docking interactions of the models with rigid binding pocket residues were 
analyzed using ADT-1.5.2.  van der Waals (vdW) interactions were determined using a 
scaling factor of 1.3 to adjust the default vdW distance (the sum of the two radii of the 
interacting atoms) for the purpose of allowing complete interaction of the adenine base 
and the methyl group in the N6 position.  Adjustment of this scaling factor should help 
compensate for contacts that may be off simply due to the rigidity of the model Fv.  The 
predicted interactions between the paratope of the anti-d6mA Fv and the epitopes of d6mA, 
dA, and A-6mA-T are shown in Figure 32, p. 106. 
The paratope for d6mA binding includes the following eleven residues:  His L33 
(=His 155), Tyr L35 (=Tyr 157), Pro L45 (=Pro 167), Ile L47 (=Ile 169), Tyr L48 (=Tyr 
170), Ala L54 (=Ala 176), Ser L55 (=Ser 177), Leu H102 (=Leu 102), Pro H103 (=Pro 
103), Leu H104 (=Leu 104), and Ala H105 (=Ala 105).  The residues Leu H102 and Ser 
L55 show hydrogen (H) bonds to the d6mA molecule, in which the main-chain carbonyl 
group of Leu H102 receives the lone hydrogen in the N6 position of adenine and the main 
chain NH group of Ser L55 donates a hydrogen to the N3 of adenine.  A total of five 
polar contacts are made with d6mA, of which approximately two interactions are with the 
deoxyribose moiety, two interactions are made with nitrogen atoms of the adenine ring 
system, and one interaction is made with the N6 lone hydrogen.  The sum of the contacts 
made with the epitope, especially for dispersion interactions, are not necessarily equal to 
the total number of contacts made against each specific component since some degree of 
overlap for contacts occurs between regions.  A total of thirty-two dispersion contacts are 
made with d6mA, of which approximately two to four show interaction with the 
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deoxyribose moiety, twenty-one show interaction with the adenine base, and thirteen 
show interaction with the N6 methyl group.   
The paratope for dA binding includes the following eight residues:  Pro L45, Tyr 
L48, Ala L54, Ser L55, Leu H102, Pro H103, Leu H104, and Ala H105.  The residues 
Leu H102 and Ser L55 show H-bonds to the dA molecule, in which the main-chain 
carbonyl oxygen of Leu H102 receives the N6 hydrogen sticking up and away from the 
bottom of the binding pocket and the main chain NH group of Ser L55 donates a 
hydrogen to the N3 of adenine.  A total of six polar contacts are made with dA, of which 
approximately two are made with the deoxyribose moiety, one is with a nitrogen of the 
adenine ring system, and three are with the N6 and the N6 hydrogens.  A total of twenty-
two hydrophobic contacts are made with dA, of which four show interaction with the 
deoxyribose moiety, eighteen show interaction with the adenine base, and four show 
interaction with the N6 hydrogens. 
An extended range of the paratope occurs to accommodate the larger volume of 
the ssDNA trinucleotide (A-6mA-T).  The central or primary paratope in this case includes 
any interactions that involve binding of the d6mA moiety, which includes the following 
six residues:  Tyr L48, Ala L54, Ser L55, Leu H102, Pro H103, and Ala H105.  No H-
bonds occurred with the d6mA moiety, but interestingly a hydrophobic π-stacking 
interaction occurred between Tyr L48 and the adenine ring on the side of d6mA facing the 
dT nucleotide.  A total of one polar contact is made with the deoxyribose of the d6mA 
moiety.  A total of sixteen dispersion contacts are made with the d6mA moiety, of which 
two show interaction with the deoxyribose moiety, ten show interaction with the adenine 
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ring system, and eleven show interaction with the N6 substituents (approximately eight 
contacts to the methyl group and three contacts to the lone hydrogen). 
Secondary and tertiary paratopes are present for the nucleotides neighboring the 
d6mA moiety.  The residues Tyr L48, Glu L49 (=Glu 171), Lys L52 (=Lys 174), and Tyr 
H33 (=Tyr 33) contribute a total of six polar contacts to the A-6mA and 6mA-T phosphate 
groups, respectively.  A total of four dispersion contacts are made with the two phosphate 
groups by Glu L49, Tyr H33, and Trp H101 (=Trp 101).  Only two residues interact with 
the dA moiety:  Asn H32 (=Asn 32) and Tyr H33.  The carboxamide oxygen of Asn H32 
receives a hydrogen from one of the N6 hydrogens of adenine.  Six dispersion and three 
polar contacts are made with the dA moiety.  Three residues interact with the dT moiety:  
Tyr L48, Glu L49, and Lys L52.  The oxygen of the phenolic hydroxyl group of Tyr L48 
receives a hydrogen from the alcohol group of the deoxyribose moiety.  Four dispersion 
and two polar contacts are made with the dT moiety. 
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Figure 32.  Predicted paratope interactions of the anti-d6mA Fv using a rigid binding 
pocket with flexible (a) (b) deoxy-N6-methyladenosine, (c) (d) unmethylated 
deoxyadenosine, and (e) (f) ssDNA trinucleotide (A-6mA-T).  Black dotted lines indicate 
H-bonds.  Grey spheres indicate hydrophobic interactions and smaller light blue or red 
spheres indicate the presence of a polar group involved in either a dispersion or a dipole 
interaction.  The maximal distance from the epitope for a van der Waals contact was the 
sum of the two radii of the interacting atoms with a scaling factor of 1.3. 
d6mA 
(a) (b) 
(c) (d) 
dA 
A-6mA-T 
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The paratopes of the rigid 7C7:C5 Fv binding pocket for each of the three docked 
antigens (d6mA, dA, and A-6mA-T) include the following common residues:  Tyr L48, Ala 
L54, Ser L55, Leu H102, Pro H103, and Ala H105.  Apparently, Tyr L48, Ser L55, and 
Pro H103 are the most critical binding residues based on the rigid body Fv docking 
models with flexible antigens.  They comprise a large number of the overall contacts, in 
which Tyr L48 has the most contacts generally followed by Pro H103 and lastly Ser L55.  
The docking of d6mA receives more paratope residues than either dA or d6mA moiety of 
A-6mA-T.  While docking of A-6mA-T provides interaction with twelve paratope residues 
total versus eleven paratope residues for d6mA and eight paratope residues for dA, the 
docking of A-6mA-T occurs over a much wider volume.  Thus, the presence of more 
paratope or paratope interactions alone does not necessarily mean a stronger binding 
affinity since Kd is relative to the number of interactions and type of interactions per 
volume of encountered epitope. 
In the docking of d6mA, residues His L33, Tyr L35, Pro L45, and Leu H104 show 
interactions with the N6 methyl group.  The overall number of interactions with the N6 
methyl group of d6mA alone and d6mA in A-6mA-T is thirteen and eight, respectively.  The 
overall number of interactions with the N6 hydrogen of dA that sticks downwards into 
the binding pocket is two, of which one is a polar interaction and the other is a dispersion 
interaction.  Table 8 summarizes the overall number of interactions by category:  
stacking, H-bond, polar, or dispersion interactions. 
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Table 8.  Summary of the total interactions of the rigid 7C7:C5 Fv with the flexible 
antigens:  d6mA, dA, and ssDNA (A-6mA-T) 
 
 Number of Interactions for Each Antigen 
d6mA dA ssDNA (A-6mA-T) 
Type of Interactions    
   
π-Stacking Interactions 0 0 1 
Hydrogen Bonds 2 2 2 
Polar Contacts 5 6 12 
Dispersion Contacts 32 22 30 
 
 
7C7:C5 Fv with Five Flexible Binding Pocket Residues and Flexible Antigen 
Docking 
 
The calculated Kd values from the rigid Fv model docking studies suggest 
relatively weak binding for all three antigens (d6mA, dA, and A-6mA-T); however, antigen 
binding pockets are not rigid.  By allowing for some of the residues around the binding 
pocket to be flexible, more contacts as well as tighter contacts should occur between 
paratope and epitope.  Accordingly, the affinity for d6mA, dA, and A-6mA-T should 
improve as a result of the ability of paratope residues to form more of a custom fit for 
each epitope.  To test this hypothesis, docking studies were performed with a model of 
the anti-d6mA Fv that included flexible residues in an area around the binding pocket.  
Five residues (Tyr L35, Ile L47, Tyr L48, Ser L55, and Leu H104) around the predicted 
binding pocket were selected to be flexible. 
The flexible residues added a total of twelve active torsions to the overall amount 
of active torsions.  The only other torsions allowed were the same active ligand torsions 
used in the rigid body docking studies.  In addition to adding flexible residues to the 
study, a few search parameters related to energy evaluations and the overall 
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conformational output were increased and a more focused grid box was applied.  A 
collection of the flexible residue docking results is shown in Figure 33, p. 112.  Antigen 
binding for d6mA and dA is limited to CDR-H3 and –L2.  In fact, the predicted binding 
pocket lies at the interface between CDR-H3 and –L2 and includes a couple of 
framework residues according to Kabat numbering scheme for CDRs.  Conformations for 
dA and ssDNA trimer (A-6mA-T) were selected based on proximity to the most favorable 
conformation for d6mA since d6mA is the closest in structure of these three antigens to 
6mAos, the antigen to which the 7C7:C5 MAb was produced. 
The most favorable conformation for d6mA binding to the 7C7:C5 binding pocket 
is shown in Figure 33a, b.  The binding energy for this conformation of d6mA was -14.57 
kcal*mol-1*K-1 and the corresponding Kd was 2.10 x 10-11 M.  The docking of d6mA in 
the binding pocket with flexible residues shows similarity to the binding of d6mA in the 
rigid body binding pocket, in which the binding of d6mA is once again deep within the 
binding pocket and the N6 methyl group is sticking down towards the deepest portions of 
the binding pocket.  The selected conformation for dA binding (shown in Figure 33c, d) 
was not the most favorable conformation for dA binding to the 7C7:C5 binding pocket in 
terms of binding energy; however, it was the closest in appearance to the most favorable 
conformation for d6mA binding. 
Besides, the most favorable energy conformations for dA found in the study 
involved the deoxyribose moiety fitting more deeply into the binding pocket in which the 
adenine base was sticking out of the binding pocket with minimal Fv interaction.  None 
of these more favorable end conformations for dA seemed reasonable on that basis.  Also, 
none of them would be applicable to dA in ssDNA since the connection of the sugar 
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moiety to phosphates and other nucleotides would prevent the sugar moiety from binding 
deep into the binding pocket.  The binding energy for the selected dA conformation is      
-13.45 kcal*mol-1*K-1 and the corresponding Kd is 1.39 x 10-10 M.  The conformation for 
dA does not bind as deep into the binding pocket as d6mA.  In fact, the N6 hydrogens of 
dA appear to interact with residues closer to the surface.  In turn, the adenine base of dA 
fits into the binding pocket at more of a diagonal orientation than the adenine base of 
d6mA, which fits into the pocket in a nearly vertical orientation.  The diagonal orientation 
of dA results in the deoxyribose moiety being closer to Ser L55 rather than Tyr L48. 
The docked conformation of the d6mA moiety of the ssDNA trinucleotide (A-6mA-
T) to the 7C7:C5 Fv (in Figure 33e, f) resembled the most favorable conformation for the 
binding of d6mA alone to the 7C7:C5 Fv.  As a result, this binding mode was selected as 
the most probable binding conformation for A-6mA-T found.  The binding energy for this 
selected conformation of A-6mA-T was -14.36 kcal/mol and the corresponding Kd is 
2.963*10-11 M.  Coincidentally, the selected conformation of A-6mA-T (shown in Figure 
33e, f) also happened to be the most favorable conformation for A-6mA-T binding found.  
All three nucleotides of A-6mA-T appear to make contacts with the surface of the Fv 
extending the paratope over a larger surface area than with either d6mA or dA.  Similar to 
the conformation found for dA docking in Figure 33c, d, the selected conformation of A-
6mA-T docking appears to bind the d6mA moiety not as deep into the binding pocket as 
d6mA alone. 
The d6mA moiety of the trinucleotide A-6mA-T may not be able to bind as deep as 
d6mA merely because it is connected to two other nucleotides that sterically prevent it 
from binding deeper into the binding pocket.  In addition, interactions with the phosphate 
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groups between nucleotides as well as interactions with each of the nucleotides may also 
prevent the d6mA moiety in A-6mA-T from binding as deep into the binding pocket as 
d6mA alone.  The possibility of a secondary binding pocket that opens up and forms after 
induced fit binding of a single d6mA in the primary binding pocket exists, but such 
information would need to be determined experimentally first. 
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Figure 33.  Docking studies using a more focused grid box than in preliminary docking 
studies, a set of five flexible residues (Tyr L35, Ile L47, Tyr L48, Ser L55, and Leu 
H104) in the area of the binding pocket of the model 7C7:C5 Fv, and a flexible antigen.  
The top (a) (b) models show binding of the 7C7:C5 Fv to d6mA. The middle (c) (d) 
models show binding of the 7C7:C5 Fv to dA.  The bottom (e) (f) models show binding 
of the 7C7:C5 Fv to A-6mA-T.  Atomic color code (grey for carbon and non-polar 
hydrogens, cyan for polar hydrogens, blue for nitrogen, and red for oxygen) was used for 
docked antigens.  See color code in Figure 30 for the Fv, p.100. 
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The docking interactions of the models with flexible Fv residues were analyzed 
using ADT-1.5.2.  van der Waals interactions were determined using a scaling factor of 
1.3 to adjust the default vdW distance for the purpose of allowing complete interaction of 
the adenine base and the methyl group in the N6 position.  Plus, adjustment of this 
scaling factor should help compensate for contacts that may be off simply due to the 
overall general rigidity of the model Fv.  The predicted interactions between the paratope 
of the anti-d6mA Fv and the epitopes of d6mA, dA, and A-6mA-T are shown in Figure 34, 
p. 116.  The paratope for d6mA binding includes the following eleven residues:  His L33, 
Tyr L35, Pro L45, Ile L47, Tyr L48, Ala L54, Ser L55, Leu H102, Pro H103, Leu H104, 
and Ala H105.   
The residues Leu H102, Tyr L48, and Ser L55 show hydrogen bonds to the d6mA 
molecule, in which the main-chain carbonyl group of Leu H102 receives the lone 
hydrogen in the N6 position of adenine, the phenolic hydroxyl group of Tyr L48 donates 
a hydrogen to the 5’ oxygen of the deoxyribose moiety, and the main chain NH group of 
Ser L55 donates a hydrogen to the N3 of adenine.  A total of six polar contacts are made 
with d6mA, of which approximately two interactions are with the deoxyribose moiety, two 
interactions are with the N3 of adenine, one interaction is with the N5 of adenine, and one 
interaction is with the N6 lone hydrogen.  A total of twenty-eight dispersion contacts are 
made with d6mA, of which approximately five show interaction with the deoxyribose 
moiety, sixteen show interaction with the adenine base, and thirteen show interaction 
with the N6 methyl group.   
The paratope for dA binding includes the following seven residues:  Tyr L48, Glu 
L49, Lys L52, Ser L55, Leu H102, Pro H103, and Leu H104.  The residues Glu L49 and 
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Ser L55 show H-bonds to the dA molecule, in which the carbonyl oxygen of the side-
chain of Glu L49 receives the N6 hydrogen sticking down into the pocket and the oxygen 
of the side-chain hydroxyl group of Ser L55 receives a hydrogen from the alcohol group 
of the deoxyribose moiety.  A total of six polar contacts are made with dA, of which 
approximately two are made with the deoxyribose moiety, two are with the N3 of 
adenine, and two are with the N6 hydrogens.  A total of eighteen dispersion contacts are 
made with dA, of which only one shows interaction with the deoxyribose moiety, sixteen 
show interaction with the adenine base, and only one shows interaction with the N6 
hydrogens.   
Once again an extended range of the paratope occurs to accommodate the larger 
volume of the ssDNA trinucleotide (A-6mA-T).  The central or primary paratope in this 
case includes any residues involved in interactions with the d6mA moiety.  Residues of the 
primary paratope against d6mA moiety include Tyr L48, Glu L49, Lys L52, Leu H102, 
and Pro H103.  Only one H-bond was found with the d6mA moiety A-6mA-T, in which the 
carbonyl oxygen of the side-chain of Glu L49 receives the N6 lone hydrogen.  A total of 
five polar contacts are made with the d6mA moiety, of which two are made with the 
adenine base (one to N3 and the other to N5) and three are made with the N6 lone 
hydrogen.  A total of eighteen dispersion contacts are made with the d6mA moiety, of 
which only one or two show interaction with the deoxyribose moiety, fourteen show 
interaction with adenine base, and six show interaction with the N6 substituents 
(approximately four contacts to the methyl group and two contacts to the lone hydrogen). 
Secondary and tertiary paratopes are present for the nucleotides neighboring the 
d6mA moiety.  The residues Ser L55 and Tyr H33 donate a hydrogen to the 6mA-T and A-
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6mA phosphate groups, respectively.  Only three residues interact with the dA moiety:  
Tyr H33, Tyr H34 (=Tyr 34), and Trp H101.  The phenolic hydroxyl group of Tyr H34 
receives a hydrogen from one of the N6 hydrogens of adenine.  Twelve dispersion and 
three polar contacts are made with the dA moiety.  Four residues interact with the dT 
moiety:  Ser L55, Tyr H99 (=Tyr 99), Ala H105, and Tyr H106 (=Tyr 106). The side-
chain hydroxyl group of Ser L55 receives a hydrogen from the alcohol group of the 
deoxyribose moiety.  Eleven dispersion and three polar contacts are made with the dT 
moiety. 
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Figure 34.  Predicted paratope interactions of the anti-d6mA Fv using five flexible 
residues in the binding pocket with flexible (a) (b) deoxy-N6-methyladenosine, (c) (d) 
unmethylated deoxyadenosine, and (e) (f) ssDNA trinucleotide (A-6mA-T).  Black dotted 
lines indicate H-bonds.  Grey spheres indicate hydrophobic interactions and smaller light 
blue or red spheres indicate that a polar group is involved in either a dispersion or a 
dipole interaction.  The maximal distance from the epitope for a van der Waals contact 
was the sum of the two radii of the interacting atoms with a scaling factor of 1.3. 
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 The paratopes of the 7C7:C5 Fv binding pocket for each of the three docked 
antigens (d6mA, dA, and A-6mA-T) include the following common residues:  Tyr L48, Ser 
L55, and Pro H103.  These three residues are apparently the most critical binding 
residues.  They comprise a large number of the overall contacts, in which Tyr L48 has the 
most contacts generally followed by Pro H103 and lastly Ser L55.  In addition to these 
residues, leucine residues have been found to make at least a few contacts to the epitope 
of d6mA, dA, and A-6mA-T.  Leu H104 makes contacts for the docking of d6mA and dA to 
the 7C7:C5 Fv binding pocket, while Leu H102 makes contacts for the docking of d6mA, 
dA, and A-6mA-T.  Residues Glu L49 and Lys L52 make at least a few contacts for 
binding dA around the hydrogens of the N6 position.  Coincidentally, Glu L49 and Lys 
L52 make several contacts on the d6mA moiety of A-6mA-T around the methyl group and 
lone hydrogen of the N6 position. 
In fact, the docking of the d6mA moiety in A-6mA-T resembles more closely the 
docking of dA than d6mA, in which five of the seven residues involved in dA docking are 
involved in docking of the d6mA moiety in A-6mA-T.  In fact, the docking of the d6mA 
moiety in A-6mA-T involves only these five paratope residues:  Tyr L48, Glu L49, Lys 
L52, Leu H102, and Pro H103.  The complete docking of A-6mA-T, however, provides 
interaction with twelve paratope residues versus eleven paratope residues for d6mA and 
seven paratope residues for dA.  As a result, the overall docking of A-6mA-T yields more 
paratope residues directly involved in docking than either d6mA or dA.   
In the docking of d6mA, residues His L33, Tyr L35, Pro L45, Ile L47, and Leu 
H104 show interactions with the N6 methyl group.  The overall number of interactions 
with the N6 methyl group of d6mA alone and d6mA in A-6mA-T is thirteen and four, 
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respectively.  The overall number of interactions with the N6 hydrogen of dA that sticks 
downwards into the binding pocket is four, of which one is a H-bond.  Table 9 
summarizes the overall number of interactions by category:  stacking, H-bond, polar, or 
dispersion interactions. 
 
Table 9.  Summary of the total interactions of the 7C7:C5 Fv with five flexible residues 
and flexible antigens:  d6mA, dA, and ssDNA (A-6mA-T) 
 
 Number of Interactions for Each Antigen 
d6mA dA ssDNA (A-6mA-T) 
Type of Interactions    
   
π-Stacking Interactions 0 0 0 
Hydrogen Bonds 3 2 5 
Polar Contacts 6 6 11 
Dispersion Contacts 28 18 41 
 
 
One additional mode of binding for dA that appeared plausible was found from 
the docking of dA in the binding pocket with the five flexible residues (Figure 35).  This 
binding mode showed dA buried deep into the binding pocket similar to the docking of 
d6mA; however, dA is in the reverse orientation (a 180° horizontal rotation).  The 
paratope for this alternate binding mode for dA includes the following paratope residues:  
Pro L45, Tyr L48, Ala L54, Ser L55, Tyr H33, Leu H102, Pro H103, Leu H104, and Ala 
H105.  Eight of these nine paratope residues for binding of dA were also paratope 
residues predicted in the binding of d6mA, while in the docking model for dA in Figures 
33c, d and 34c, d (p. 112, 116), only five of the seven paratope residues in binding of dA 
were also predicted in the binding of d6mA.  The docking model for dA in Figure 35 
shows nine polar contacts and twenty-two dispersion contacts.  The number of dispersion 
contacts in the flexible Fv docking model in Figure 35 is identical to the number of 
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dispersion contacts found in the rigid Fv docking model in Figure 31c, d and 32c, d (p. 
102, 106).   
 
 
Figure 35.  Reverse orientation binding mode found in the docking of flexible dA to the 
7C7:C5 Fv with five flexible residues in the binding pocket.  Top (a) (b) models show the 
position and orientation of docking of dA in the binding pocket of the 7C7:C5 Fv.  
Bottom (c) (d) models show the paratope interactions of the 7C7:C5 Fv with dA in a 
reverse orientation of binding.  Black dotted lines indicate H-bonds.  Grey spheres 
indicate hydrophobic interactions and smaller light blue or red spheres indicate that a 
polar group is involved in either a dispersion or a dipole interaction.  The maximal 
distance from the epitope for a van der Waals contact was the sum of the two radii of the 
interacting atoms with a scaling factor of 1.3.  Color code for the Fv is the same as in 
Figure 30, p. 100.  Atomic color code (grey for carbons and non-polar hydrogens, cyan 
for polar hydrogens, blue for nitrogen, and red for oxygen) is used for the antigen. 
 
The binding energy for docking of dA in this flexible binding pocket docking 
model in Figure 35 is -14.22 kcal/mol and the corresponding Kd is 3.757 x 10-11 M.  As a 
result, it is more favorable than the one selected in Figures 33c, d and 34c, d (p. 112, 
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116).  In addition, the contribution from intermolecular energy is much closer to that 
reported for the selected rigid Fv docking model for dA.  The intermolecular energy for 
the docking model in Figure 35 is -4.82 kcal/mol vs. -4.62 kcal/mol for the rigid Fv 
docking model in Figures 31c, d and 32c, d (p. 102, 106) vs. -3.59 kcal/mol for the 
flexible Fv docking model in Figures 33c, d and 34c, d.   
Nevertheless, a few inconsistencies exist with the flexible Fv docking model in 
Figure 35.  First, no H-bonds were found to occur in this docking model for dA.  
Hydrogen bonds are typically important in determining the specificity of anti-ssDNA 
antibodies.  However, three dipole-dipole contacts between the OH groups of Tyr L48, 
Ser L55, and Tyr H33 and three different polar groups on the dA may require only a 
slight adjustment in either separation or rotation between paratope and epitope groups to 
form H-bonds.  Second, none of the other antigens suggest this reverse orientation 
docking mode to occur.  Third, the most favorable Fv docking mode of A-6mA-T [Figure 
33e, f and 34e, f (p. 112, 116 )] greatly resembles the reported docking mode for dA in 
Figures 33c, d and 34e, f.  Fourth, slot blot results suggest an affinity difference between 
binding of d6mA and dA to the 7C7:C5 Fv of at least six fold, whereas the Kd for the 
docking model in Figure 35 suggests an affinity difference between binding of d6mA and 
dA to the 7C7:C5 Fv of only two fold. 
In conclusion, the resulting more favorable energy for docking of dA in Figure 35 
may simply be due to the deeper binding of dA into the binding pocket, in which more 
contacts occur.  This docking model hence further supports the predicted binding pocket.  
In addition, it also supports the hypothesis that the final docked state of dA in the 7C7:C5 
Fv is likely to occur deep in the binding pocket as opposed to closer to the surface of the 
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7C7:C5 Fv.  On the other hand, the docking model selected in Figures 33c, d and 34c, d 
(p. 112, 116) is consistent with the predicted orientation of antigen docking in the 7C7:C5 
Fv.  The possibility of combining the deeper binding as found in the docking models for 
d6mA in Figures 31a, b-34a, b (p. 102, 106, 112, 116) and in the docking models for dA in 
Figures 31c, d, 34c, d with the forward orientation (the orientation of the N6 position of 
d6mA or dA towards His L33 and away from Ser L55) seems to represent the most logical 
prediction for the docking of dA.  Nevertheless, the reverse horizontal orientation of dA 
docking cannot be ruled out.  The N6 position for dA contains two polar hydrogens, 
while the N6 position for d6mA contains only one polar hydrogen.  This additional polar 
hydrogen results in the N6 position of dA being more polar than the N6 position of d6mA.  
The His L33 residue easily makes dispersion contacts with the N6 methyl group of d6mA, 
but the corresponding hydrogen of dA sticking down is too small to reach His L33 for 
interactions.  As a result, the positioning of the –N6H2 group in dA may favor being 
closer to Ser L55, a polar residue, as shown in Figure 35c, d. 
 
Conformational Changes in the Five Flexible Residues in the Selected Docking 
Models 
 
The five flexible residues (Tyr L35, Ile L47, Tyr L48, Ser L55, and Leu H104) in 
all of the flexible binding pocket docking models share identical positioning of their    
Cα-Cβ bonds with their corresponding rigid binding pocket docking models.  As a result, 
the Cα-Cβ bond serves as an unchanging axis for rotation of amino acid side chains in the 
five flexible residues.   In Tables 10-12, conformational changes that compare the five 
flexible residues in the docking models with these same residues in the corresponding 
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rigid docking models are listed.  Two conformational changes were looked at for docking 
of d6mA, dA, and A-6mA-T using ADT-1.5.2. 
The first change investigated was the largest change in position of an atom in the 
flexible residues vs. the same atom in the corresponding rigid residues.  This change in 
position is measured as the largest distance of separation between an atom in the flexible 
Fv docking models and the same atom in the corresponding rigid Fv docking models.  
The second change investigated was the angle of rotation of a side chain group of a 
flexible residue along the Cα-Cβ axis relative to the orientation of the same side chain 
group in the corresponding rigid residue.  This rotation was measured by calculating the 
difference between the dihedral angles of the specified atoms (listed in Tables 10-12) in 
the flexible residues in the docking models vs. the same atoms in the corresponding rigid 
residues in the docking models.  All angles of rotation were inspected visually to support 
the accuracy of the calculated angles. 
 
Table 10.  Conformational changes of Tyr L35, Ile L47, Tyr L48, Ser L55, and Leu H104 
as flexible vs. rigid in anti-d6mA docking 
 
     
*NA = not applicable, due to no changes in the angle of rotation  
 
 
Residue 
 
Largest Distance of Separation 
 
 
Angle of Rotation 
 
 
    Atom             Distance (Å) 
 
   Atoms              Rotation (°) 
Tyr L35    H of OH              0.333   C-C-O-H                 24 
Ile L47 
     Cδ                      0.559     Cα-Cδ                    17 
Tyr L48    H of OH              1.945   C-C-O-H               125 
Ser L55    O of OH              2.399   C-C-O-H               176.5 
Leu H104 
     Cγ                      1.205     Cα-Cδ                   NA 
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Table 11.  Conformational changes of Tyr L35, Ile L47, Tyr L48, Ser L55, and Leu H104 
as flexible vs. rigid in anti-dA docking 
 
 
Residue 
 
Largest Distance of Separation 
 
 
Angle of Rotation 
 
 
    Atom             Distance (Å) 
 
   Atoms              Rotation (°) 
Tyr L35   O of OH             0.277   C-C-O-H                 22 
Ile L47 
       Cδ                  0.320     Cα-Cδ                    13 
Tyr L48       C2aromatic         3.778   C-C-O-H               115 
Ser L55   H of OH            3.312   C-C-O-H               125 
Leu H104 
       Cγ                 1.196     Cα-Cδ                  NA 
 
 
 
Table 12.  Conformational changes of Tyr L35, Ile L47, Tyr L48, Ser L55, and Leu H104 
as flexible vs. rigid in anti-A-6mA-T docking 
 
 
Residue 
 
Largest Distance of Separation 
 
 
Angle of Rotation 
 
 
    Atom             Distance (Å) 
 
   Atoms              Rotation (°) 
Tyr L35       NA                       0      NA                       0 
Ile L47       NA                       0      NA                       0 
Tyr L48   O of OH
 
             1.864   C-C-O-H                44 
Ser L55   H of OH              3.313   C-C-O-H              106 
Leu H104 
       Cγ                   1.196     Cα-Cδ                  NA 
 
The residues Tyr L48 and Ser L55 showed rather large separations and relative 
rotations between the specified atoms of the flexible vs. rigid binding pocket, while the 
residues Tyr L35 and Ile L47 showed very small separations and relative rotations if any 
between the specified atoms of the flexible vs. rigid binding pocket.  The larger changes 
in conformation are primarily in the orientation of the side chain groups.  In the case of 
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Tyr L48, the measured angle of rotation is particularly influenced by the position of the 
OH group.  A rather small separation and rotation occurs in the aromatic ring of Tyr L48 
in the flexible binding pocket model for d6mA docking [Figure 34a, b (p. 116)], while a 
much larger rotation occurs in the aromatic ring of Tyr L48 in the flexible binding pocket 
model for dA docking (Figure 34c, d).   
The change in position of Tyr L48 in the flexible binding pocket is likely to be 
related to the necessary rotation of the OH group for its involvement in H-bonding with 
the 5’ oxygen of the deoxyribose moiety in the docking of d6mA.  The flexible binding 
pocket docking model of dA, on the other hand, does not show any H-bond from Tyr L48 
because dA docked closer to the surface of the 7C7:C5 Fv, in which this interaction with 
the 5’ oxygen of the deoxyribose moiety was out of reach.  Nevertheless, Tyr L48 of the 
docked dA in the flexible binding pocket must rotate its ring to maximize contacts with 
the adenine.  This rotation of the phenyl group of Tyr L48 in docking of dA is much 
larger than the rotation of the phenyl group of Tyr L48 in docking of d6mA.  The 
additional rotation of the phenyl group of Tyr L48 seems to contribute to a more snug fit 
of the docked dA than would have occurred without this rotation.  The rotation of the 
phenyl group is unnecessary for the docked d6mA because it docked deeper into the 
binding pocket fitting snug against Tyr L48 as in its starting position (identical position 
as in rigid Fv docking models). 
Ser L55 of the flexible binding pocket docking models showed significant 
rotations from its starting position.  In the case of Ser L55, the change in rotation in 
docking of d6mA is noticed in the OH group of the side chain, in which the OH group 
makes nearly a 180° rotation moving it closer towards the surface of the binding pocket 
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and further away from the N3 of adenine in d6mA.  This rotation does not result in any H-
bonds involving the OH group of Ser L55, but an H-bond does occur between N3 of 
adenine and the main chain NH group of Ser L55.  As a result, this rotation may help 
bind d6mA deeper into the binding pocket by allowing Ser L55 to make a wider range of 
contacts with the d6mA, including contacts closer to the upper surface of the binding 
pocket.  A similar but smaller rotation is noticed in docking of dA and A-6mA-T.    In the 
docking of dA, however, the rotation of the OH group of Ser L55 allowed for Ser L55 to 
form an H-bond with the alcohol group of the deoxyribose moiety.  Similarly, the rotation 
of the OH group of Ser L55 in docking of A-6mA-T allowed for two H-bonds to form:  
one with the deoxyribose of the dA moiety and one with the neighboring phosphate 
group. 
In the flexible binding pocket docking models, a 1.2 Å shift in the Cγ atom 
positions this carbon away from the adenine of d6mA, dA, and d6mA moiety of A-6mA-T.  
Whether it is nearly a 180° rotation or merely a shifting of the Cγ atom cannot be 
determined by analyzing the docking models since the Cγ is linked to two symmetric 
methyl groups, which appear to maintain relatively close positions to their initial 
positions.  This shift in position of the Cγ may allow more room for the adenine of d6mA, 
dA, and d6mA moiety of A-6mA-T to fit into the binding pocket, but even more so may 
provide more room for other neighboring residues in the binding pocket, such as His L33, 
Tyr L35, and Pro H103.  An additional possibility is that the formation of a more 
favorable conformation for Leu H104 occurs upon docking of d6mA, dA, or A-6mA-T. 
The flexible Tyr L35 and Ile L47 show minimal rotations and overall changes 
from their starting positions.  This lack of change in Tyr L35 and Ile L47 is quite logical 
  126
as they are some of the deeper residues of the binding pocket, in which only d6mA docks 
deep enough to make contacts with these residues.  The absence of change in these 
residues in the A-6mA-T flexible binding pocket docking model is reflective of the 
inability of the d6mA moiety to dock deep into the binding pocket in this model.  In the 
docking models that show change in Tyr L35 and Ile L47, a minor shift occurs in the 
position of the phenyl group of Tyr L35 and the Cγ and Cδ atoms of Ile L47 that moves 
them slightly further away from the binding pocket. 
 In the case of the docking model for d6mA, Tyr L35 and Ile L47 both make 
contacts with the d6mA.  However, the change in position of the OH group of Tyr L35 
shifts it slightly closer to the N6 methyl group of d6mA, while the change in position of 
the Cγ and Cδ ethyl group of Ile L47 shifts it slightly further away from the N6 methyl 
group of d6mA.  Similar but smaller changes are noticed in the conformations of the side 
chains of Tyr L35 and Ile L47 in the flexible binding pocket docking of dA than for the 
flexible binding pocket docking of d6mA.  These changes show no relation to how close 
they are to the dA or to interactions with the dA, but they may have been influenced by 
the shifting of the phenyl group of Tyr L48 more towards the adenine of dA. 
 
Final Analysis of the 7C7:C5 Fv Docking Models and Calculated Binding Energies 
While analyzing the individual conformational changes in the side chains of 
residues given flexibility in the binding pocket may help to explain why at least some of 
the rotations occurred in these side chains, this analysis overlooks the quality of the rigid 
binding pocket docking models.  First, the rigid Fv docking models show an overall 
greater amount of consistency in docking modes between the d6mA, dA, and A-6mA-T.  
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For instance, all eight of the paratope residues involved in the rigid binding pocket 
docking of dA are also found in the paratope for docking of d6mA, but only five of the 
seven paratope residues involved in the flexible binding pocket docking of dA are also 
found in the docking of d6mA.  In addition, all six of the paratope residues involved in the 
rigid binding pocket docking of the d6mA moiety of A-6mA-T are also found in the 
paratope for docking of d6mA, but only three of the five paratope residues involved in the 
flexible binding pocket docking of the d6mA moiety of A-6mA-T are also found in the 
paratope for docking of d6mA. 
Second, more interactions occur in the rigid Fv docking models for d6mA and dA 
than in the corresponding flexible Fv docking models.  These additional interactions lead 
to more favorable intermolecular binding energies in the rigid Fv docking models.  In 
contrast, a more favorable intermolecular energy occurs in the flexible Fv docking model 
for A-6mA-T than in the rigid Fv docking model for A-6mA-T.  This energy difference is 
largely due to an increased number of interactions with the adjacent nucleotides and 
phosphate groups in the flexible Fv docking model for A-6mA-T.  A list comparing the 
intermolecular energies involved in the binding of d6mA, dA, and A-6mA-T to the 7C7:C5 
Fv are reported in Table 13.   
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Table 13.  Intermolecular energies from binding of the 7C7:C5 Fv to d6mA, dA, and A-
6mA-T in the selected rigid and flexible binding pocket docking models 
 
 
Antigen 
 
 
Intermolecular Energy (kcal/mol) 
 
 
 
 
Rigid Binding Pocket 
 
 
Flexible Binding Pocket 
 
d6mA 
 
 
-5.5 
 
-5.44 
 
dA 
 
 
-4.62 
 
-3.59 
 
A-6mA-T 
 
-5.57 
 
 
-7.92 
 
 
Comparison between the rigid and flexible Fv docking models of d6mA shows that 
the two docking models strongly resemble one another in paratope interactions and 
intermolecular energies of binding.  The flexible Fv docking contributes an additional H-
bond between the binding pocket and d6mA, but shows fewer vdW contacts than the rigid 
Fv docking of d6mA.  The ideal scenario would be to maintain all of the vdW contacts 
found in the rigid Fv docking models and add an additional H-bond between Tyr L48 of 
the binding pocket and the deoxyribose of d6mA or dA.  In comparing flexible vs. rigid 
docking models, the overall changes in the number of interactions are by far the greatest 
for A-6mA-T in favor of the flexible Fv docking model.  This change in the number of 
interactions is easily accounted for by the increase in interactions of the adjacent 
phosphate groups and nucleotides. 
In the rigid Fv docking model for A-6mA-T, the thymine is in an awkward 
position, in which it is turned away from the surface of the Fv.  The flexible Fv docking 
model for A-6mA-T shows both of the adjacent nucleotides against the surface of the Fv.  
In consideration of these additional interactions, the largest change in intermolecular 
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energy is between flexible and rigid Fv docking models in the docking of A-6mA-T.  
However, all of the flexible binding pocket docking models appear to overestimate the 
affinity of the 7C7:C5 Fv for d6mA, dA, and A-6mA-T.  On the other hand, the rigid 
binding pocket docking models appear to underestimate the affinity of the 7C7:C5 Fv for 
d6mA, dA, and A-6mA-T. 
The overestimation of the affinity in the flexible Fv docking models is due to 
substantial intramolecular energy contributions to the binding energy.  These energy 
contributions are not from interactions within the protein, as much of the changes of the 
flexible residues in the binding pocket were directly related to association with each of 
the docked antigens.  Some of the internal energy contribution, however, appears to be 
not due to the association with the docked antigen, but rather a further opening of the 
binding pocket to more comfortably fit the docked antigen and to allow more favorable 
conformations in some of the residues of the binding pocket to occur as a result of this 
opening. 
The underestimation of the affinity in the rigid Fv docking models appears to 
result from two factors.  First, an abundant number of vdW interactions were found and 
generally a few H-bonds.  The shear number of overall interactions would normally 
suggest a higher affinity.  For instance, assuming a contribution of -1 kcal/mol per H-
bond and a contribution of -0.3 kcal/mol per dispersion interaction in binding, a simple 
calculation of the number of dispersion interactions and H-bonds in the docking of d6mA 
reveals that the energy contribution from intermolecular interactions is approximately -13 
kcal/mol.  A common torsional energy penalty of 1 kcal/mol was found in ADT-1.5.2 
that is attributed to torsions and rotations of the antigen.  The resulting binding energy 
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based solely on the number of interactions and these general assumptions is -12 kcal/mol 
for the docking of d6mA to the 7C7:C5 Fv.  Nevertheless, some overlap among residues 
occurs with vdW contacts and the contribution of -1 kcal/mol in binding is relative to the 
solution and prior H-bonds of the Fv and antigen before the binding of the antigen to the 
Fv.  Thus, the resulting binding energy may be a few kcal/mol less than the estimated -12 
kcal/mol. 
A way of adjusting the calculated binding energies from the rigid Fv and flexible 
Fv docking models is to average the binding energies of the two sets of models for each 
antigen.  These average binding energies would approximate the energies of binding of 
d6mA, dA, and A-6mA-T to a binding pocket of two and a half flexible residues.  Given 
that only two main residues (Tyr L48 and Ser L55) show considerable flexibility in the 
binding pocket of the 7C7:C5 Fv that directly relates to interactions with each antigen, 
the flexibility of these two residues is quite logical.  The additional half flexible residue 
would apply to minor changes in the remainder of residues in the binding pocket, 
particularly Pro H103 which showed contacts with adenine of d6mA, dA, and d6mA 
moiety of A-6mA-T.  Typically, prolines do not show much rotational capabilities, but 
they are capable of bending flexibility 163.  The averages of the binding energies from the 
rigid Fv and flexible Fv docking models for each antigen are listed in Table 14.  An 
intermediate Kd for the docking of each antigen to the 7C7:C5 Fv was calculated based 
on these average binding energies.  The binding energies and the corresponding Kd from 
each set of docking models is also reported in Table 14. 
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Table 14. Binding energies and inhibitor constants from docking studies with the  
7C7:C5 Fv  
 
 
  
 
   
Rigid Body Fv Docking 
 
Flexible Residue Fv Docking 
Intermediate Docking 
(Based on the average ∆G of rigid and 
flexible Fv docking) 
 
 
Antigens 
 
Binding Energy 
(kcal* 
mol-1*K-1) 
 
Dissociation 
Constant, Kd  
(10-3 M) 
 
Binding Energy 
(kcal* 
mol-1*K-1) 
  
Dissociation 
Constant, Kd 
(10-10 M) 
 
Binding Energy 
(kcal* 
mol-1*K-1) 
 
Dissociation 
Constant, Kd 
(10-7 M) 
 
d6mA 
 
-5.15 
 
0.169 
 
-14.57 
 
0.2104 
 
-9.86 
 
0.592 
 
dA 
 
-3.56 
 
2.46 
 
-13.45 
 
1.3884 
 
-8.505 
 
5.831 
 
A-6mA-T 
 
-2.37 
 
18.2 
 
-14.36 
 
0.2963 
 
-8.365 
 
7.835 
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DISCUSSION 
 
Assessment of the 7C7:C5 Fv Docking Models 
The sequences for the 7C7:C5 variable genes were obtained and, in turn, the 
primary structures for the 7C7:C5 variable regions were determined.  Based on the 
primary structures, homology modeling using Modeller9v4 was performed to generate 
two separate three-dimensional models of the 7C7:C5 Fv.  One model Fv was based on 
crystallographic structures of Fab fragments in an antigen unbound conformation and the 
other model Fv was based on crystallographic structures of Fab fragments in an antigen 
bound conformation.  While modeling with high identity (80-95% sequence identity) is 
generally preferred, the idea of modeling based on antigen-bound versus –unbound 
conformations appears to be relatively novel with surprisingly promising results.  
Comparison of the antigen-bound-template model Fv versus the unbound-template model 
Fv revealed a binding pocket which is clearly present in the antigen-bound-template 
model Fv but not in the unbound-template model Fv.  The antigen-bound-template model 
Fv shows movement of Tyr L48 and Ser L55 and perhaps slighter movements in other 
spatially neighboring residues resulting in a binding pocket that is open in the antigen-
bound-template model Fv but closed off in the unbound-template model Fv.   
The “blind docking” approach of predicting binding pockets has shown promising 
results 164.  In fact, blind docking results using only a single docking job of 100 docking 
trial runs in AutoDock were used to correctly predict the binding pocket and 
corresponding ligand binding mode found in crystallographic structures for 34 out of 43 
tested proteins.  In these 34 proteins, the predicted binding pocket and ligand binding 
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mode yielded the energy minimum (most favorable energy).  In three of the remaining 
nine cases among the forty-three tested proteins, the crystallographic binding pocket and 
corresponding ligand binding mode was found as the energy minimum in subsequent 
docking jobs (experiments) using AutoDock.  The last six crystallographic binding 
pockets and corresponding ligand binding modes were found to rank from 2nd to 7th in 
terms of most favorable energy relative to the energy minimum. 
Thus, to further inspect the validity of the only visually apparent binding pocket, 
rigid Fv blind docking studies with flexible antigens were done to check areas of antigen 
docking along the upper VH and Vκ interface (interface region in the opposite direction 
from the amino termini of the CH1 and Cκ regions).  These studies showed that docking 
of the antigens d6mA, dA, and d6mA of ssDNA (A-6mA-T) within the predicted binding 
pocket of the 7C7:C5 Fv gave the most favorable binding energy for both d6mA and dA 
and the second most favorable binding energy for A-6mA-T.  The most favorable 
conformation found for A-6mA-T did not show the d6mA bound into the binding pocket, 
but this conformation showed the d6mA moiety near the binding pocket.  All Kd 
calculations using a rigid body binding pocket of the 7C7:C5 Fv in AutoDock-4.0 were 
relatively high (10-2 to 10-4 M). 
As a result, an induced-fit model of docking seemed to be more likely between 
d6mA, dA, and A-6mA-T in determination of Kd.  In support of this hypothesis, other anti-
ssDNA binding domains were found to undergo induced-fit conformational changes that 
allow for contacts to the buried nucleic acid to be maximized 42, 49-50, 82.  Accordingly, 
five flexible residues within the predicted 7C7:C5 binding pocket showed rotational 
capabilities and, thus, seemed like a good starting point for docking studies using an 
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induced-fit binding model.  The docking studies with the five flexible binding pocket 
residues produced conformations with Kd of 10-10 to 10-11 M, which show a 107 to 109 
fold higher affinity than the rigid body binding pocket docking studies. 
Comparison of the intermolecular energy between d6mA docking to the rigid body 
binding pocket and to the flexible residue binding pocket is almost identical, in which 
intermolecular interactions are actually favored in the rigid body binding pocket by -0.06 
kcal/mol.  The primary source of this change in Kd happens to occur through the 
contribution of internal energy or energy generally associated with the conformation of 
the ligand involved in binding.  Upon making residues flexible in the binding pocket, 
however, the internal energy increased substantially more than what is common for 
ligand internal energy alone. 
The primary source of the increase in internal energy was from energy that 
resulted from changes in the conformations of the flexible binding pocket residues.  
These changes in residue conformations were found in some cases to maximize 
interactions between the Fv and the docked antigen.  In other cases, these conformational 
changes simply opened the binding pocket slightly more giving more room for residues 
within this area to take on more favorable conformations and for interactions of the 
antigen with deeper residues of the binding pocket to be more accessible.  Typically, the 
internal energy term is close to zero in docking studies, but these studies used rigid body 
proteins 77.  Furthermore, the appearance of an internal energy term is often associated 
with the desirable effect of placing top ranked binding mode clusters with more favorable 
binding energies. 
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For instance, occasionally, top ranked binding modes (or binding modes with no 
unacceptable clashes or unusual conformations) will result in a calculated low free 
energy.  The internal energy term in AutoDock-4.0 is primarily a result of energy 
differences in the protein before and after ligand docking 77.  This energy contribution 
that results from conformational changes in the binding pocket of the protein is primarily 
overlooked in rigid protein docking.  Addition of internal energy to calculated free energy 
has been found to help boost the free energy of appropriate docking modes in accordance 
with their conformational rankings. 
Nevertheless, these changes in internal energy help to more accurately mimic 
“induced-fit” binding, in which residues of the protein are actually in a state of 
conformational flux during the binding process 165-166.  This state of flux is dynamic and 
is brought on by interaction with the ligand, in which interaction with the ligand may 
spatially push to enhance interactions within the protein itself.  Such secondary 
interactions may or may not be associated with multivalency, in which binding of a 
primary ligand opens a secondary pocket in the protein for binding of a secondary ligand. 
Figure 36 shows the primary binding pocket of d6mA and a possible secondary 
binding pocket adjacent to it on the left that may further open upon d6mA binding and, 
consequently, accept a second d6mA or possibly even the dA moiety adjacent to the d6mA 
moiety of A-6mA-T.  Interestingly, in Figures 32e, f and 34e, f (p. 106, 116), the dA 
moiety of A-6mA-T contacts the surface of the 7C7:C5 Fv near this possible secondary 
binding pocket in both rigid and flexible Fv docking models.  Of the highlighted residues 
in Figure 36, Tyr H33 belongs to CDR-H1 and Tyr H99 and Tyr H106 belong to CDR-
H3.  Tyr H27 and Arg H98 are considered framework residues.  
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Figure 36.  Possible secondary binding pocket on the left of the primary binding pocket 
of the 7C7:C5 Fv.  Residues selected or highlighted for this secondary binding pocket 
include Tyr H27, Tyr H33, Arg H98, Tyr H99, and Tyr H106. 
 
Admittedly, treatment of ligand receptor residues as flexible can result in large 
changes in Kd, particularly due to the exponential relationship between ∆G and Kd 165-166 
and, thus, their usage should be considered cautiously.  Four flexible protein binding site 
residues of thyroid hormone receptor β (TRβ) were used in a study towards calculation of 
a binding free-energy of -11.78 kcal/mol using AutoDock 4.0 167.  No strategy was 
reported for scaling the internal energy contribution in the study by Du et al 167. 
Interestingly, the interacting surface area was predominantly hydrophobic, which 
happens to be the same circumstance for interaction of the 7C7:C5 Fv with d6mA and 
related antigens.  The 7C7:C5 Fv also happens to form two main chain H-bonds with 
d6mA and dA.  Such H-bonds are associated with firm anchoring of the protein to the 
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interacting ligand and with conformational stabilization that directs the induced-fit 168-169.  
As a result, use of flexible residues around the 7C7:C5 Fv binding pocket did not seem 
unreasonable. 
Ultimately, the use of flexible residues in a protein model is a choice of the 
primary researcher.  In this case, the calculated ∆G and corresponding Kd of antigen 
interactions with the rigid body Fv were all too unfavorable to be normal for the Fv of a 
MAb produced specifically against d6mA through hybridoma technology.  As a result, 
five flexible residues were incorporated into the binding pocket of the Fv.  The resulting 
binding modes gave Kd of 10-10 M to 10-11 M that seem to be at least slightly below 
normal for the range of anti-nucleic acid binding (Kd of 10-7 M to 10-10 M) found in the 
literature 55-56, 170-171. 
In the tutorial for using AutoDock-4.0 with ADT-1.5.2, only two macromolecule 
(protein) residues were selected for flexibility producing an additional six active torsions 
(six rotatable bonds) to the total number of active torsions involved in ligand binding 157.  
The five residues selected to be flexible in the 7C7:C5 binding pocket produced twelve 
additional active torsions, allowing for approximately double the flexibility of the binding 
pocket of the protein in the tutorial.  As a result, the number of flexible residues applied 
to the binding pocket in the tutorial suggests a possible overuse of flexibility in the 
binding pocket of the 7C7:C5 Fv.  Additionally, the resulting ∆G and Kd of the d6mA and 
related antigen binding modes to the 7C7:C5 Fv suggests an overuse of flexibility in the 
binding modes.  Lastly, evidence from biological phenomena such as the catalysis of 
methyl group transfer from SAM to adenine in DNA by M.TaqI involves two critical 
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residues (an ASN and a PRO) for the transfer process 23.  These two residues involve 
interactions on opposite sides of the adenine base in DNA.   
Conformational flexibility for such transfer processes can be critical and, thus, 
modeling of such processes should involve setting the primary interacting residues to be 
flexible.  In light of this knowledge, the docking models of d6mA and related antigens to 
the 7C7:C5 Fv would likely have produced a more accurate ∆G and Kd, if only TYR L48 
and SER L55 of the three main binding residues (TYR L48, SER L55, and Pro H103) 
were given flexibility.  These residues are considered the main binding residues simply 
because they make the majority of interactions with each of the three antigens (d6mA, dA, 
and A-6mA-T) used in this study.  Prolines are generally treated as rigid in modeling 
simply because they tend to lack rotatable bond flexibility in its side-chain as a result of 
being a five-membered ring, in which any flexibility generally occurs in the form of 
folding or bending flexibility as opposed to rotatable bond torsions 163. 
One possible solution for ∆G and Kd being too high (unfavorable) in the rigid 
binding pocket docking and too low (favorable) in the flexible residue binding pocket 
docking is to calculate an average of the ∆G values from the docking experiments of the 
rigid Fv and the corresponding ∆G values from the docking experiments of the Fv with 
flexible residues.  The average ∆G could then be used to calculate an intermediate Kd.  
The 7C7:C5 Fv in solution may experience an intermediate amount of flexibility in 
between the rigid and flexible residue docking models shown in the current study.  As a 
result, calculation of intermediate ∆G and Kd makes the most sense in the given 
circumstance.  The calculated intermediate (based on an average of the obtained ∆G 
value from rigid and analogous flexible docking models) ∆G and corresponding Kd for 
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d6mA, dA, and A-6mA-T are -9.86 kcal/mol and 5.92 x 10-8 M, -8.505 kcal/mol and 5.831 
x10-7 M, and -8.365 kcal/mol and 7.835 x 10-7 M, respectively.  All of these calculated 
intermediate values for ∆G and Kd seem quite reasonable for binding of d6mA, dA, and A-
6mA-T.  Given these intermediate values for Kd, the binding affinity of the 7C7:C5 Fv 
against d6mA is approximately ten fold more favorable than it is against dA and thirteen 
fold more favorable than it is against A-6mA-T. 
 
Comparison of Docking using Rigid Body 7C7:C5 Fv with Flexible Antigen vs. 
7C7:C5 Fv with Five Flexible Residues and Flexible Antigen 
 
The docking model comparisons between the 7C7:C5 Fv with a rigid binding 
pocket versus the 7C7:C5 Fv with flexible residues in its binding pocket suggest that if 
the 7C7:C5 binding pocket favors flexibility in the binding of d6mA, dA, and A-6mA-T, 
then a more apparent difference in the binding of d6mA versus dA and d6mA moiety of A-
6mA-T would occur.  Given the sheer similarity of structure among the tested antigens, 
the difference in the final docked state should be more subtle between d6mA and dA than 
the results from the flexible Fv docking models.  This subtle difference seems accurately 
represented by the rigid Fv docking models, in which the binding modes of the adenine 
ring system and deoxyribose moieties are nearly identical for d6mA and dA.  In fact, the 
main difference in the mode of d6mA vs. dA is that approximately eleven additional vdW 
interactions are made with the N6 methyl group of d6mA than the corresponding N6 
hydrogen of dA.  Comparison of the Kd between d6mA and dA in the rigid Fv docking 
models reveals that docking of d6mA produces a Kd that is approximately six fold less 
than the Kd for docking of dA.  This same difference in affinity was demonstrated to 
occur experimentally by slot blot. 
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After careful analysis of the two sets of docking models, the evidence strongly 
favors the rigid Fv docking models as being closer to the actual final docked state for at 
least two of the three tested antigens (dA and A-6mA-T).  The major significant difference 
between rigid and flexible Fv docking models is the depth of binding for dA and d6mA 
moiety of A-6mA-T, in which the rigid Fv docking models show deeper docking of dA 
and A-6mA-T.  The depth of docking of dA is analogous to the depth of docking of d6mA.  
The d6mA moiety in A-6mA-T in the rigid Fv docking models appears to bury as deep into 
the binding pocket as it can proceed, which is not the case for the d6mA moiety in the 
flexible Fv docking models.  In the case of flexible Fv docking, the d6mA moiety of A-
6mA-T appears to dock at more of a diagonal orientation similar to the docking of dA.  In 
the rigid Fv docking models, the docking of d6mA, dA, and d6mA moiety into the binding 
pocket of the 7C7:C5 Fv occurs in a nearly vertical position for these antigens. 
However, even in the rigid Fv docking models, the docking of the d6mA moiety of 
A-6mA-T is not as deep as the docking of d6mA or dA alone due to the additional 
nucleotides and phosphates covalently linked to the d6mA moiety, which place steric 
restrictions on the movement of the d6mA moiety into the binding pocket.  These 
additional nucleotides and phosphates result in surface interactions with the Fv outside of 
the primary binding pocket.  Many of these additional interactions serve in a 
compensatory manner for the d6mA moiety not being able to bind as deep as d6mA alone.  
The flexible Fv docking of A-6mA-T appears to more accurately represent the binding 
contribution from interactions of the nucleotides adjacent to the d6mA moiety in terms of 
their positioning towards the Fv surface.  In the rigid Fv docking of A-6mA-T, the dT 
moiety is awkwardly turned up and away from the Fv surface. 
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In both rigid Fv and flexible Fv docking models, d6mA binds deep into the binding 
pocket of the 7C7:C5 Fv and, thus, the binding modes appear quite similar with perhaps a 
more induced-fit appearance in the flexible Fv docking model, in which rotational ability 
of the phenolic hydroxyl group of Tyr L48 allows it to act as a hydrogen bond donor to 
the alcohol group of the deoxyribose moiety.  Nevertheless, the number of overall vdW 
interactions slightly favors the rigid Fv docking model.  Total interactions found with the 
N6 methyl group were equal for the rigid and flexible Fv docking models.  By combining 
information from the rigid and flexible Fv docking models, the docking of d6mA quite 
possibly incorporates all of the interactions found in the rigid Fv docking model with an 
additional H-bond from the flexible Fv docking model.  This additional H-bond only 
required minor aspects of flexibility, such as rotation of the phenolic hydroxyl group of 
Tyr L48 towards the alcohol group of the deoxyribose moiety.   
Upon further analysis of the flexible Fv docking models for docking of dA and A-
6mA-T, these models were found to possibly represent an initial/transitional docking state 
for d6mA and related antigens.  In support of this hypothesis, the binding modes of dA 
and d6mA moiety of A-6mA-T in the flexible Fv binding pocket show dA and d6mA moiety 
in significant interactions with many upper surface residues of the binding pocket such as 
Glu L49 and Lys L52.  Specifically, these interactions with Glu L49 and Lys L52 of the 
paratope occur at the N6 position of A and 6mA, in which vdW contacts and a H-bond is 
made.  Glu L49 and Lys L52 make many more contacts at the N6 position to the d6mA 
moiety of A-6mA-T than to dA alone.  The majority of these hydrophobic contacts are 
made with the N6 methyl group.  In the case of the d6mA moiety, Glu L49 H-bonds with 
the N6 lone hydrogen that faces up towards the binding pocket exit.  This H-bond, in 
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turn, results in the initial entrance of the N6 methyl group into the binding pocket.  This 
interaction suggests that the d6mA moiety initially binds slightly deeper in the binding 
pocket than dA because the H-bond occurs from the N6 hydrogen sticking upwards as 
opposed to the N6 hydrogen sticking downwards as occurs in dA. 
Additionally, the docking of dA and d6mA moiety occurred in more horizontally 
slanted positions in the flexible Fv binding pocket than in the rigid Fv binding pocket.  
These positions allowed for Ser L55 to H-bond with the alcohol group of the deoxyribose 
moiety on approximately the opposite vertical end from the Glu L49 H-bond.  The initial 
tucking of the N6 methyl group downwards into the binding pocket by particularly Glu 
L49 results in active pulling of the N6 methyl group and, in turn, the adenine base deeper 
into the binding pocket.  This active pulling may result from surface contacts that 
essentially push the N6 position and bottom of the adenine ring down into the binding 
pocket. 
One driving force for this active system may be that the number of favorable 
contacts increases as the methyl group and the adenine base move deeper into the binding 
pocket.  From the other vertical end of the d6mA moiety, the Ser L55 acts as a “closing 
gate” to push the d6mA moiety from the front against the rear of the binding pocket 
resulting in the d6mA moiety moving in a vertical rotation deeper into the binding pocket.   
As the rotation of d6mA moiety into the binding pocket proceeds it contacts Tyr L48 with 
its edges rotating it more towards face to face contacts.  The pressure from contacting Tyr 
L48, in turn, forces pressure against Pro H103 resulting in slight bending of Pro H103.  
Thus, Tyr L48 acts like one side of a clamp and Pro H103 acts like a spring moiety.  
Given the similarity in structure of d6mA, dA, and d6mA moiety, the mechanism of 
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binding should be nearly identical.  As a result, the predicted mechanism of binding of 
d6mA, dA, and d6mA is shown in Figure 37. 
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Figure 37.  Predicted mechanism for the mode of binding of deoxy-N6-methyladenosine 
and related antigens to the 7C7:C5 Fv binding pocket.  Only critical residues that direct 
the binding of d6mA were included in the shown mechanism.  Orange dotted arrows 
indicate direction of horizontal rotation, blue dotted arrows indicate direction of 
compression, purple arrows indicate breaking of an interaction, and long black arrows 
indicate a progression of d6mA towards its final binding state.  H-bonds are represented as 
black dotted lines.  R groups with black wiggly lines indicate further amino acid linkages.  
R1 groups indicate both carboxy1 and amide groups in a peptide bond that links to further 
amino acids. 
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Structural Features of the 7C7:C5 Fv Docking Models  
All of the docking models for the 7C7:C5 Fv show significant contribution from 
an aromatic amino acid (Tyr L48) involved in H-bonding and several vdW interactions, a 
polar amino acid (Ser L55) involved in H-bonding and a few vdW interactions, and a 
non-polar amino acid (Pro H103) involved in a couple of vdW interactions.  Interestingly, 
these residues match up quite closely with the conserved catalytic motif IV of N-DNA 
MTs, in which the residues are Asn/Asp/Ser-Pro-Pro-Tyr/Phe 23.  Slashes indicate 
either…or  and dashes indicate linkages.   
Key paratope residues of the 7C7:C5 Fv also match up quite closely with the 
adenine binding pocket in the active site of aminoglycoside phosphotransferase enzyme 
(APH(3’)-IIIa) 72.  Three key residues (a tyrosine, a serine, and an alanine) for binding 
adenine occur in this active site, of which all three of these residue types occur in the 
7C7:C5 Fv paratope.  Furthermore, these residues serve to provide similar interactions in 
all three of the mentioned adenine binding domains.  For instance, the Asn of motif IV of 
M.TaqI (an adenine MT) 23, the active site Ser of APH(3’)-IIIa 72, and Ser L55 of the 
7C7:C5 Fv are all examples of polar amino acids that provide important H-bonds in 
interacting with adenine.  In docking of d6mA and dA to the 7C7:C5 Fv, this H-bond is 
made to N3 of the adenine base.  Additionally, the vdW contacts from Ser L55 are made 
primarily to the middle rear edge (edge slightly above the N3 position of adenine) of the 
adenine base in d6mA and dA. 
Of the motif IV residues in M.TaqI, the Tyr residue of motif IV is found to 
engage in a π-stacking interaction and a H-bond on one face of the adenine base and the 
Asn and adjacent Pro residue of motif IV are aligned along the other face of the adenine 
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base, in which both of these residues contribute H-bonds along with likely vdW 
interactions 23.  The remaining Pro residue of motif IV may be involved in vdW 
interactions along the edge of the five membered ring of adenine.  Although no Phe 
residues were found in the interaction of the 7C7:C5 Fv with d6mA or dA, one Phe 
residue (not part of motif IV) of M.TaqI was involved in an edge-to-face π interaction 
along the N3-N4 of adenine 23.   
Similar to Tyr L48 of the binding pocket of the 7C7:C5 Fv, the Tyr residue of the 
active site of APH(3’)-IIIa engages in a face-to-face π-stacking interaction with the six-
membered ring of the adenine base 72.  Nevertheless, in the case of the 7C7:C5 Fv 
paratope interactions with the adenine base of d6mA, dA, and d6mA moiety of A-6mA-T, 
Tyr L48 is only involved in a π-stacking interaction with the d6mA moiety of A-6mA-T 
and additionally makes several hydrophobic contacts to this moiety.  Tyr L48 was not 
found to engage in a H-bond with the adenine base of the d6mA moiety of A-6mA-T.  
Similarly, the Tyr of the active site of APH(3’)-IIIa was not found to engage in a H-bond 
with the adenine base 72.   
However, the possibility of the phenolic hydroxyl group of Tyr L48 H-bonding to 
the N3 position in the docking of d6mA moiety of A-6mA-T does exist.  Such a H-bond 
would only require rotation of the phenolic hydroxyl group towards the N3 position.  
Unlike docking of the d6mA moiety of A-6mA-T, Tyr L48 was involved in a H-bond with 
the deoxyribose moiety of d6mA alone.  While dA did not show a H-bond between the 
deoxyribose moiety and Tyr L48 in its flexible Fv docking model, this docking model 
seemed to represent transitional states of binding and, thus, its final docked state would 
more than likely also contain such a H-bond from Tyr L48.  The d6mA moiety of A-6mA-
  146
T, on the other hand, does not appear to be in range for a H-bond between its deoxyribose 
moiety and Tyr L48 due to the involvement of Tyr L48 in a stacking interaction with the 
lower portion of the six-membered ring of adenine. 
On the other side of the six-membered adenine ring in d6mA, dA, and d6mA moiety 
of A-6mA-T, Pro H103 and at least one CDR-H3 Leu residue provided the primary source 
of hydrophobic contacts.  One possibility for the lack of π-stacking interactions from Tyr 
L48 in the docking of d6mA and dA is that the residues interacting with the adenine base 
on the other side are incapable of stacking interactions because they are not flat and, thus, 
cause misalignment of the adenine base for such flat interactions with Tyr L48.  
Nevertheless, in the docking of A-6mA-T the covalent linkages to phosphates and, in turn, 
the linkages of the phosphates to other nucleotides helps to restrict the d6mA moiety 
enough to allow the six-membered ring of adenine to align in a face to face planar 
arrangement with Tyr L48 resulting in a π-stacking interaction. 
All crystal structures of anti-poly(dT) or dTdC Fabs thus far have shown at least 
one π-stacking interaction involving a tyrosine paratope residue with each thymine or 
cytosine base 42, 49-50, 82.  The influence of the neighboring phosphate and nucleotide 
linkages, respectively, on π-stacking interactions has yet to be determined.  The 
crystallographic structure of an anti-mononucleoside or a mononucleotide with the 
appropriate mononucleoside or mononucleotide bound would have to be obtained to 
determine if any π-stacking interactions actually occur.  In addition, both thymine and 
cytosine are pyrimidines and, thus, are six-membered aromatic rings versus the aromatic 
five- and six-membered conjoined rings of adenine.  Thus, congruency of the aromatic 
rings may be an important aspect for stacking interactions. 
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Furthermore, in M.TaqI, the Tyr of motif IV contributes its stacking interaction 
with the lower bottom of the six-membered ring of adenine in DNA 23.  Similarly, the 
rigid Fv docking model showed that Tyr L48 of the 7C7:C5 Fv contributes its stacking 
interaction with the lower bottom of the six-membered ring of adenine in ssDNA.  As a 
result, despite the aromaticity of the five-membered ring in adenine through 
hyperconjugation, stacking interactions with tyrosine residues thus far appear to be 
limited to the six-membered ring of adenine.  This factor alone may make it easier for a 
thymine or cytosine to align with tyrosine than adenine in mononucleoside or 
mononucleotide form and could help to explain why docking of the d6mA or dA alone did 
not result in a π-stacking interaction. 
 
Summary of the 7C7:C5 Fv Binding Pocket and Paratopes 
 The 7C7:C5 Fv primary binding pocket is located along the upper (opposite 
direction from the constant region), frontal VH (left side) and Vκ (right side) interface.  
The primary binding pocket is located at the interface between CDR-H3 and CDR-L2 
and only involves these two out of the six CDRs.  A couple of framework residues also 
comprise the binding pocket.  These residues include Tyr L35, Pro L45, Ile L47, and Tyr 
L48, of which all four interact directly with d6mA.  Framework residues, especially FR 
residues that flank CDRs, of other Fvs have been previously found to directly interact 
with epitopes 93, 144, 172-174.  A hypothetical secondary binding pocket shown in Figure 36, 
p. 136, may open further during docking of the d6mA moiety of A-6mA-T into the primary 
binding pocket, in which the dA moiety may be allowed to dock into this secondary 
binding pocket that is directly to the left of the primary binding pocket. 
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The 7C7:C5 Fv paratope is essentially a suborder of specific residues in the 
7C7:C5 Fv binding pocket, in which the number of residues directly involved in antigen-
binding depends on the specific antigen docked into the binding pocket.  Based on the 
collective information of all the docking models of the 7C7:C5 Fv reported herein, the 
predicted 7C7:C5 Fv anti-d6mA paratope includes the following eleven residues:  His 
L33, Tyr L35, Pro L45, Ile L47, Tyr L48, Ala L54, Ser L55, Leu H102, Pro H103, Leu 
H104, and Ala H105.  Of these eleven residues, three (His L33, Tyr L35, and Ile L47) are 
missing from the paratope against dA as a result of a hydrogen in place of a methyl group 
in the N6 position. 
Accordingly, the methyl group in the N6 position is favored over the 
corresponding hydrogen by approximately eleven vdW contacts.  His L33, Tyr L35, and 
Ile L47 contribute a total of eight vdW contacts to d6mA all of which are in the vicinity of 
the N6 methyl group.  As a result, the main difference in binding affinity is attributed to 
the larger size of the N6 methyl group than the corresponding N6 hydrogen.  This size 
difference allows the N6 methyl group to not only fit deeper into the binding pocket, but 
also to provide a greater surface volume for making vdW contacts than a N6 lone 
hydrogen.   
Ser L55 and Leu H102 contribute to main-chain H-bonding of the 7C7:C5 Fv 
with d6mA and dA.  This H-bonding is believed to be nucleotide base-specific, in which 
the N3 and N6 positions of adenine are involved in the H-bonding.  In addition, these H-
bonds are believed to be of the utmost importance in d6mA and dA arriving at their final 
docked conformations in the 7C7:C5 Fv binding pocket.  Tyr L48 also contributes an H-
bond requiring the rotation of the phenolic hydroxyl group towards the 5’ oxygen of the 
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deoxyribose moiety in d6mA and dA.  This H-bond is not base-specific, but contributes to 
maintaining d6mA and dA firmly into the 7C7:C5 Fv binding pocket.  More importantly, 
Tyr L48 is by far the largest contributor of hydrophobic contacts. 
No π-stacking interactions were found to occur with the lone mononucleotide 
forms of d6mA and dA; however, one π-stacking interaction was found to occur with the 
d6mA moiety of A-6mA-T.  This interaction may be possible only because of orientation 
restrictions placed on the d6mA moiety via the covalent linkages to phosphate groups and, 
in turn, covalent linkages of the phosphate groups to the corresponding adjacent 
nucleotides.  While these additional linkages and adjacent nucleotides may help to 
contribute to stacking of Tyr L48 with the six-membered ring of adenine of the d6mA 
moiety, they also appear to prevent or at least perhaps redistribute other important 
interactions.  In the docking model in which the Tyr L48 stacking interaction was found 
with the d6mA moiety of A-6mA-T, no H-bonds were made with the d6mA moiety of A-
6mA-T. 
Hypothetically, these H-bonds with minor rearrangement could be redistributed to 
interact with the phosphate groups as shown in the flexible Fv docking model for A-6mA-
T or with the adjacent nucleotides as shown in the rigid and flexible Fv docking models 
for A-6mA-T.  Such interactions with the phosphate groups and adjacent nucleotides 
function as compensatory interactions in place of those interactions that were prevented 
by linkages to the phosphate groups and adjacent nucleotides.  Additionally, it seems 
rather unlikely that at least some of the residues that H-bond with d6mA would not also H-
bond with the d6mA moiety of A-6mA-T.  Under this assumption, the H-bonds from 
residues like Tyr L48, Ser L55, and Leu H102 may simply be redirected to other areas of 
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the epitope of A-6mA-T than are present in docking of d6mA alone.  For instance, looking 
at the rigid Fv docking model for A-6mA-T, approximately a 90° rotation of the phenolic 
hydroxyl group of Tyr L48 would bring this group in the proper orientation to H-bond to 
the N3 position of the adenine ring of the d6mA moiety. 
In summary of the interactions involved in docking of d6mA and related antigens 
to the 7C7:C5 Fv, three H-bonds were found to likely occur with d6mA and dA and a few 
H-bonds may or may not also occur with d6mA moiety of A-6mA-T; five to six, six, and 
one to five polar contacts occur with d6mA, dA, and d6mA moiety of A-6mA-T, 
respectively; and, lastly, 28-32, 18-22, and 16-18 non-stacking hydrophobic contacts 
occur with d6mA, dA, and d6mA moiety of A-6mA-T, respectively.  Only one π-stacking 
interaction occurred with the d6mA moiety of A-6mA-T.  No stacking interactions were 
found for d6mA or dA.   
 
Implications for the Potential Uses of the 7C7:C5 Fv 
A monoclonal antibody, the 7C7:C5 MAb, was previously produced against N6-
methyladenosine 96, a naturally occurring methylated nucleotide presently known to 
occur in prokaryotic and eukaryotic DNA and in viral and eukaryotic RNA 1, 7.  This 
MAb was demonstrated to interact with higher affinity for d6mA than dA or d5mC.  While 
the 7C7:C5 MAb showed cross-reactivity to dA, the affinity was approximated by slot 
blot to be six fold greater for d6mA than for dA.  In the case of the competition ELISAs 96, 
insignificant cross-reactivity to dATP and d5mCTP was noticed mainly because the 
amount of CV NY-2A genomic DNA (50 ng) used in the solid phase was below the 
normal limits of detection for these antigens.  By slot blot, the limits of detection for a 
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strand of pUC-19 DNA (2686 bases) was determined to be around 200 ng, while the limit 
of detection of a strand of pUC-19 DNA with a single d6mA was determined to be 100 ng 
and below.  Furthermore, detection of CV NY-2A genomic DNA while only at 50 ng 
contains many d6mA and, thus, was easily detected by ELISA 96. 
The 7C7:C5 MAb may have higher affinity for d6mA in ssDNA than d6mA in 
dsDNA.  This specificity would be unlikely to be a result of biochemical differences 
between d6mA in dsDNA versus d6mA in ssDNA, but rather it would likely be due to 
conformational restrictions.  In dsDNA, adenosine, particularly the N6 position of 
adenosine, is facing the interior of the structure and, thus, may not be as accessible as 
adenosine in ssDNA since removal of the second strand of DNA results in adenosine 
being open for interaction.  In immunochemical blots, the –N6HCH3 of d6mA simply 
yields a stronger stain than the –N6H2 of dA, suggesting that this area of 6mA is 
significant for tighter binding.  However, the appearance of stain for unmethylated DNA 
suggests that some interaction must occur with the rings of adenine and possibly the 
phosphodeoxyribose backbone of DNA as well. 
The binding mode of d6mA, dA, and A-6mA-T was inferred to be of an 
intermediate nature between the rigid and flexible Fv docking models with the primary 
interactions demonstrated by the rigid Fv docking models and additional interactions 
represented by the flexible Fv docking model for d6mA.  Such an intermediate binding 
mode has been suggested previously, in which movement or rotation of residues 
primarily occurs in rigid groups 82.  As a result, an intermediate Kd was calculated based 
on the average ∆G of binding between the rigid Fv and flexible Fv docking models for 
each docked antigen.  The Kd values for each antigen docked to the 7C7:C5 Fv were as 
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follows:  5.92 x 10-8 M, 5.831 x10-7 M, and 7.835 x 10-7 M for the docking of d6mA, dA, 
and A-6mA-T, respectively.  These Kd equate to approximately a ten and thirteen fold 
greater affinity for d6mA than dA and A-6mA-T, respectively.   
While an experimental Kd or Ka has yet to be determined for the binding of d6mA 
moiety in ssDNA to the 7C7:C5 Fv, the Kd appears to be directly influenced by the depth 
of binding of the d6mA moiety into the binding pocket of the 7C7:C5 Fv.  The depth of 
binding in the selected docking models of A-6mA-T to the the 7C7:C5 Fv suggests that 
the Kd of 7.835 x 10-7 M is reflective of a maximum dissociation (minimum affinity) of 
binding, as keeping the d6mA moiety any further out of the binding pocket seems 
illogical.  In addition, AutoDock-4.0 did not appear to adequately maximize interactions 
of the two neighboring nucleotides to the d6mA moiety of A-6mA-T, particularly in the 
rigid Fv docking model.  As a result, the correct Kd for docking of A-6mA-T to the 
7C7:C5 Fv may range in between 7.835 x 10-7 M and 5.92 x 10-8 M.  Lastly, whether or 
not any synergistic or obstructive effects occur in the binding of d6mA in ssDNA to the 
complete MAb, which are not present in the binding of d6mA in ssDNA to the Fv alone, 
has yet to be analyzed. 
From a practical standpoint, the affinity for the d6mA moiety of A-6mA-T is of 
primary concern, as this form of d6mA occurs in single-stranded DNA.  Based on the 
experimental Kd and the current calculated Kd of the 7C7:C5 Fv for A-6mA-T, the use of 
the 7C7:C5 Fv or MAb would be on the weaker affinity side for therapeutic use.  Thus, 
its current uses should primarily be limited to genotypic or diagnostic detection methods.  
An affinity enhancement via point mutations could be done to improve the 7C7:C5 Fv 
affinity against d6mA in DNA to 109 M-1, which is the desired affinity for therapeutic 
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uses.  A study with MAbs (ED-10 and ED-84) against unmethylated DNA found a Ka of 
109-1010 M-1, confirming that such high affinities are possible between MAbs and     
DNA 55. 
The use of the 7C7:C5 Fv or MAb as a diagnostic tool and perhaps the use of an 
affinity enhanced version of the 7C7:C5 Fv or MAb as a therapeutic tool requires 
answering two primary questions first.  1) What is the primary cross-reactive antigen for 
the 7C7:C5 Fv?  2) What is the difference in binding affinity of the primary antigen and 
the primary cross-reactive antigen against the 7C7:C5 Fv?  Adenosine by far bears the 
closest structural resemblance to 6mAos, the antigen used to develop the anti-6mAos MAb, 
among the other possible ribonucleosides and naturally occurring methylated 
ribonucleosides.  As a result, Aos is most likely to bind to the anti-6mAos MAb with higher 
affinity than other ribonucleosides such as:  5-methylcytidine (5mCos), N4-methylcytidine 
(4mCos), guanosine (Gos), or N7-methylguanosine (7mGos).  Therefore, only the docking of 
dA was modeled as a control for comparison to the docking of d6mA. 
Based on rigid Fv docking models, d6mA was found to bind to the 7C7:C5 Fv with 
six fold greater affinity than dA.  This affinity difference supports the difference in 
affinity approximated by slot blot.  The difference in affinity based on average ∆G values 
between rigid and flexible Fv docking models was ten fold in favor of d6mA over dA.  All 
experimental evidence thus far suggests that this magnitude of affinity difference is 
sufficient for distinction between a single d6mA in a DNA sequence and DNA sequences 
without any d6mA.  Thus, the 7C7:C5 MAb is ideal for uses in diagnostics. 
One example for the use of the 7C7:C5 MAb would be through its application to a 
relatively fast and simple diagnostic format such as an ELISA or a lateral flow 
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chromatography device.  For instance, a TaqI MT (M.TaqI) site (TCG6mA) happens to be 
present in bovine viral diarrhea virus type II (BVDV-2) but not in BVDV-1.  Infection 
with BVDV-2 is much more pathogenic to cattle than BVDV-1, in which BVDV-2 can 
lead to hemorrhagic diarrhea.  This rapid diagnostic strategy can even be applied to two 
different strains of influenza A virus that infect humans: (A/Michigan/1/1985(H3N2)) 
#AF008872, a strain of unspecified pathogenesis, and (A/New_York/1/18(H1N1)) 
# AF116576, a strain that resulted in a rapid and acute pathogenesis of an infected 30 
year old male ultimately resulting in death 175.  While the hemagglutinin (HA) genes of 
both of these strains contain a M.TaqI site, only the aforementioned H1N1 HA gene 
contains an M.EcoRI (GA6mATTC) site.  As a result, upon isolating the HA gene and 
methylating with an M.EcoRI, immunochemical detection of the M.EcoRI site with the 
7C7:C5 MAb can be used to distinguish between these two strains of influenza A. 
Whether or not the use of 6mAos or d6mA makes a difference in the binding affinity 
is a rather important question to its potential future use as a therapeutic delivery tool for 
small interfering RNA (siRNA).  The difference between 6mAos and d6mA is merely an 
additional alcohol group that occurs in ribose but not deoxyribose.  The 5’ oxygen of 
d6mA was shown to be involved in a H-bond with Tyr L48 in the flexible Fv docking 
model of the 7C7:C5 Fv.  As a result, if a difference in binding affinity did exist, the most 
likely difference in binding affinity would occur through an additional H-bond in the 
favor of the ribonucleoside (6mAos).  This additional interaction would favor the use of the 
7C7:C5 Fv towards binding of 6mAos in RNA as opposed to d6mA in DNA. 
Nevertheless, the general methods of immunization described by Erlanger and 
Beiser 98 that provided the background information used for the immunization process in 
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production of the 7C7:C5 MAb decisively stated that the production of anti-DNA 
antibodies was successful by these immunization methods but for some unknown reason 
attempts at producing anti-RNA antibodies did not show the same success.  This 
occurrence may be due to the inherent requirement of high specificity involved in RNA 
binding.   High affinity binding of RNA has been shown to predominantly involve 
hydrophobic stacking interactions and hydrogen bonding, but also specific charged 
interactions in key positions 83, 176-179.  Furthermore, binding of A-RNA helices involves a 
deeper and narrower groove than the major groove of B-DNA making it more difficult 
for proteins to fit into these grooves 179.  Fortunately, RNA is somewhat more plastic than 
DNA and leaves much of its surface area for interaction at the ends of its grooves, in 
which unstacked bases in the RNA strand can be either pulled into binding pockets or 
positioned accordingly to allow the protein for sequence-specific binding.  As a result, 
the 7C7:C5 Fv may be able to bind to a 6mAos nucleotide in RNA if it is in a more 
accessible position along the RNA strand. 
An Fv has numerous advantages in terms of therapeutics over a complete MAb.  
Single-chain (sc) Fvs retain high affinity for their target antigens, do not exhibit 
undesirable recognition of non-specific cells associated with crystallizable constant 
fragments (Fcs), and have far shorter half-lives than complete MAbs limiting the 
possibility of eliciting an undesirable immune response 180-182.  Also, Fvs can be used to 
construct recombinants via an expression vector.  Recombinant technology can be used to 
humanize an antibody or to produce a fusion protein. 
A fusion protein composed of protamine for the binding of siRNAs covalently 
linked to the C terminus of an anti-glycoprotein (gp) 160 Fab, a HIV-1 envelope 
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glycoprotein, was used in a dose dependent manner for successful delivery of siRNAs to 
gp160 or cells transfected with gp160 182.  This treatment resulted in a 49% decrease of 
HIV-1 productively infected cells.  The same fusion protein was also used for siRNA 
delivery for tumor suppression of murine melanoma B16 cells, in which a maximum 
suppression of three-fold was obtained.  This example of siRNA delivery could easily be 
applied to any target using bispecific dimeric Fvs (diabodies) or even bispecific Fv-CH3-
Fv constructs (minibodies) in which one Fv could be used to carry the siRNA and the 
other Fv could be used to target entry or gateway receptors on cancer cells or viral  
infected cells. 
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APPENDIX A 
 
List of Online Resources 
AutoDock, http://autodock.scripps.edu/  
Cygwin, http://cygwin.com/  
 
Expert Protein Analysis System Proteomics Server, http://ca.expasy.org/  
 
Fermentas, http://www.fermentas.com/  
 
Force Field Explorer, http://dasher.wustl.edu/ffe/  
 
Gibco, http://invitrogen.com/content.cfm?pageid=11040  
 
H++, http://biophysics.cs.vt.edu/H++/hppdetails.php  
 
Invitrogen, http://www.invitrogen.com/content.cfm?pageid=1  
 
Modeller, http://salilab.org/modeller/  
 
National Center for Biotechnology Information, http://www.ncbi.nlm.nih.gov/  
 
New England Biolabs, http://www.neb.com/nebecomm/default.asp  
 
PROCHECK, http://www.biochem.ucl.ac.uk/~roman/procheck/procheck.html  
 
RCSB Protein Data Bank, http://www.rcsb.org/pdb/home/home.do  
 
Sigma-Aldrich, http://www.sigmaaldrich.com/united-states.html  
  
Swiss-PDB Viewer/DeepView, http://spdbv.vital-it.ch/  
 
Technelysium Pty. Ltd., http://www.technelysium.com.au/  
The University of Michigan DNA Sequencing Core, http://seqcore.brcf.med.umich.edu/  
 
UCSF Chimera, http://www.cgl.ucsf.edu/chimera/ 
 
Wavefunction, Inc., http://www.wavefun.com/cart/catalog/Spartan-Software-p-1-c-2.html
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APPENDIX B 
 
Modeller9v4 Command Files 
# Homology modelling by the automodel class 
from modeller import *              # Load standard Modeller classes 
from modeller.automodel import *    # Load the automodel class 
 
log.verbose()    # request verbose output 
env = environ()  # create a new MODELLER environment to build this 
model in 
 
# directories for input atom files 
env.io.atom_files_directory = ['.', '../atom_files'] 
 
a = automodel(env, 
              alnfile  = '7C7C5Fv.ali',     # alignment filename 
              knowns   = 
('1QOK','1HQ4','1F8T','1S5I','32C2','1AY1','1KCU','3CFE','2A0L','1ORS',
'1EZV','1BAF','1KEN','1KCS','2FON','1I9I','1E6O', '2FAT', '1AIF'),     
# codes of the templates 
              sequence = '7C5U')             # code of the target 
a.starting_model= 1                 # index of the first model  
a.ending_model  = 1                 # index of the last model 
                                    # (determines how many models to 
calculate) 
a.make()                            # do the actual homology modelling 
 
Figure 38.  Modeller9v4 command file for homology modeling of the antigen unbound 
template model of the 7C7:C5 Fv. 
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# Homology modelling by the automodel class 
from modeller import *              # Load standard Modeller classes 
from modeller.automodel import *    # Load the automodel class 
 
log.verbose()    # request verbose output 
env = environ()  # create a new MODELLER environment to build this 
model in 
 
# directories for input atom files 
env.io.atom_files_directory = ['.', '../atom_files'] 
 
a = automodel(env, 
              alnfile  = '7C7C5Fvb.ali',     # alignment filename 
              knowns   = 
('1QOK','1ORS','1CF8','1F90','1BAF','1KCR','1KEN','2A0L','1BGX','1KC5',
'1NCW','3CFD','1EZV','1S5I','1KCS','2FON','1I9I','1E6J', '2FD6', 
'2FBJ'),     # codes of the templates 
              sequence = '7C5V')             # code of the target 
a.starting_model= 1                 # index of the first model  
a.ending_model  = 1                 # index of the last model 
                                    # (determines how many models to 
calculate) 
a.make()                            # do the actual homology modelling 
 
Figure 39.  Modeller9v4 command file for homology modeling of the antigen bound 
template model of the 7C7:C5 Fv 
 
 
 
 
  175
APPENDIX C 
 
AutoDock-4.0 Rigid Fv Docking Log Files 
 
MODEL        5 
USER    Run = 5 
USER    Cluster Rank = 1 
USER    Number of conformations in this cluster = 1 
USER   
USER    RMSD from reference structure       = 32.352 A 
USER   
USER    Estimated Free Energy of Binding    =   -5.15 kcal/mol   
 [=  (1)+(2)+(3)-(4)] 
 
USER    Estimated Dissociation Constant, Kd =  168.88 uM  
(micromolar)           [Temperature = 298.15 K] 
USER     
USER    (1) Final Intermolecular Energy     =   -5.50 kcal/mol 
USER        vdW + Hbond + desolv Energy     =   -5.47 kcal/mol 
USER        Electrostatic Energy            =   -0.03 kcal/mol 
USER    (2) Final Total Internal Energy     =   -0.80 kcal/mol 
USER    (3) Torsional Free Energy           =   +1.10 kcal/mol 
USER    (4) Unbound System's Energy         =   -0.06 kcal/mol 
 
Figure 40.  AutoDock-4.0 docking log file for the most favorable binding mode of d6mA 
to the 7C7:C5 Fv using rigid Fv docking. 
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MODEL        7 
USER    Run = 7 
USER    Cluster Rank = 1 
USER    Number of conformations in this cluster = 1 
USER   
USER    RMSD from reference structure       = 32.351 A 
USER   
USER    Estimated Free Energy of Binding    =   -3.56 kcal/mol   
 [=   (1)+(2)+(3)-(4)] 
 
USER    Estimated Dissociation Constant, Kd =    2.46 mM  
(millimolar)       [Temperature = 298.15 K] 
USER     
USER    (1) Final Intermolecular Energy     =   -4.62 kcal/mol 
USER        vdW + Hbond + desolv Energy     =   -4.59 kcal/mol 
USER        Electrostatic Energy            =   -0.03 kcal/mol 
USER    (2) Final Total Internal Energy     =   -0.73 kcal/mol 
USER    (3) Torsional Free Energy           =   +1.10 kcal/mol 
USER    (4) Unbound System's Energy         =   -0.69 kcal/mol 
 
Figure 41.  AutoDock-4.0 docking log file for the most favorable binding mode of dA to 
the 7C7:C5 Fv using rigid Fv docking. 
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MODEL       10 
USER    Run = 10 
USER    Cluster Rank = 2 
USER    Number of conformations in this cluster = 1 
USER   
USER    RMSD from reference structure       = 43.672 A 
USER   
USER    Estimated Free Energy of Binding    =   -2.37 kcal/mol   
 [=   (1)+(2)+(3)-(4)] 
 
USER    Estimated Dissociation Constant, Kd =   18.20 mM  
(millimolar)       [Temperature = 298.15 K] 
USER     
USER    (1) Final Intermolecular Energy     =   -5.57 kcal/mol 
USER        vdW + Hbond + desolv Energy     =   -4.92 kcal/mol 
USER        Electrostatic Energy            =   -0.65 kcal/mol 
USER    (2) Final Total Internal Energy     =   -1.24 kcal/mol 
USER    (3) Torsional Free Energy           =   +4.12 kcal/mol 
USER    (4) Unbound System's Energy         =   -0.32 kcal/mol 
 
Figure 42.  AutoDock-4.0 docking log file for the second most favorable binding mode of 
A-6mA-T to the 7C7:C5 Fv using rigid Fv docking. 
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APPENDIX D 
 
 
AutoDock-4.0 Docking Log Files for Fv with Five Flexible Residues 
MODEL       19 
USER    Run = 19 
USER    Cluster Rank = 1 
USER    Number of conformations in this cluster = 1 
USER   
USER    RMSD from reference structure       = 1.802 A 
USER   
USER    Estimated Free Energy of Binding    =  -14.57 kcal/mol   
 [=  (1)+(2)+(3)-(4)] 
 
USER    Estimated Dissociation Constant, Kd =   21.04 pM  
(picomolar)        [Temperature = 298.15 K] 
USER     
USER    (1) Final Intermolecular Energy     =   -5.44 kcal/mol 
USER        vdW + Hbond + desolv Energy     =   -3.51 kcal/mol 
USER        Electrostatic Energy            =   -0.05 kcal/mol 
USER        Moving Ligand-Fixed Receptor    =   -3.56 kcal/mol 
USER        Moving Ligand-Moving Receptor   =   -1.88 kcal/mol 
USER    (2) Final Total Internal Energy     =  -11.45 kcal/mol 
USER        Internal Energy Ligand          =   -0.67 kcal/mol 
USER        Internal Energy Receptor        =  -10.78 kcal/mol 
USER    (3) Torsional Free Energy           =   +1.10 kcal/mol 
USER    (4) Unbound System's Energy         =   -1.23 kcal/mol 
     
Figure 43.  AutoDock-4.0 docking log file for the most favorable binding mode of d6mA 
to the 7C7:C5 Fv using flexible Fv docking. 
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MODEL       23 
USER    Run = 23 
USER    Cluster Rank = 16 
USER    Number of conformations in this cluster = 1 
USER   
USER    RMSD from reference structure       = 3.839 A 
USER   
USER    Estimated Free Energy of Binding    =  -13.45 kcal/mol   
 [=  (1)+(2)+(3)-(4)] 
 
USER    Estimated Dissociation Constant, Kd =  138.84 pM  
(picomolar)      [Temperature = 298.15 K] 
USER     
USER    (1) Final Intermolecular Energy     =   -3.59 kcal/mol 
USER        vdW + Hbond + desolv Energy     =   -2.16 kcal/mol 
USER        Electrostatic Energy            =   -0.06 kcal/mol 
USER        Moving Ligand-Fixed Receptor    =   -2.22 kcal/mol 
USER        Moving Ligand-Moving Receptor   =   -1.37 kcal/mol 
USER    (2) Final Total Internal Energy     =  -11.55 kcal/mol 
USER        Internal Energy Ligand          =   -0.72 kcal/mol 
USER        Internal Energy Receptor        =  -10.83 kcal/mol 
USER    (3) Torsional Free Energy           =   +1.10 kcal/mol 
USER    (4) Unbound System's Energy         =   -0.59 kcal/mol 
 
Figure 44.  AutoDock-4.0 docking log file for the sixteenth most favorable binding mode 
of dA to the 7C7:C5 Fv using flexible Fv docking.  This binding mode was selected for 
the docking of dA to the 7C7:C5 Fv due to its similarity to the most favorable binding 
modes in the docking of d6mA and the d6mA moiety of A-6mA-T to the 7C7:C5 Fv. 
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MODEL       13 
USER    Run = 13 
USER    Cluster Rank = 3 
USER    Number of conformations in this cluster = 3 
USER   
USER    RMSD from reference structure       = 3.360 A 
USER   
USER    Estimated Free Energy of Binding    =  -14.22 kcal/mol   
 [=  (1)+(2)+(3)-(4)] 
 
USER    Estimated Dissociation Constant, Kd =   37.57 pM  
(picomolar)         [Temperature = 298.15 K] 
USER     
USER    (1) Final Intermolecular Energy     =   -4.82 kcal/mol 
USER        vdW + Hbond + desolv Energy     =   -2.74 kcal/mol 
USER        Electrostatic Energy            =   -0.01 kcal/mol 
USER        Moving Ligand-Fixed Receptor    =   -2.75 kcal/mol 
USER        Moving Ligand-Moving Receptor   =   -2.08 kcal/mol 
USER    (2) Final Total Internal Energy     =  -11.09 kcal/mol 
USER        Internal Energy Ligand          =   -0.71 kcal/mol 
USER        Internal Energy Receptor        =  -10.38 kcal/mol 
USER    (3) Torsional Free Energy           =   +1.10 kcal/mol 
USER    (4) Unbound System's Energy         =   -0.59 kcal/mol 
 
Figure 45.  AutoDock-4.0 docking log file for the third most favorable binding mode of 
dA to the 7C7:C5 Fv using flexible Fv docking.  This binding mode shows dA docked 
deep in the binding pocket of the 7C7:C5 Fv, but the dA is docked in an orientation that 
is horizontally opposite of the most favorable binding mode found for d6mA. 
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MODEL       31 
USER    Run = 31 
USER    Cluster Rank = 1 
USER    Number of conformations in this cluster = 1 
USER   
USER    RMSD from reference structure       = 9.702 A 
USER   
USER    Estimated Free Energy of Binding    =  -14.36 kcal/mol   
 [=  (1)+(2)+(3)-(4)] 
 
USER    Estimated Dissociation Constant, Kd =   29.63 pM  
(picomolar)        [Temperature = 298.15 K] 
USER     
USER    (1) Final Intermolecular Energy     =   -7.92 kcal/mol 
USER        vdW + Hbond + desolv Energy     =   -5.61 kcal/mol 
USER        Electrostatic Energy            =   -0.14 kcal/mol 
USER        Moving Ligand-Fixed Receptor    =   -5.75 kcal/mol 
USER        Moving Ligand-Moving Receptor   =   -2.18 kcal/mol 
USER    (2) Final Total Internal Energy     =  -11.45 kcal/mol 
USER        Internal Energy Ligand          =   -1.35 kcal/mol 
USER        Internal Energy Receptor        =  -10.11 kcal/mol 
USER    (3) Torsional Free Energy           =   +4.12 kcal/mol 
USER    (4) Unbound System's Energy         =   -0.89 kcal/mol 
 
Figure 46.  AutoDock-4.0 docking log file for the most favorable binding mode of A-
6mA-T to the 7C7:C5 Fv using flexible Fv docking. 
 
 
 
